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9An Introduction to the immune system and to 
the principles of cancer vaccination.
The immune system
 T Cells and B cells
The system that we refer to as “the immune system” is in fact a collection 
of many smaller systems, each with specialized features that serve to 
protect us against different types of virusses and germs (pathogens). The 
cells that orchestrate the production of antibodies (B cells) are the best-
known “sub-system”. Antibodies are proteins that stick to a pathogen, 
thereby neutralizing it. Each B cell produces a type of antibody that 
has unique sticking properties, making it stick to specific pathogens. 
In order to do so, the gene in each B cell that encodes the antibody, is 
randomly compiled from a set of genomic building blocks at the birth of 
the B cell in the bone marrow. This compilation process is called genetic 
recombination. Consequently, each of the millions of B cells that the 
bone marrow generates through life, produces antibodies with a random 
and unique target specificity. Time will tell whether they can stick to an 
invading pathogen, or whether they are useless. The only thing that the 
bone marrow makes sure about their specificity, is that they do not stick 
to “self” proteins (proteins that belong to oneself). B cells that do so 
are killed before they are released in the system (so-called “negative 
B cell selection”). What is left recognizes “non-self” proteins only. Such 
“foreign” non-self proteins are called “antigens”. 
By the production of antibodies, B cells can kill from a long distance. 
When released, antibodies easily disperse in all tissues, sticking in large 
amounts to the surface of the pathogen that matches their specificity. 
Once bound by antibodies, other “sub-systems” will kill the pathogen. 
However, antibodies can only stick to the outside of invaders and infected 
cells, since they cannot pass through cellular walls (“cell membranes”). 
Therefore, pathogens that disguise their surface molecules to look like 
our own or pathogens that hide inside cells of the patient cannot be 
fought with antibodies. For this purpose, we have T cells. These cells 
are part of a sub-system that can recognize non-self proteins expressed 
inside our own cells. The work described in this thesis exclusively 
concerns T cells. 
T cells have a T cell receptor (TCR) that is recombined just like antibodies 
and T cells are subsequently negatively selected just like B cells are. 
Contrary to B cells, the TCR of a T cell is not secreted in the circulation 
but remains attached to the T cell. Furthermore, it is not designed to stick 
to the enemy but to so-called MHC-molecules: molecules that any cell in 
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our body constantly replaces on its surface, with always a fresh part of the 
cells entrails right on top of it (a fragment of a protein: a peptide). Upon 
binding of the TCR to the MHC molecule, this peptide is sandwiched in 
between them. Therefore it determines the strength of the TCR - MHC 
interaction. As mentioned previously, T cells with a TCR that can bind 
to a MHC molecule with a self-peptide on top of it have been parsed by 
negative-T-cell selection during their development in the thymus. Hence, 
any cell presenting an MHC/peptide complex that can be bound by a 
TCR is non-self by exclusion; therefore it is killed instantly by the T cell 
carrying this TCR. Due to the negative selection processes, neither the T 
nor the B cell system will react to self-proteins. This non-responsiveness 
originating from negative T and B cell selection is referred to as “central 
self-tolerance”. There are other forms of immunological tolerance that 
do not come about by negative selection in the thymus (T cells) or the 
bone marrow (B cells). These are referred to as “peripheral tolerance”.
In order for inexperienced B and T cells (freshly produced, “naive” T or 
B cells) to start killing cells that express (produce) a non self (“foreign”) 
protein, the mere presence of this protein will not suffice. In short two 
things are needed to activate them: 1) the foreign protein, and 2) alarm 
signals (“danger signals”). Danger signals are provided by another very 
important subsystem: the Antigen presenting cells (APCs). These cells 
are capable of sensing the presence of invading pathogens and ‘signal’ 
their presence to the rest of the immune system. If both the foreign 
protein and danger signals are present, T and B- cells will start to divide 
and to prepare for killing (T cells) or antibody production (B cells). The 
“activated” T cells can be identified by molecules that either appear 
(e.g. CD45RO) or disappear (e.g. CD27) from their cell membrane and 
by the secretion of substances (e.g. IFN-γ, IL-2 and IL-4) that support the 
fulfillment of their killer (“cytotoxic”) duties. Importantly, the presence 
of a foreign protein in the absence of danger signals usually leads to 
tolerization of naïve T cells specific for this protein instead of activation. 
This is a very important peripheral tolerance mechanism.
The B cell en the T-cell subsystems are sometimes referred to as the 
humoral and cellular immune systems, respectively. They are the most 
complex and evolutionary advanced sub-systems of our immune 
system. Together they form the “adaptive” part of our immune system, 
referring to their “memory”-function: once a foreign protein has been 
encountered, the B and T cell systems adapt to become hyper vigilant for 
pathogens expressing this protein. This is partly due to a small portion 
of the B and T cells that persists once the pathogen has been cleared 
after having participated in the immune attack. Some B cells continue 
to produce antibodies and some T cells continue to patrol the body. 
Importantly, contrary to inexperienced T or B cells, the re-appearance 
of the pathogen in the absence of danger signals can reactivate these 
“experienced” T and B cells. 
AN INTRODUCTION  TO THE IMMUNE SYSTEM AND TO THE PRINCIPLES OF TUMOR VACCINATION
11
Furthermore, a distinct sub-type of T cells ‘helps’ in the maintenance 
of both cellular an humoral memory. These cells (the T helper- or Th 
cells) are characterized by the presence of a ‘CD4’ molecule on their 
membrane. Altogether, the adaptations leading to immunological 
memory are responsible for us getting our childhood diseases only once. 
None of the other sub-systems of our immune-system has this capacity. 
The other systems always remain as they were at birth, therefore they are 
collectively named “innate-immunity”.
 APCs
APCs are part of our innate immunity and reside in all parts of our body, 
especially those parts that border the exterior world. These borders are 
lined with so-called epithelia: special cells that form a barrier. Roughly, 
there are 4 types: lining the gut, the airways, the urogenital system or the 
body surface (the skin or dermis). As any infectious disease starts with 
a bug crossing one of these borders, APCs are constantly on guard here 
for intruders. 
The upper layer of the skin (epidermis) is equipped with a dense 
network of specialized APCs, called Langerhans cells (LC). In deeper 
layers of the skin dermal dendritic cells (DCs) are on guard. Both these 
cells have a spider-like appearance projecting long protrusions of their 
body (dendrites) deep in the surrounding tissue. Using these dendrites, 
they sample all molecules present in the tissue. Furthermore, APCs that 
do not have dendrites, called macrophages, patrol the skin as well. These 
cells are able to ingest larger particles, including whole cells.
APCs are pivotal to T and B cell activation. If the pathogen recognition 
receptors of an APCs sense danger (i.e. the presence of an intruder) the 
APC will change its “phenotype” (properties) and start to make its way to 
the lymph node that drains the infected area (the draining lymph node, 
DLN). This is named the “maturation” of an APC. In the DLN, the antigens 
that were taken up in the tissues are presented by the APC to naive T and 
B cells, leading to their activation. For presentation to T cells the antigens 
are hashed, stuck on top of the MHC molecules and brought to the 
membrane of the APC. For B cells the APC just glues some of the antigen 
to its surface, for B cells to snoop it of. Importantly, the presentation by 
APCs of antigens produced in other cells is called “cross presentation”1. 
Interestingly, from all the antigens present in the infected tissue, only 
some will be efficiently cross presented by the APC. 
Activating the immune system to fight against a tumor
 Tumor antigens
Contrary to self proteins, antigens can be recognized by antibodies and 
T cells. However, tumors are exclusively build from self proteins, since 
all cancers originate from one of our own cells that has gone through 
i
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many uncontrolled divisions, creating a lump of meat consisting of its 
offspring. If the T and B cell systems are to fight a cancer, what non self 
proteins should they recognize then? Tumor derived proteins that T or 
B cells can recognize are named “tumor antigens”. Different classes of 
tumor antigens can be identified2:
1) Some cancers are caused by viruses. Especially the human papilloma 
virus (HPV) is renowned for its potential to cause cervical carcinoma 
in sexually active women. The HPV derived proteins driving the 
uncontrolled cell division in cervical carcinomas are non-self and can 
be recognized by T and B cells. These antigens are referred to as “virally 
derived tumor antigens”
2) Usually, the cell that started the cancer did so because a chemical 
agent or a radiation beam struck one of its genes, mutating it in a gene 
driving uncontrolled cell-division. In some cases, the DNA mutation 
results in the production of a mutated protein that (if it differs enough 
from the normal version) can be recognized by T and B cells as a “tumor 
specific antigen”. In many cases however, the mutation occurs in DNA 
that does not encode a protein, but solely has a regulatory function in the 
cell division process.
3) During their uncontrolled divisions, tumor cells make many mistakes 
in the copy-process of their genes, leading to more mutations and 
further deregulation of their behavior. This may cause tumor cells to 
start producing proteins that were produced only during embryonic 
development of the patient and were never produced since. As the B 
and T cell systems develop for a large part after birth, T- and B cells 
are not negatively selected against these proteins. Therefore, they may 
recognize these so-called “differentiation-antigens”.
4) Sometimes a TCR or an antibody can recognize a self-protein that the 
tumor produces in abnormal and unphysiological amounts (so-called 
“overexpressed antigens”). This happens just because there is suddenly 
so much of it. The efficacy of the central tolerization process varies per 
self-protein: for some self-proteins the central tolerance is absolute 
while for other self-proteins overexpression may lead to the activation 
of T and B cells.
5) Some tissues, the testis in particular, produce many proteins that are 
not protected by central tolerance but by local (peripheral) tolerance 
mechanisms. In the testis this is because during spermatogenesis the 
genes of our parents are recombined to new variants, leading to the 
expression of foreign proteins. When testis antigens are accidentally 
expressed by tumors without peripheral tolerance mechanisms, T and 
B cells may recognize them. Such antigens are called “cancer/testis 
antigens”.
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6) As mentioned previously, central tolerance can be incomplete for 
self proteins in tissues outside the testis as well. In these cases this is 
compensated for by peripheral tolerance mechanisms. Potentially, when 
such tissues give rise to a tumor that breaches peripheral tolerance (by 
eliciting strong danger signals) suddenly these proteins can activate T 
and B cells. The Mart-1 and Gp100 tumor antigens in pigment cells of the 
skin (melanocytes) belong to this group.
It may seem that T and B cells of cancer patients have a high chance to 
recognize fragments of tumor antigens (peptides) presented to them on 
top of MHC molecules. Unfortunately this is not the case, as most tumors 
do not express any tumor antigen. Moreover, regarding T cells, only 
peptides that can stick on top of a MHC molecule can be presented. Such 
peptides are called “T cell epitopes”. Since MHC molecules vary from 
person to person, each individual will recognize other T cell epitopes 
in a tumor antigen. Hence, the T cells of a patient with an ‘unlucky’ set of 
MHC molecules may in theory fail to recognize a good tumor antigen. 
 T cells and cancer
Occasionally, tumors regress spontaneously without any form of 
therapy. Many such spontaneous regressions are thought to be immune 
mediated3. Since these regressions are mainly restricted to certain 
cancer types, e.g. renal cell carcinoma, neuroblastoma, lymphomas 
and melanomas (cancer from melanocytes)4;5, from early days the focus 
of tumor immunology has been on these cancers. Experiments in the 
eighties, in which immune cells were isolated from cancer patients 
and reinjected after ex vivo (in a culture dish) stimulation, suggested 
that T cells are a key player in the immune mediated anti tumor effect6. 
Extensive analyses of antitumor immune responses in patients with 
spontaneous tumor regressions have reinforced this notion since7;8.
Cancer immunotherapy aims at the eradication of a tumor by activation 
of tumor specific T cells (so-called “immunization”). To this purpose 
various immunization strategies are employed. Here I’ll categorize these 
T cell inducing immunization methods against cancer.
 Protective or therapeutic immunization
The majority of experimental cancer immunization strategies consists 
of “therapeutic immunization”. This means that once the patient has 
the disease, tumor vaccines are employed to mount a sufficiently early, 
sizable and fully differentiated T cell response. Conversely, “protective 
immunization” strives to generate tumor specific T cell immunity before 
onset of the disease. Theoretically, as tumor antigens – except virally 
derived antigens – are self proteins, there is a risk for autoimmunity (an 
immune attack against friendly self tissue) upon immunization against 
non-virally derived tumor antigens. In case of protective vaccination this 
risk is unjustifiably big compared to the small chance to develop the 
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tumor. For this and other reasons this strategy is currently pursued for 
virally induced tumors only, e.g. for hepatocellular carcinoma (caused 
by the hepatitis B virus) and for cervical carcinoma (caused by HPV). 
 aspecific or specific immunization
Most tumors are notoriously unalarming to APCs, leading to peripheral 
tolerization of tumor specific T cells (if there are any). To breach such 
tolerization, ‘ancient’ cancer vaccines tried to jam the alarm bells. These 
vaccines are referred to as “aspecific cancer vaccines”, since they do not 
provide an antigen. More recent cancer vaccines provide both antigens 
and danger signals. These vaccines are referred to as “specific cancer 
vaccines”. In specific vaccines, the components meant to provide the 
danger signal, are referred to as ‘adjuvants’.
In order to mislead APCs to make alarm, some adjuvants consist 
of molecules derived form notorious pathogens (so called PAMPs, 
pathogen associated molecular patterns). Specialized trouble sensors of 
APCs (Toll-like receptors, TLRs) can detect PAMPs, resulting in danger 
signals. Examples of PAMPs are bacterial cell wall components (LPS, 
sticks to TLR4) and unique bacterial DNA sequences (CpGs, stick to 
TLR9). Other adjuvants mimic signal molecules that have a function in the 
alarm-cascade. Some adjuvants consist of these molecules themselves 
(e.g. IL-2 and GM-CSF) and other adjuvants manipulate their function by 
sticking to them (e.g. CD40 agonistic (stimulating) antibodies, CTLA-4 
antagonistic (blocking) antibodies and CD28 agonistic antibodies).
 passive or active immunization
Roughly there are two methods that lead to immunity against a (tumor) 
antigen: activating the patients own naive T and B cells or injecting 
antigen experienced T cells or antibodies straight away. The first is called 
active immunization and the second passive immunization. “Vaccination” 
is a synonym for active immunization. 
Most passive immunization methods do not result in immune memory. 
However, passive immunization works very fast and leads to strong, albeit 
short, immunity. More importantly, passive immunization circumvents 
both central and peripheral tolerization of T and B cells. This makes it 
very suitable for therapeutic cancer vaccination. For the induction of 
protective long-term immune memory, active immunization methods are 
the strategy of choice.
Nevertheless, many active cancer immunization methods are being 
tested in cancer patients all over the world. This may be due to the 
relatively low costs of active cancer vaccines. Up to this moment however, 
the therapeutic effect of these vaccines has been disappointingly low. On 
the other hand, the immunological knowledge that has resulted from the 
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pursuit of active cancer vaccines has been useful for the development of 
other vaccines as well. 
Currently, passive cancer immunization is an accepted therapeutic 
strategy in for certain types of cancer. Examples are the antibodies 
directed against breast cancer antigens (herceptin) and certain 
lymphoma antigens (rituximab) that are used in the treatment of patients 
suffering from these cancers. Although the infusion of such antibodies 
never leads to the complete eradication of the tumor, it can considerably 
delay disease progression. Regarding T cells, the experimental infusion 
of tumor specific T cells has lead to impressive results in end stage 
melanoma patients8. Furthermore, the implantation of a gene that 
encodes a tumor specific TCR in T cells of a cancer patient (“TCR gene 
transfer”), is a novel form of passive immunization9. The first clinical tests 
with this type of gene-therapy are currently ongoing. 
 Various means to include antigens and adjuvants in T cell vaccines
Cancer specific T cell vaccines combine an adjuvant to provide danger 
signals with an antigen to direct the response towards the tumor. 
The first successful T cell vaccine ever, protected against smallpox7. 
The recipient was inoculated with viable cow pox virus isolated from 
diseased cows, resulting in a non-lethal infectious disease similar to 
smallpox, but milder. While the viral activity provided danger signals, 
the antigens of the cow-pox virus (sufficiently similar to those of the 
human smallpox virus) induced a T cell response that would protect 
the child against future smallpox infection. Since cow pox infection can 
be fatal in immunocompromized patients (patients with a weakened 
immune system), the method became obsolete. The smallpox virus has 
eventually been exterminated worldwide by a very similar, but safer, 
vaccination strategy10.
Currently, some cancer patients are experimentally vaccinated 
analogous to this approach. Patients are injected with an viable (but 
weakened “attenuated”) pathogen (the “vector”) to provide danger 
signals, while the expression of tumor antigens is accomplished by 
genetic modification of this vector. In many such vaccines, an attenuated 
pox-virus (MVA, Modified Vaccinia Ankara) is employed for this 
purpose11. Inherently, these vaccines contain many non tumor specific 
vector-derived antigens. 
This disadvantage is absent in “autologous tumor vaccination”. In this 
procedure, the patients own tumor material, containing all relevant tumor 
antigens is excised, homogenized and irradiated to preclude further cell 
divisions. Before reinjection of this material, adjuvant is added (e.g. BCG, 
an inactivated form of Mycobacterium Bovis, a pathogen very similar to 
the one that causes tuberculosis) in order to provide danger signals12. 
i
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The results of tests with MVA based and autologous cancer vaccines 
have been disappointing13.
In order to increase vaccine strength, many experimental tumor 
vaccines try to focus the T cell response to a limited and defined number 
of tumor antigens. Such tumor vaccines incorporate a single or a small 
set of antigens, or even a single antigenic peptide. Peptide vaccines 
are inherently MHC-restricted, since the peptides that they contain can 
only be presented to T cells if the MHC of the vaccinee is appropriate. 
Moreover, designing such vaccines requires knowledge about the 
antigenic epitopes that are present in the tumor.
The antigen of an active specific vaccine can also be administered in the 
form of DNA. DNA holds (“encodes”) the blueprints for all our proteins 
and is contained in the nucleus (the central compartment) of each cell. 
Apart from one extra step, the mechanism of “DNA vaccination” is the 
same as that of conventional protein and peptide vaccines. This step 
implies so-called “transfection”: upon injection of the DNA, the DNA 
molecules enter cells of the patient surrounding the injection site. 
Subsequently, once the DNA enters the nucleus, the transfected cell 
will mistake the plasmid DNA for its own and will start to produce the 
antigen that the DNA vaccine encodes. For optimal transfection in living 
tissues (“in vivo”) the DNA string should have no loose ends (it should 
be a circle, a ‘plasmid’) and it should be a lot of DNA. After cells have 
been transfected with the DNA vaccine and are producing the antigen 
that it encodes, the immune system will respond to this antigen just as it 
responds to the antigens in a protein vaccine.
Yet another immunization method that is currently pursued, is the 
injection of autologous APCs that have been “loaded” in a culture dish 
(“in vitro”) with antigens or peptides. Such APCs can also be transfected 
in vitro with DNA encoding these peptides. Although the method is 
complicated an laborious, it has proven to be both a potent immunization 
method and a powerful tool for research on the mechanisms involved in 
T cell priming. 
Developing and Testing vaccines
The immune system is highly complex. Although most sub-systems may 
have been identified and dissected, our understanding of their cellular 
interplay is incomplete. Moreover, our insight in the internal wiring of 
immune cells is just evolving. Therefore, we cannot simulate the immune 
system in a test tube and use this to test experimental vaccines; either 
we experiment on Homo Sapiens or we use a comparably complex 
substitute organism to develop new vaccines. 
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The most convenient substitute for Homo Sapiens is the Mus Musculus; the 
mouse. It breeds fast, doesn’t need much space and has a comparably 
complex immune system. However, there are considerable differences. 
As far as anatomy is concerned there are obvious differences in skin 
anatomy that are particularly relevant for the development of dermal 
DNA vaccines: mice have a thin skin with extensive hair growth whereas 
human skin is thicker and virtually hairless. Furthermore, the weight of 
an adult mouse is approximately 30g, which is 2500 times less than that of 
a human adult. Calculating the dose of a vaccine to be used in humans by 
multiplying the dose in mice with this factor, results in unacceptably large 
doses for humans (or unworkably small doses for mice). Biochemically, 
there are many differences as well. For example the lack of TLR9 
expression in human skin and the high resistance of mice to LPS, a toxic 
contamination in DNA preparations. Collectively these issues make the 
“translation” of a mouse vaccine to a human vaccine a difficult task.
Altogether, mice are suitable for uncovering fundamental immunological 
mechanisms and for the first steps in the development of experimental 
vaccines. For a trustworthy assessment of the applicability of an 
experimental vaccine in humans, it is wise to switch to an animal model 
that better resembles humans, for example monkeys such as the rhesus 
macaque (Macaca Mulatta). 
i
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INTRODUCTION TO THE WORK DESCRIBED IN THIS THESIS
Introduction to the work described in this 
thesis
Five reasons why T cells fail to reject tumors spontaneously
Unfortunately, in the vast majority of patients suffering from a cancer T 
cells will not spontaneously eradicate the tumor. Although it is tempting to 
speculate that many tumors are eradicated by our cellular immune system 
before they are diagnosed, this is not the case. Based on the comparison 
of cancer incidence in healthy and immunocompromized individuals, 
the role of the immune system in such “tumor-immunosurveillance” is 
modest at most14 and mainly confined to virally induced tumors. Here I 
will give a brief overview of the hurdles that stand between T cells and 
their eradication of a tumor.
1a) Tumors may not express tumor antigens. To put it differently: the 
T cell repertoire of the patient may be centrally tolerized towards 
all proteins expressed by the tumor to an extent that hampers their 
activation. If this is the case, no T cell response will ever occur during the 
disease. 
1b) Neither is a spontaneous T cell response likely to occur if the T cell 
repertoire is peripherally tolerized towards the tumor antigens. Although 
in some instances danger signals provided by the tumor may breach this 
tolerance.
2) Since all tumor antigens – except virally derived antigens – are 
inherently self-proteins, the tumor specific response usually consists of 
T cells with suboptimal, low-affinity TCRs. Hence, these T cells may get 
insufficiently stimulated to fully differentiate to effector cells and exert 
their cytotoxic effects15;16.
3) If fully differentiated tumor specific T cells do occur in a cancer 
patient, they can be anergized or even killed by interactions with the 
tumor cells or the tumor stroma17;18. The expression of FasL by tumor cells 
or the secretion of TGF-ß by the tumor stroma are notorious examples.
4) If such fully differentiated T cells are not hindered by the tumor or 
the tumor stroma and can fulfill their cytotoxic duties, then the size and 
expansion rate of the tumor mass may preclude T cell mediated tumor 
eradication. To put it differently, the cells may arrive too late or the 
number of T cells may not be sufficient 19, this thesis.
5) Even if fully differentiated T cells, unhindered by interactions 
with the tumor or the tumor stroma arrive sufficiently early, they may 
encounter a tumor that is refractory to T cell killing due to loss of MHC 
19
expression. This renders the tumor specific T cell response useless at 
once20. 
Only if all these hurdles have been passed, T cells may spontaneously 
eradicate the tumor. But even than the patient may not be cured. The 
uncontrolled division in tumor cells will have spawned progeny with 
varied phenotypes; when any of these cells possesses a phenotypic 
trait that hampers T cell killing, this cell will survive the T cell attack 
and give rise to a new tumor that will be resistant to T cell killing. This 
phenomenon has been termed “cancer immuno editing”21.
To investigate the quantity and the quality of spontaneously occurring 
melanoma specific T cell responses in light of these issues, we studied 
melanoma specific T cell responses in 62 end stage melanoma patients. 
The results are described in the first chapter of this thesis.
Challenges for cancer vaccines
Cancer vaccines have to face all the challenges mentioned above. 
Concerning the first hurdle, active immunization will clearly have no 
benefit for tumors that do not express tumor antigens (hurdle 1a). In this 
case passive immunization is the immunotherapy of choice; by transfer of 
tumor specific T cells that either may or may not have been transduced 
with TCR encoding genes. 
Theoretically, a sufficiently potent active vaccination strategy might be 
able to induce tumor specific T cells, if they are present but reside in a 
peripherally tolerized state (hurdle 1b). Experimental cancer vaccines 
cannot yet breach peripheral tolerance towards tumor antigens, without 
breaching that to self proteins as well. But one day the growing insight in 
peripheral tolerance mechanisms, combined with stronger vaccination 
methods, may make this possible.
Chances for successful tumor specific vaccination are higher if the 
cancer patient possesses a non-tolerized T cell repertoire that is non 
functional because it consists of T cells with a low-affinity TCR (hurdle 2). 
In this case, the extra stimulation provided by the vaccine may help these 
T cells to differentiate to full-blown effector cells.
In cases where such cells are hindered by tumor-mediated 
immunomodulation (hurdle 3) or faced with an overwhelming tumor 
load (hurdle 4) active immunization may be beneficial as well, simply 
by activating T cells at an earlier stage of the disease. However, in most 
patients a combination of low TCR affinity, high tumor load and tumor 
immuno-modulation will make successful active immunization a very 
difficult feat22;23. 
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A more realistic target to pursue with the active immunization methods 
that so far have been developed, is to design vaccines against virally 
derived tumors expressing highly immunogenic tumor antigens 
(e.g. cervical carcinoma). With the current state of the art, for most 
other cancers passive immunization methods are more likely to be 
successful8.
However, it should be kept in mind that when the tumor cells do not 
express MHC (hurdle 5), all T cell mediated therapies will fail to impact 
on the tumor. Still, NK cell based immuno therapies may have potential in 
this situation. However, NK cell mediated therapies fall outside the scope 
of this thesis.
Although up to this day active therapeutic immunization in patients 
suffering from non-virally induced tumors has never generated 
satisfactory results, we tested the effect of a peptide vaccine adjuvanted 
with GM-CSF and tetanus toxoid in end stage melanoma patients in the 
hope that this combination might sort some effect. In the second chapter 
the results of this study are presented and discussed.
The development and evaluation of a novel active immunization 
method
Active specific immunization using DNA offers several advantages over 
peptide vaccines: low production costs, flexibility in the use of antigen 
(resulting from the relief of constraints posed by large scale protein 
or peptide production), and remarkable keeping qualities. However, a 
major disadvantage of DNA vaccines is their modest potency and the 
length of the canonical DNA vaccination regimen24. In addition, there 
have been doubts about its safety, as theoretically the vaccine could 
integrate in the genome of host cells. These concerns however were 
soothed in recent trials.
Since the first report of successful DNA vaccination in the early nineties25;26, 
most DNA vaccines have been administered either intramuscularly by 
injection or intradermally using a gene gun27. Originally, the gene-gun 
principle was developed to shoot DNA through the tough cellulose wall 
of plant cells, using DNA coated to gold or tungsten bullets28. Although 
animal cells do not have this cellulose shell, the bullet principle 
became a standard for human tissue transfection as well. Through the 
years however, many other means of dermal DNA injection have been 
developed. Examples are the Med-E-Jet29, the Pigjet30 the Biojector31 and 
the Medijector32. Most of these tools pneumatically inject an aerosolized 
DNA solution in the skin. Yet other methods include topical skin creams33 
and even the use of polynucleotide coated suture34. Furthermore, oral 
and intranasal administration of DNA vaccines are currently explored as 
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well35. All these dermal administration methods are high-tech, requiring 
dedicated instruments and batches of specially prepared DNA. 
In the work described in chapter 3 we set out to improve the main 
weaknesses of DNA vaccination: its time consuming regimen and its 
feeble potency. In order to achieve this we explored antigen production 
and presentation after intramuscular and dermal DNA vaccination. 
To deliver the DNA intradermally we employed a very low-tech 
administration method: a tattoo device.
Since most DNA immunization methods that were proven to be effective 
in mice failed in larger species (i.e. in apes, monkeys and humans36) we 
tested the DNA tattoo method introduced in chapter 3 in a small Macaca 
Mulatta immunization study. The results of this study are described in 
chapter 4.
Requirements for antigens encoded in DNA vaccines
An increasing amount of evidence in mouse models points out that 
dermal DNA vaccines depend on cross presentation37. Additionally, cross 
presentation has been identified as an important step in the induction of 
T cell responses against tumors38. 
What determines the efficacy of the cross-presentation of antigens? 
In other words, what protein characteristics are required for optimal 
transfer from the antigen producing cells (the “antigen donor cells”) to 
the antigen presenting cells, and why? Understanding the selectivity in 
cross-presentation could reveal some tricks that pathogens or tumors 
may play to avoid presentation. Moreover, it would be very useful for the 
optimization of dermal DNA vaccines as well.
In chapter 5 the results of a study on the impact of the antigen stability 
on the efficiency of its cross presentation are presented. These data shed 
light on the in vivo mechanism of cross presentation. Furthermore, they 
are highly relevant for the design of DNA vaccines.
The development of tools for vaccine research
The efforts to improve intradermal DNA vaccination are hindered by 
a lack of knowledge about its mechanism. To clarify the mechanisms 
involved in dermal DNA vaccination we developed a tool that enables us 
to follow the cellular events in the dermis after DNA tattooing. The tool 
comprises a intravital microscopy method and is presented in chapter 
6.
Since the efficacy of any T cell inducing vaccine is predominantly defined 
by the number and the cytotoxicity of the T cells that it induces, sensitive 
and specific T cell detection tools are pivotal for the development 
of vaccines. Historically, T cells directed towards a certain antigen 
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could only be discriminated from the rest of the T cells in ‘functional’ 
assays: T cells produce cytokines upon incubation with their cognate 
antigens, discerning them from naive or non-specific T cells. With the 
advent of fluorochrome labeled MHC/peptide tetramers T cells could 
be discriminated from each other directly, by the specificity of their 
TCR, irrespective of their functionality. Moreover, the ease of tetramer 
stainings facilitated the analysis of the kinetics of T cell responses39.
However, tetramer analysis in laboratory animals and patients requires 
knowledge of the MHC haplotype of the individual, since tetramers 
are inherently MHC restricted. Combined with the complexity of their 
production, this MHC restriction has discouraged the use of tetramers 
in outbred (non MHC identical) primates and humans. Furthermore, it 
has hindered the development of high throughput methods for T cell 
analysis, for example by tetramer arrays40. A significant improvement in 
the production process of tetramers is described in the seventh and last 
chapter of this thesis. Besides facilitating the use of tetramer analysis in 
outbred populations, it will facilitate novel means of high-throughput T 
cell analysis. 
Overview of the work described in this thesis
The first chapter, entitled “On the role of melanoma-specific CD8+ T cell 
immunity in disease progression of advanced-stage melanoma patients”, 
describes the meager impact of T cells on disease progression in 
malignant melanoma patients. Subsequently, the second chapter “Phase 
I clinical study with multiple peptide vaccines in combination with 
tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive 
melanoma patients”, reports the results of a peptide vaccination study 
in such patients.
After reading through the disappointing results of this trial, the spirit 
may be brightened by the prospect of a new experimental immunization 
method. The article reporting on the efficacy of this “ DNA tattoo” method 
in mice is entitled “A rapid and potent DNA vaccination strategy defined 
by in vivo monitoring of antigen expression”. Chapter 4 “Intradermal 
DNA tattooing primes robust T cell responses in Macaca Mulatta” reports 
on the results of a small rhesus macaque study, intended to evaluate this 
immunization method in larger animals.
Chapter 5 addresses a fundamental immunological question: what 
properties should a vaccine encoded protein that is produced in the 
upper layer of the skin upon DNA tattooing have for efficient shipping to 
the DLN and presentation to T cells that reside there? The paper entitled 
“In vivo antigen stability affects vaccine efficacy” at the end of this 
chapter identifies one important property: it should be a stable protein.
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The sixth chapter, “High-throughput intravital imaging of fluorescent 
markers and FRET probes by DNA tattooing”, describes a method 
to microscopically study the cellular events in the skin of living mice 
following DNA tattooing. The insights gained from these studies may be 
useful for a better insight in immunological processes in the skin and 
especially for the improvement of dermal DNA immunization methods.
The final chapter, entitled “Design and use of conditional MHC class I 
ligands”, describes a novel method to produce MHC-peptide tetramers. 
The technology facilitates new methods for high-throughput enumeration 
of T cells with multiple specificities. 
i
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Abstract
Cytotoxic T-cell immunity directed against melanosomal differentiation antigens 
is arguably the best-studied and most prevalent form of tumor-specific T-cell 
immunity in humans. Despite this, the role of T-cell responses directed against 
melanosomal antigens in disease progression has not been elucidated. To address 
this issue, we have related the presence of circulating melanoma-specific T 
cells with disease progression and survival in a large cohort of patients with 
advanced-stage melanoma who had not received prior treatment. In 42 (68%) of 
62 patients, melanoma-specific T cells were detected, sometimes in surprisingly 
large numbers. Disease progression during treatment was more frequent in patients 
with circulating melanoma-specific T cells, and mean survival of patients with 
circulating melanoma-specific T cells was equal to the survival of patients without 
melanoma-specific T cells. These data suggest that the induction of melanosomal 
differentiation antigen-specific T-cell reactivity in advanced stage melanoma is a 
late event most likely due to antigen load and spreading and is not accompanied 
by a clinically significant antitumor effect. These melanoma-specific T cells may 
be functionally distinct from T cells raised during spontaneous regression or upon 
vaccination.
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Introduction
Melanoma is considered one of the most immunogenic tumors. Spontaneous 
remissions occasionally occur in melanoma patients albeit infrequently 
and immunotherapy-induced remissions correlate with autoimmune skin 
depigmentation (1, 2, 3, 4). These phenomena have, at least in part, been attributed 
to a cellular immune response, because the presence of tumor-infiltrating T 
lymphocytes in primary melanoma and in melanoma lymph node metastases are 
independent positive prognostic factors (5 , 6).
In past years, extensive efforts to identify target molecules for melanoma-reactive 
T cells have resulted in the identification of a large set of melanoma-associated 
antigens (7). These antigens can be classified as melanocyte lineage-specific antigens 
(MART-1/Melan-A, tyrosinase, gp100) and antigens derived from genes expressed 
in testis and a variety of cancers (including MAGE-family, NY-ESO-1, PRAME). 
Melanocyte lineage antigens are expressed in a large fraction of melanomas, and a 
substantial number of epitopes from these antigens that are recognized by cytotoxic 
T cells have been mapped (8). With the aid of soluble tetramerized MHC complexes 
containing these epitopes, melanosomal antigen-specific CD8+ T cells have been 
detected in peripheral blood from melanoma patients (9). Large expansions of these 
T cells are primarily observed in the peripheral blood or tumor-infiltrated lymph 
nodes from stage III and particularly stage IV melanoma patients. In patients with 
tumors that are confined to the primary site, such as in stage I and II melanoma, MHC 
tetramer-positive T cells have been found, but at significantly lower frequencies (10) 
. Despite the presence of naturally occurring melanoma-specific T-cell immunity 
in a large proportion of melanoma patients, spontaneous remissions in this group 
of patients are extremely rare and it is currently unclear what the significance is of 
spontaneous melanoma-specific T-cell immunity for these patients.
Patients & Methods
Patients.
Peripheral blood samples were taken from 62 HLA-A*0201 advanced-stage 
melanoma patients (stage IV) at the time that they had been diagnosed with 
metastatic melanoma. None of the patients had undergone prior treatment for 
metastatic melanoma. Patients were treated with standard chemotherapy with or 
without cytokine therapy mostly as part of a clinical trial (11), as indicated in Table 1
MHC Tetramers.
MHC class I tetrameric complexes were prepared as previously described with minor 
modifications (12). HLA-A2.1-peptide complexes were generated with the following 
five antigenic peptides: (a) influenza-A matrix
58–66
; (b) GILGFVFTL, MART-
1
26–35
; (c) ELAGIGILTV (A27L variant 13); (d) tyrosinase
368–376
, YMDGTMSQV 
(N370D variant 14); and (e) gp100
280–288
, YLEPGPVT (A288V variant 15). MHC 
class I-peptide complexes were subsequently purified, biotinylated by biotin 
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ligase, purified and converted to tetramers by the addition of phycoerythrin-labeled 
streptavidin (Molecular Probes), and stored at –20°C in 16% glycerol/0.5% BSA.
MHC-Tetramer Staining.
It has previously been shown that CD8 can play a critical role in the binding of 
MHC tetramers to antigen-specific T cells (16, 17, 18) . In particular, in case of low-
affinity T-cell receptors, the simultaneous binding of CD8 to the MHC α3 domain 
is necessary to obtain a sufficiently stable complex between MHC tetramers and 
antigen-specific T cells, and in such cases, costaining with CD8 can block MHC 
tetramer binding (16, 17, 18) . In line with this, we observed diminished MHC tetramer 
staining of a tyrosinase-specific T-cell clone in the presence of CD8 monoclonal 
antibody. Likewise, a large fraction of the tyrosinase-specific CD8+ T cells in the 
peripheral blood of advanced-stage melanoma patients became undetectable by 
MHC tetramer staining in the presence of CD8 monoclonal antibody (data not 
shown). To overcome this issue, peripheral blood mononuclear cells (PBMCs) 
were stained with a set of lineage (lin) marker antibodies specific for B-cells 
(CD19), natural killer cells (CD16), monocytes (CD14) granulocytes (CD13), and 
CD4+ T cells (CD4), and the linnegative lymphocyte subset was used for analysis. 
Linnegative lymphocytes are >95% CD8-positive and HLA-A2.1/tyrosinase tetramer-
positive cells within the linnegative population are likewise >95% CD8-positive, 
thereby validating this strategy (Fig. 1)
Thawed PBMC samples were incubated overnight at 37°C in Iscove’ s medium 
with 10% FCS to recover PBMCs and eliminate apoptotic cells (9) . After washing, 
the cells were incubated for 5 min in cold PBS with 0.5% BSA and 1% normal 
mouse serum to block Fc-receptors. Two million cells per sample were incubated 
for 10 min with 2 µg/ml phycoerythrin-labeled MHC-tetramer at 37°C (19). CD8+ T 
cells were negatively selected by staining with a large set of FITC-labeled lineage 
marker antibodies (CD4, CD13, CD14, CD16, CD19; Becton-Dickinson). Cells 
were stained with propidium iodide to be able to gate out dead cells. Samples were 
analyzed by flow cytometry using a FACScalibur and Cell Quest software (Becton 
Dickinson). Forward and side scatter parameters were used to define lymphocyte 
populations. 
Background and detection limits were separately established for each tetramer by 
staining of PBMCs from four HLA-A2-negative individuals with phycoerythrin-
labeled MHC-tetramers and the panel of FITC-labeled antibodies. If more than 
50,000 CD3+/CD8+ cells could be analyzed by flow cytometry in the HLA-A2-
positive samples, the mean percentage of MHC-tetramer positive cells +3x SD of 
four HLA-A2-negative PBMC samples was used as the detection limit for positive 
MHC-tetramer staining. If less than 50,000 CD3+/CD8+ cells could be analyzed, the 
mean percentage +6x SD was used as the detection limit.
Immunohistochemistry.
ON THE ROLE OF MELANOMA-SPECIFIC CD8+ T-CELL IMMUNITY IN PROGRESSION OF ADVANCED-STAGE MELANOMA 
27
Formalin-fixed paraffin-embedded material of melanoma metastases was 
available from 17 of 62 patients. Sections (4-µm) were stained for MART-1 
(Ab-3; Neomarkers; 1:250), tyrosinase (clone T311; Neomarkers; 1:100), gp100 
(HMB-45; DAKO; 1:200) or HLA-A (HC-A2; generously donated by J. Neefjes, 
Netherlands Cancer Institute, Amsterdam; 1:400). For all stainings except for 
gpl00, microwave antigen retrieval in citrate buffer was performed. Stainings were 
performed with standard alkaline-phosphatase three-step immunohistochemistry. 
Statistics.
End point of the study was overall survival, measured from start of treatment 
until death or last follow-up. Patients alive at the time of analyses were censored. 
Survival estimates and curves were made with the Kaplan-Meier technique, and 
differences between groups were tested by a log-rank test. Cox proportional 
hazard analysis was used to estimate the size of the effect (hazard ratio) with 95% 
confidence intervals. The relation of MART-1 with response (in three categories) 
was tested by a Cochrane-Armitage trend test. Wilcoxon test was used to perform 
a statistical analysis on the phenotypical characteristics that distinguish naïve and 
effector/memory MART-1-specific T cells. 
Results
Patients.
Between 1998 and 2002, 62 HLA-A*0201-positive patients were enrolled (Table 
1). All patients had advanced-stage melanoma (stage IV) with a median organ 
involvement of 2 (range 1–5). The majority (42 of 62) of the patients had visceral 
metastases, mostly in lung and/or liver. Nonvisceral metastases (20 of 62) were 
most often located in lymph nodes and subcutis. Five patients were treated with 
standard dacarbazine (800 mg/m2, every 3 weeks), 10 patients were treated with 
temozolomide (200 mg/m
2
 for 5 days, every 4 weeks) and 47 patients were treated 
with combined chemobiotherapy (temozolomide for 5 days, triple cytokine 
interleukin 2, interferon-α, granulocyte macrophage colony-stimulating factor for 
12 days, every 4 weeks). The latter two treatments were given as part of Phase II 
and III clinical trials.
Analysis of Patient-Derived Peripheral Blood Samples.
Peripheral blood samples were obtained before initiation of therapy and were 
analyzed for the presence of melanoma-specific CD8+ T cells (Fig. 2) . In 33 
patients (53%) MART-1-specific CD8+ T cells were detectable, and 17 patients 
(27%) displayed expansions of tyrosinase-specific CD8+ T cells. Eight of these 
latter patients also had MART-1-specific T cells. Only 1 patient tested positive 
for gp100-specific CD8+ T cells; this patient also had high numbers of circulating 
MART-1-specific T cells (18% of total CD8+ T-cell pool). In the vast majority of 
samples that contained tyrosinase-specific T cells, these CD8+ T cells were clearly 
detectable when counterstained using the panel of lineage marker antibodies but 
were difficult to detect when costaining with anti-CD8 antibody was performed. In 
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line with this, the avidity of tyrosinase-specific T cells appears lower than that of 
MART-1- or gp100-specific T cells, as judged from the intensity of MHC tetramer 
staining. As a control, influenza A virus-specific CD8+ T cells could be detected in 
70% of patients analyzed (n = 36). In the majority of patients [27 (64%) of 42] with 
MHC tetramer+ T cells, the frequencies of melanoma-specific T cells in peripheral 
blood were above 1:1000 CD8+ T cells, ranging from 1:6 to 1:900.
MART-1-specific CD8+ T cells have been detected in the peripheral blood of healthy 
individuals in frequencies up to 1 of 1,000 (20). Data from Dutoit et al. (21) indicate 
that these populations are a direct reflection of a high thymic output of T cells with 
this specificity, and, in line with this, these MART-1-specific T cells display a naïve 
phenotype. To establish whether the MART-1-specific T-cell populations detected 
in our cohort arose through antigen-driven expansion, the MHC tetramer-positive 
CD8+ T cell subset was analyzed directly ex vivo for cell surface expression of 
naïve-, effector-, and memory-type-associated markers. In humans, the CD45RA 
and CD45RO surface antigens have been used to identify naïve and memory T 
cells, respectively, and costaining for CD27 expression may be used to distinguish 
between effector cells and naïve or memory T cells (22). Using the Wilcoxon test, 
we found two statistically distinct patterns of cell surface expression (Table 2) . 
In patients with low but detectable frequencies (< 0.2%) of MART-1-specific T 
cells, expression of CD45RA and CD27 were high (P = 0.033 and P = 0.0015, 
respectively); and expression of CD45RO was low (P = 0.0004). This pattern of 
cell surface expression reflects a naïve phenotype. In contrast, in patients with high 
frequencies (> 0.5%) of MART-1-specific T cells CD4RO expression was high, 
whereas expression of CD45RA and CD27 was often reduced as compared with 
naïve T cells. In patients with 0.2–0.5% MART-1-specific T cells, both naïve and 
antigen-experienced phenotypes were found.
In summary, in line with prior data (20), two groups of patients can be distinguished: 
one group [15 (45%) of 33 with low numbers of MART-1-specific CD8+ T cells 
in peripheral blood and a second group [18 (55%) of 33] with high numbers 
of MART-1-specific T cells. The phenotype of the MART-1-specific T cells of 
the majority of these patients has been analyzed; the analysis confirms that in 
patients with low numbers of MART-1-specific T cells, these cells display a naïve 
phenotype, whereas those cells in patients having high numbers are phenotypically 
antigen experienced. 
Melanoma-Specific T cells and Survival.
Although the presence of melanocyte differentiation antigen-specific T cell 
immunity in patients with stage IV disease is well documented, the relevance 
of these T-cell responses in terms of response to treatment or survival remain 
unknown. We, therefore, attempted to relate the presence of melanoma-specific T 
cells to survival in this large cohort of HLA-A*0201+ stage IV melanoma patients. 
Median follow-up was 46 months. At the time of analysis, 55 patients had died 
and the median survival of all patients was 7.8 months (Fig. 3 ; 95% confidence 
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interval, 6.0–9.7 months). This is in close agreement with the median survival 
observed in several randomized clinical trials using dimethyltriazeno-imidazole-
carboxamide- or temozolomide-based treatment regimens for advanced-stage 
melanoma patients (23 , 24). 
To test whether the presence of circulating melanoma-specific CD8+ T cells was 
related to clinical outcome, survival of patients that had detectable numbers of 
circulating melanoma-specific T cells was compared with those without these 
cells (Fig. 4A). This analysis revealed that the presence of T cells specific for 
melanocyte lineage antigens is not associated with a survival benefit (log-rank, P 
= 0.354). Survival curves of patients with either MART-1 or tyrosinase-specific T 
cells compared with patients without any melanoma-specific T cells, likewise, do 
not show any detectable survival advantage (P = 0.721 and P = 0.346 respectively; 
Fig. 4, B and C). To test whether a possible antitumor effect would manifest itself in 
patients with MART-1-specific T cells displaying an effector/memory phenotype, 
survival was also analyzed for this group (n = 8; Fig. 4D). No statistically 
significant difference between survival of patients with effector/memory T cells 
and those without circulating T cells was observed (log-rank, P = 0.224).
In summary, the presence of melanoma-specific T cell populations in peripheral 
blood does not lead to a survival benefit for patients with advanced-stage 
melanoma. 
We considered the possibility that the melanoma-specific T cells we observed could 
have a limited capacity to kill tumor cells, for instance, because of a low avidity. In 
such a scenario, a high T-cell response would not predict a subsequent antitumor 
effect but would merely be a reflection of a growing tumor mass. To test this 
hypothesis, patients were divided into three groups: those with disease progression 
within 2 months after blood sampling, those with stable disease, and those with 
partial/complete response within this time period. When comparing these groups 
for the presence of circulating MART-1-specific T cells, we found a statistically 
significant (two-sided P = 0.0133, Cochran-Armitage trend test) predominance 
of high numbers (≥0.1%) MART-1 specific T cells in the group of patients with 
progressive disease in the first 2 months after blood sampling (Table 3)
Immune Escape through Loss of HLA-A Expression.
Tumors may evade the action of tumor-specific T cells by down-regulation of either 
MHC class I cell surface expression or by reducing antigen expression. To address 
this issue, we examined antigen and HLA-A expression by immunohistochemistry 
in tumor material that was available from only 17 of the 62 patients (data not 
shown). All 17 melanoma metastases expressed MART-1 and tyrosinase, whereas 
gp100 expression was homogeneously expressed in tumor material of 13 of 17 
patients. Twelve of these 17 patients had circulating MART-1-specific T cells, 3 
patients had tyrosinase-specific T cells, and 1 patient had gp100-specific T cells. 
In 7 of 17 metastases, HLA-A expression was lost. Lack of HLA-A expression was 
observed in 5 of 12 metastases from patients with detectable melanoma-specific T 
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cells, and 2 of 5 patients without detectable melanoma-specific T cells. These data 
demonstrate that although MHC class I loss does not directly correlate with the 
presence of detectable tumor-specific T-cell responses, the frequent occurrence of 
class I loss suffices to explain the lack of antitumor effect in a substantial fraction 
of the advanced-stage melanoma patients.
Discussion
Several groups have reported the presence of naturally occurring melanoma-specific 
T-cell reactivity in melanoma patients (7 , 9 , 25, 26, 27, 28, 29, 30, 31), but little is known on 
the time frame of appearance and even less on the possible role of these cells in 
limiting tumor outgrowth. To address this issue, we have examined spontaneous 
cytotoxic T-cell immunity against melanosomal antigens, MART-1, tyrosinase, and 
gp100 in a large group of advanced-stage (IV), HLA-A*0201-positive melanoma 
patients and have correlated these responses with patient survival. T-cell responses 
were analyzed before the initiation of treatment and should, therefore, reflect the 
natural response of the immune system to the growing tumor mass. 
These data demonstrate that, in accordance with other studies, substantial 
expansions of CD8+ T cells specific for melanosomal antigens can occur in patients 
with metastatic disease, amounting up to 18% of the total CD8+ T-cell population 
in peripheral blood. Importantly, these high numbers of tumor-specific CD8+ T cells 
do not have a measurable positive influence on patient survival. 
Although the primary goal of this study was to evaluate a postulated benefit of 
spontaneous melanocyte lineage-specific T-cell responses, it may be useful to 
discuss these data in relation to immunotherapeutic approaches in this patient group. 
Several mechanisms may account for the fact that the T-cell populations specific 
for these melanoma antigens do not measurably impinge on tumor growth, and, 
depending on the mechanism involved, immunotherapeutic approaches that aim 
to strengthen these responses may or may not be worth pursuing. We considered 
two mechanisms: “immune escape” and “insufficient number or activity of tumor-
specific T cells. 
With regard to immune escape, tumors may evade the action of tumor-specific 
T cells by down-regulation of either MHC class I cell surface expression or by 
reducing antigen expression. In the tumor samples available for this study, we 
found loss of HLA-A expression in a substantial portion of the cases, whereas in all 
of the cases, antigen expression was maintained. This frequent occurrence of class 
I loss suffices to explain the lack of antitumor effect in a substantial fraction of the 
advanced-stage melanoma patients. In addition, it cannot be excluded that in part of 
the remaining cases, escape from T-cell attack is achieved by other means. 
With regard to insufficient number or activity of tumor-specific T cells, in 7 of 12 
patients with detectable tumor-specific T-cell reactivity, there was no concomitant 
loss of HLA-A or antigen expression. It is tempting to speculate that in these 
patients the number and/or activity (be it either homing capacity or cytolytic 
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function) of the tumor-specific T cells was insufficient to mediate a significant 
antitumor effect. Because vitiligo is associated with successful immunotherapy (1, 2, 
3, 4), further indirect evidence for this notion is provided by the observation that none 
of the 42 patients with detectable T-cell responses against melanosomal antigens 
showed signs of vitiligo. Lack of vitiligo despite substantial numbers of T cells in 
some of the patients may point to functional differences between T cells induced by 
immunotherapy and the spontaneous responses observed in this study. 
MHC tetramers used in this study are indicative of the T-cell receptor specificity 
of the different melanoma-associated antigen-specific T-cell populations. It has 
been demonstrated that MHC tetramer binding does not always fully correlate with 
functionality (32). However, in one patient the available blood samples did allow 
simultaneous MHC tetramer and intracellular IFN-γ staining. In this patient with 
high numbers of both MART-1 and gp100-specific T cells, intracellular IFN-γ was 
produced against peptide-pulsed target cells directly ex vivo. This result, however, 
does not preclude the possibility that for other patients the detected melanoma-
specific T-cell populations were nonfunctional or tolerized. 
On the basis of the current data, it seems that spontaneously occurring melanocyte 
lineage-specific immunity in stage IV melanoma patients is largely a reflection of 
increasing tumor mass and spreading, and stage IV melanoma patients are unlikely 
to benefit from these immune responses other than in exceptional cases. These 
melanoma-specific T cells may be functionally distinct from T cells that play a role 
in situations of spontaneous regression that rarely occur in these patients or from T 
cells that are detected on successful immunotherapy. Escape from immunity by loss 
of expression of target molecules either by immune selection or genetic instability 
of tumor cells forms one major factor that limits the effect of tumor-specific CTLs 
in part of this advanced-stage patient group. In the remaining patients, the limited 
efficacy of the tumor-specific T-cell response may well be related to the poor 
quality and suboptimal numbers of tumor-specific T cells at early time points 
during the disease. Efforts to enhance these responses by vaccination strategies or 
through adoptive therapy are, therefore, worth pursuing and are meeting increasing 
success (4 , 33 , 34). 
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 Table 1 Patient characteristics 
NO. OF PATIENTS 62
MEDIAN AGE 48 YR (RANGE, 21–79 YR)
SEX
FEMALE 24 (39%)
MALE 38 (61%)
METASTATIC SITES, N (MEDIAN) 2 (1–5)
VISCERAL 42 (68%)
NONVISCERAL 20 (32%)
SERUM LACTATE DEHYDROGENASE (MEDIAN) 370
TREATMENT
DTICA 5 (5.1%)
TEMOZOLOMIDE 10 (6.2%)
CHEMOBIOTHERAPY 47 (76%)
a DTIC, dimethyltriazeno imidazole carboxamide.
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Fig. 1. Peripheral blood cells were stained with HLA-A2.1 tetramers containing the 
tyrosinase
368–376
 peptide followed by staining with a panel of lineage antibodies, as 
described in “Patients and Methods.” Cells were analyzed by flow cytometry (left 
panel), and lineage antigen negative and MHC tetramer-positive cells were sorted 
by fluorescence-activated cell sorting (Cell sorting). Enriched MHC tetramer-
positive, lineage antigens negative cells (middle panel) were briefly incubated at 
37°C, stained with CD8 monoclonal antibody, and reanalyzed by flow cytometry 
(right panel). Typically >95% of these cells are CD8+.
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Fig. 2. A, representative dot plots of MHC-tetramer staining versus lineage 
antibodies. Top three panels, HLA-A*0201 melanoma patients (HLA-A2+) 
with detectable MART-1
26–35 (27L)
-, tyrosinase
368–376 (370D)
-, and gp100
280–288 (288V)
-
specific CD8+ T cells in peripheral blood. Bottom three panels, control staining 
of HLA-A2.1-negative melanoma patients (HLA-A2–) with HLA-A2.1/MART-1, 
tyrosinase, and gp100 tetramer. 
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B, scatter diagram of all patients with circulating melanoma-specific T cells, 
separated by antigen-specificity (MART-1, tyrosinase, or gp100). On the basis 
of the literature, presence of naïve MART-1-specific T cells (MART-sp. T cells) 
amounts to about 0.1% (20) . Tm-positive, MHC tetramer-positive.
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PATIENT NO. CD45RA (%) CD27 (%) CD45RO (%) CCR7 (%)
MART-
1-SPEC.A T 
CELLS (%)
GROUP A
NKI9822 92 93 17 NT 0.5
NKI9834 100 100 45 NT 0.2
NKI9829 85 80 15 NT 0.2
NKI9852 75 100 30 NT 0.2
NKI9839 65 83 28 NT 0.1
NKI9843 91 100 0 NT 0.1
NKI9818 75 100 13 NT 0.1
NKI0032 91 79 9 82 0.1
NKI0057 94 95 23 76 0.05
GROUP B
NKI9835 34 64 76 NT 17.3
NKI9836 51 31 52 NT 2.8
NKI9828 81 26 51 NT 2.6
NKI9849 14 97 98 NT 0.9
NKI9810 30 38 87 NT 0.9
NKI0002 99 31 64 1 0.5
NKI0043 3 27 93 3 0.2
NKI0021 84 54 28 7 0.2
a MART-1-spec., MART-1-specific; nt, not tested.
Table 2 Naïve versus effector/memory phenotype of MART-1-specific T cells. 
Panel antibody negative and MHC tetramer-positive T cells were costained with the 
indicated antibodies. Numbers represent percentages surface antigen positive cells 
from total MART-1-specific CD8+ T cells. On the basis of differential expression of 
CD45RA, CD45RO, and CD27, patients with circulating MART-1-specific T cells 
can be divided into two statistically distinct groups, A and B. Group A, MART-
1-specific T cells displaying a naïve phenotype with high CD45RA (Wilcoxon 
test, 2-sided P = 0.033), high CD27 (Wilcoxon test, 2-sided P = 0.0015), and low 
CD45RO (Wilcoxon test: 2-sided P = 0.0004). When tested, CCR7 expression was 
high, supporting a naïve phenotype. The frequency of these T cells in peripheral 
blood is low, mostly <0.2% of peripheral CD8+ T-cell pool. Group B, MART-1-
specific T cells present at higher frequency in peripheral blood (mostly <0.5% 
of CD8+ T-cell pool) display an effector/memory phenotype with mostly high 
expression of CD45RO and low CCR7 expression (when tested). 
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Fig. 3. Kaplan-Meier survival curve of total cohort of HLA-A*0201+ stage IV 
melanoma patients. The median survival is 7.8 months (95% confidence interval, 
6.0–9.7 months) with 55 deaths.
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Fig. 4. Kaplan-Meier survival curves of HLA-A*0201+ patients with and without 
circulating melanoma-specific T cells. A, MART-1, tyrosinase- and gp100-specific 
CD8+ T cells; log-rank P = 0.354; hazard ratio, 1.32 [95% confidence interval (CI), 
0.74–2.33]. 
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B, tyrosinase-specific T cells only; log-rank P = 0.721; hazard ratio, 0.89 (95% CI, 
0.48–1.63). C, all MART-1-specific T cells; log-rank P = 0.346; hazard ratio, 1.29 
(95% CI, 0.75–2.21). D, established effector/memory MART-1-specific T cells (n 
= 8); log-rank P = 0.224.
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Table 3 Expanded MART-1-specific T cells preferentially in patients with 
rapid progressive diseasea. Patients were divided into three groups depending 
on their evaluated response to two courses of treatment. Treatment consisted of 
chemotherapy ± biotherapy (see Table 1 ). Responses were evaluated according 
to RECISTb criteria (35). The presence of expanded (>0.1%) MART-1-specific cells 
was compared with the presence of no or few MART-1-specific T cells (<0.1%). 
MART-1-SPECIFIC CD8+ T CELLS
RESPONSE <0.1% >0.1% TOTAL
CR/PR 12 2 14
SD 11 0 11
PD 21 16 37
TOTAL 44 18 62
a Statistical analysis was performed with Cochran-Armitage trend test. 
b RECIST, response evaluation criteria in solid tumors; CR/PR, complete or partial 
response; SD, stable disease; PD, progressive disease. 
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Phase I clinical study with multiple peptide 
vaccines in combination with tetanus toxoid 
and GM-CSF in advanced-stage HLA-A*0201-
positive melanoma patients.
Abstract
Successful induction of functional tumor specific T cells by peptide vaccination in 
animal models has resulted in many clinical trials to test this approach in advanced-
stage melanoma patients. In this phase I clinical trial, 11 end-stage melanoma 
patients were vaccinated intradermally with three peptides: MART-1 
(26-35)
 E27L 
(ELAGIGILTV), tyrosinase 
(368-376)
 N375Q (YMDGTMSQV) and gp100
(209-217)
 
T210M (IMQVPFSV), admixed with Tetanus Toxoid and GM-CSF. The peptide 
vaccine was well tolerated at all tested doses, and led to grade 1-2 toxicity only. 
Although all patients did show a rise in anti-tetanus IgG titers, in only three patients 
peptide-specific CD8+ T cells were induced. In two cases the response was directed 
against MART-1(26-35) and consisted of 0.2% and 3.3% of the CD8+ population; 
however, in both instances these cells did not produce IFN-γ on stimulation with 
the unmodified peptide. The third patient mounted a small (0.1%) respons against 
GP100. In a fourth patient a non-functional tyrosinase specific response (0.6%) 
was found that was present prior to vaccination, but was not affected in size nor 
in function by the vaccine. None of the 11 patients responded clinically according 
to RECIST criteria. Although this study is a small scale phase I clinical trial, the 
efficacy that was observed was disappointingly low. In accordance with previously 
published peptide vaccination studies, these results add to the increasing evidence 
that peptide vaccination in itself is not potent enough as an effective melanoma 
immunotherapy in advanced-stage patients.
A. Bins, H. Mallo, J. Sein, F. Vyth-Dreese, B. Nuijen, G. de Gast and J. 
Haanen
Division of Immunology; Division of Medical Oncology; Division of Clinical 
Chemistry, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX 
Amsterdam, the Netherlands.
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Introduction
Malignant melanomas express a range of tumor associated antigens (TAAs) (1) 
that can potentially serve as targets for T cell attack. Although tumor specific T 
cells can be detected in many end stage melanoma patients (2), the spontaneous 
occurrence of effective T cell responses, leading to tumor regression, is very rare. 
Therefore, the successful induction of functional tumor specific T cells in animal 
models using peptide vaccination (3;4), has resulted in various clinical trials to test 
this approach in melanoma patients.
In this phase I study, we tested a peptide vaccination strategy based on a novel 
combination of features to increase vaccine efficacy (5-10). 1) The vaccine 
consisted of three separate melanocyte differentiation antigen derived peptide 
vaccines, in order to widen the tumor specific T cell repertoire stimulated by the 
vaccine (6;10) : MART -1 
(26-35) 
E27L (ELAGIGILTV)(11), Tyrosinase 
(368-376) 
N375Q 
(YMDGTMSQV) (12) and GP100 
(209-217)
 T210M (IMQVPFSV)(12). The anchor 
residues in these peptide sequences are modified to improve HLA-A*0201 binding 
(7). 2) As it has been shown to exert immunostimulatory functions in the treatment 
of end stage melanoma, granulocyte-monocyte colony stimulating factor (GM-
CSF) was added to the vaccine (13). 3) Additionally, in order to facilitate T cell help 
(14), Tetanus Toxoid was admixed as well. Tetanus Toxoid consists of formaldehyde 
treated, inactivated tetanus toxin and contains pan-DR epitopes (PADREs) (15) that 
can be presented in the context of multiple MHC class II molecules. 4) All injections 
were given subcutaneously (8) in adjuvant Montanide ISA-51 (16). Furthermore, each 
of the peptide vaccines was injected on a separate location, to avoid competition 
for HLA-A*0201 binding during antigen presentation by antigen presenting cells 
(APCs) (5). 
Considering the lack of correlation between disease prognosis and the presence of 
tumor specific cells after peptide vaccination (17;18), we assessed the effect of the 
vaccination by analyzing both the expansion and the functionality of the induced T 
cell populations. For this purpose, we performed tetramer and ELIspot analyses of 
blood samples collected before and after vaccination. In addition, we tested peptide 
specific delayed type hypersensivity (DTH) responses. 
Material and Methods
Stage IV melanoma patients that were HLA-A*0201 positive, above 18 years of 
age, having progressive disease after chemotherapy with or without non-specific 
immunotherapy, were eligible for the study. Additional criteria were a WHO 
performance score of 0 or 1, adequate bone marrow, renal and liver function 
(WBC>3.0/nl, platelets>100/nl, creatinine clearance > 50 ml/min, bilirubin < 
1.5xULN), a life expectancy of 3 months or more and signed informed consent.
Excluded from the study were patients with brain metastases larger than 2 cm in 
diameter or a second malignant disease. Patients that were pregnant or lactating, 
taking systemic corticosteroids or requiring antibiotics for severe infections were 
also excluded, as were those with severe cardiac, respiratory or metabolic disease, 
or HIV seropositivity.
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All patients received 4 vaccinations at 1 week intervals, each vaccination consisting 
of three separate subcutaneous injections of MART-1
(26-35)
, tyrosinase
(368-376)
 and 
gp100
(209-217)
, mixed with 10 EI Tetanus Toxoid and 100 µg GM-CSF in Montanide 
ISA-51. To prepare the mixtures, the peptides were dissolved in a 0.9% NaCl water 
solution, and 100ug GM-CSF and 10IE Tetanus Toxoid were added, to a total of 
1 ml. To this solution, 1.2 ml montanide ISA-51 was mixed by vigorous shaking, 
resulting in a homogeneous emulsion.
The injections were given subcutaneously, in the proximal part of a limb, in an 
area near draining lymph nodes (DLN). Patients that had undergone a lymph node 
dissection in the axilla region were vaccinated near the inguinal region, and vice 
versa. Two subsequent vaccinations were never placed in the same limb. The 
peptide dose was increased from 250μg in patients 1 to 4, to 500μg in patients 5 to 
8, to a maximum dose of 1000μg in patients 9 to 11.
Before start of the vaccination (week 0) and 5 weeks after the start of the study, 
blood samples were collected for analysis. The samples were analyzed for the 
presence of tumor specific T cells by tetramer staining as described previously 
(2). In short, thawed PBMC samples were incubated overnight at 37°C in Iscove’ s 
medium supplemented with 10% FCS to recover PBMCs and to eliminate apoptotic 
cells. After washing, the cells were incubated for 5 min in cold PBS with 0.5% BSA 
and 1% normal mouse serum to block Fc receptors. Two million cells per sample 
were incubated for 10 min with 2 µg/ml phycoerythrin labeled MHC-tetramer 
at 37°C and CD8pos T cells were negatively selected by staining with a large set 
of FITC-labeled lineage marker antibodies (CD4, CD13, CD14, CD16, CD19; 
Becton-Dickinson). Cells were stained with propidium iodide to be able to gate 
out dead cells. Samples were analyzed by flow cytometry using a FACScalibur and 
Cell Quest software (Becton Dickinson). 
Additionally, ELIspot assays were done, according to the instructions of the 
manufacturer (U-cytech biosciences, Utrecht, the Netherlands). Briefly, 96-well 
plates (Costar 3799) were incubated with coating antibody (U-cytech) overnight 
at 370 C., washed with phosphate buffered saline (PBS) and coated with coating 
buffer for 2 hours. Meanwhile, the patient PBL were thawed, washed and incubated 
1 hour in Iscoves Modified Dulbecco’s Medium (IMDM) supplemented with 5% 
Fetal Calf Serum (FCS) at 2x106 cells/ml. Next, the coating buffer was removed 
from the plate, 100µl cell suspension was brought in each well, peptides were 
added at concentrations of 1, 0.5, 0.25 or 0.1 µg/ml and the plate was incubated 
overnight at 370C. After removal of the cell suspension the plate was washed with 
PBS and developed according to the instructions of the manufacturer. The plates 
were read using bioreader 4000 pro-X ELIspot reader (Bio-sys, Karben, Germany). 
Elispot and tetramer T cell counts higher than 3x the standard deviation of a panel 
of negative controls were considered positive.
Furthermore, also at week 0 and week 5, an ELISA was performed to determine 
the Tetanus Toxoid specific antibody titer, together with a DTH test for reactivity 
against any of the three peptides. The DTH tests were read 48 hours after 
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application, and an induration of more than 5 mm was scored as positive. In the 
first 2 of the 11 patients, TT was admixed to the peptides solutions used in the DTH 
tests. However, this caused considerable discomfort and was left out in the rest of 
the tests. 
At 5 and 13 weeks after the vaccination, tumor progression was analyzed by 
Computer Assisted Tomography (CAT), Magnetic Resonance Imaging (MRI) or 
Positron Emission Tomography (PET) scans, and scored according to RECIST 
criteria.
The protocol was reviewed and approved by the Institutional Review Board of 
The Netherlands Cancer Institute / Antoni van Leeuwenhoek Ziekenhuis. All the 
patients signed for informed consent before participating in the clinical trial.
Results
11 patients were included in the study (table 1). All patients had unresectable stage 
IV disease, and had been treated with standard chemotherapy prior to enrollment. 
Four patients had received prior aspecific immunotherapy with GM-CSF, IFN-α 
and low dose IL-2 in combination with temozolomide.
At all tested doses the peptide vaccines were tolerated well, and led to grade 1-2 
toxicity only. All patients developed a local redness at the site of injection, leading 
to some discomfort. Four patients experienced systemic side effects, in two cases 
leading to some difficulty in performing activities of daily living (ADL). (Table 
2).
On vaccination, all patients except one showed a significant increase in tetanus 
toxoid specific antibody titers (Figure 1). On the contrary, peptide specific cellular 
T cell responses induced by the vaccines were much less consistent. 
At 5 weeks after the start of the vaccination, 3 of the 11 patients (27%) showed 
a significant increase in T cells specific for one of the peptides in the vaccine. 
In 2 of these patients the response was present prior to vaccination and directed 
against MART-1
(26-35)
 E27L (0.1% in patient I and 2.1% in patient II). In both 
patients, approximately a third of these cells were CD45RA negative, indicating 
recent antigen encounter. In patient I none of these pre-existing T cells could 
be detected in the ELIspot assay, but patient II showed some ELIspot reactivity 
prior to vaccination. The size of the tetramer positive populations in both patients 
increased upon vaccination with the MART-1
(26-35)
 E27L peptide (0.2% and 3.3%), 
and in both patients the responses became clearly detectable in the ELIspot assay, 
indicating a change in the capacity to secrete IFN-γ (Fig. 2a/b). 
The third patient that showed an increase in tumor specific T cells upon vaccination, 
did not have any circulating melanoma specific T cells prior to vaccination, but 
mounted a small gp100
(209-217)
 specific response (0.1%, Fig. 2c) and a MART-1
(26-35)
 
E27L specific response on vaccination (0.2%) , detectable by tetramer stain and 
ELIspot assay.
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Interestingly, in a fourth patient a sizable pre-existing tyrosinase
(368-376)
 specific 
response was detected by tetramer staining (0.8%) that decreased on vaccination 
(0.7%) and could not be detected by ELIspot neither before nor after vaccination 
(Fig. 2d). This suggested that these cells resided in a non-functional state that could 
not be reversed by the vaccination, contrary to the MART-1
(26-35)
 E27L specific T 
cells in patient I and II.
As an explanation for this difference we considered the fact that, in contrast 
to the modified MART-1
(26-35)
 E27L epitope, the posttranslationally modified 
tyrosinase
(368-376)
 N375Q epitope is naturally expressed by the tumor. Therefore, the 
tyrosinase
(368-376)
 specific T cells could be more liable to tolerization by the tumor 
then the MART-1
(26-35)
 E27L specific T cells. In order to assess the tumor cross-
reactivity of the MART-1
(26-35)
 E27L specific T cells, we repeated the MART-1
(26-35)
 
specific ELIspot and tetramer analyses, using the unmodified MART-1
(26-35)
 peptide 
(EAAGIGILTV) and cognate tetramers, produced by “exchange” technology (19). 
Similar pre-existing MART-1
(26-35) 
specific T cell numbers were detected using the 
unmodified MART-1
(26-35) 
tetramers (0.1% in patient I and 1.6% in patient II). The 
same applied for the MART-1
(26-35) 
specific T cell counts after vaccination (0.3% in 
patient I and 2.1% in patient II). Hence, compared to the modified version the same 
pattern emerged using unmodified MART-1
(26-35) 
tetramers. Strikingly however, 
using the unmodified peptide in the ELIspot assay no MART-1
(26-35) 
specific T cell 
reactivity could be detected in both of the patients after vaccination (Fig. 3a/b), in 
analogy to the tyrosinase
(368-376)
 response in patient IV.
Furthermore, none of the four patients scored positive in the DTH tests against any 
of the three peptides. Only the first two patients enrolled in the study, that received 
skin tests with Tetanus Toxoid admixed to the peptide, scored highly positive. As 
mentioned previously, this component was subsequently removed. 
Finally, none of the detected immune responses coincided with any clinical 
response. Although in one patient of the lowest dosing group, the tumor evaluation 
at week 5 and week 13 showed stabilization of the disease, no tumor specific T 
cells could be detected in the blood of this patient. Though it may be that the 
disease stabilization was caused by the vaccination, it could well be part of the 
natural disease course in this patient.
The median survival of the patients after vaccination was 4 month (table 3), 
comparable to the survival in untreated stage IV melanoma cohorts (20).
Discussion
The results of the phase I peptide vaccination trial in end-stage melanoma patients 
described in this report are in accordance with previously published peptide 
vaccination studies. In short, the treatment may induce vaccine specific T cell 
responses in a minority of these patients (approx. 10-50%), but clinical responses 
are rare (approx. 2.5-5%)(21). 
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The meager clinical responses obtained in therapeutic tumor vaccination trials in 
general, and in this melanoma specific peptide vaccination trial in particular, are 
partially explained by the high tumor burden in the treated patients, which grows 
fast and may tolerize the tumor specific T cell repertoire (17). This, in combination 
with the suboptimal affinity of these inherently autoreactive cells, makes active 
immunization in these patients a difficult feat.
The presence of vaccine induced T cells in the circulation and the occurrence 
of clinical responses hardly correlate (22). Our data seem to suggest that non-
functionality of tumor specific T cells may in part explain this paradox. In summary, 
after the vaccination three of eleven patients had a tumor specific response of a 
magnitude comparable to responses seen in viral infections. One directed against 
Tyr (0.7%) and the other two against (unmodified) MART-1
(26-35)
 (0.3% and 2.1%). 
In all these cases however, the cognate ELIspot counts were negligible.
Interestingly, in the 2 patients with MART-1
(26-35)
 specific T cells after vaccination, 
these cells did produce IFN-γ on stimulation with the altered MART-1
(26-35)
 E27L 
peptide ligand. The high MART-1
(26-35)
 specific precursor frequency (23) in humans 
may facilitate the emergence of these tumor non-cross reactive T cells upon 
vaccination with the modified peptide. 
Although in this study the T cell responses after peptide vaccination neither 
induced DTH responses nor tumor regression, it is clearly established that T cells 
can induce tumor regression, when present in sufficiently high numbers and in the 
right activation status (24). From this perspective, the induction of tumor specific T 
cells using current peptide vaccination strategies simply falls short. 
Strategies to improve this success rate include co-injection of immunostimulatory 
adjuvants, such as TLR agonists and cytokines (25-27) or vaccination with peptide-
loaded Dendritic Cells (DC) (28;29). Another interesting approach is the use of 
peptides that are not constricted to a minimal epitope, but contain a larger part of 
the antigen sequence, spanning the entire protein as a pool (30). In addition, recent 
developments in DNA vaccination hold a promise (31).
However, the gap between T cell numbers induced by any form of vaccination, 
and those necessary for tumor regression in end-stage melanoma patients (24) is 
large. Although abovementioned improvements could bridge this gap, it seems 
worthwhile to explore other means of cancer immunotherapy.
The transfer of autologous tumor infiltrating lymphocytes (TILs), propagated 
ex vivo, is the most effective current experimental immunotherapy in melanoma 
patients (23). Moreover, the adoptive transfer of autologous PBL transduced with 
TCR genes, may lead to an equally potent, yet more versatile treatment. In view 
of the significantly greater success of adoptive therapies, it seems wise to focus 
on adoptive therapy for the treatment of melanoma. Possibly, the mechanisms 
revealed in such studies could lead to the design of more effective vaccination 
approaches in the distant future.
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Table1, population characteristics
Demography
Total number      11
Caucasian      11
Median age (range)     45  (30-63)
Female / Male      3 / 8  
Prior treatment 
No prior treatment     0
Prior radiation      3
Prior chemotherapy     10
Prior non-specific immunotherapy    4
Site of primary tumor
Skin        10
Eye        1
Site of metastasis  
Lung        4 
Skin        4 
Bone        2
Liver        1 
Mediastinum      1 
Table 2, Toxicity according to CTC criteria
Local
Grade 1: itching; erythema    6
Grade 2: Pain or swelling      11  
Systemic
Grade 1: Mild fatigue over baseline   5
Grade 1: Fever 38.0 - 39.0 degrees C   2
Grade 2: Moderate or causing difficulty performing ADL 2
2
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Table 3, Median survival and blood levels of S100 and LDH before and 2 month 
after vaccination
   Median   Range
Survival 4 month   1 - >36+
S100 (µg/l) before: 0.3   before: 0.1 - 0.7  
   after 2.1   after: 0.1 - 9.3
LDH (U/l) before: 374   before:104 -1819    
   after 461  after: 100 - 2540
Figure 1
Tetanus toxin specific IgG titers of the enrolled patients before and after 
vaccination. One of the eleven patients could not be tested at week 5.
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Survival, S100 and LDH levels in bloodsamples taken before and 5 weeks after the 
start of the vaccination. 
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Figure 2
Analysis of vaccine specific T cell responses before and after vaccination. (a) 
MART-1 
(26-35)
 E27L specific Tetramer staining (right) and Elispot assay (left), 
before (above the black line) and 5 weeks after start of vaccination (below the 
black line) in patient I. (b) The same display for patient II. 
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(c) Gp100
(209-217) 
specific T cell response in patient III and (d) tyrosinase
(368-376) 
specific responses in patient IV. The percentage in the upper left corner of the 
scatterplot represents the fraction of tetramer positive cells in the CD8 positive 
lymphocyte population. In the ELIspot assay 4 peptide concentrations were tested 
in triplicate or duplicate. The average number of spots per well for each tested 
pepide concentration is depicted at the right side of the figure.
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Figure 3
MART-1 
(26-35)
 specific responses after vaccination in patient I and II, measured 
using the unmodified MART-1
(26-35)
 (EAAGIGILTV) peptide for ELIspot and 
tetramer analysis. The percentage in the upper left corner of the scatterplot 
represents the fraction of tetramer positive cells in the CD8 positive lymphocyte 
population. In the ELIspot assay 4 peptide concentrations were tested in triplicate. 
The average number of spots per well for each tested pepide concentration is 
depicted at the right side of the figure.
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A rapid and potent DNA vaccination strategy 
defined by in vivo monitoring of antigen 
expression
Adriaan D Bins1, Annelies Jorritsma1, Monika C Wolkers1, Chien-Fu Hung2, 
T-C Wu2, Ton N M Schumacher1 & John B A G Haanen1 
Abstract
Induction of immunity after DNA vaccination is generally considered a slow 
process. Here we show that DNA delivery to the skin results in a highly 
transient pulse of antigen expression. Based on this information, we developed 
a new rapid and potent intradermal DNA vaccination method. By short-interval 
intradermal DNA delivery, robust T-cell responses, of a magnitude sufficient to 
reject established subcutaneous tumors, are generated within 12 d. Moreover, this 
vaccination strategy confers protecting humoral immunity against influenza A 
infection within 2 weeks after the start of vaccination. The strength and speed of 
this newly developed strategy will be beneficial in situations in which immunity is 
required in the shortest possible time.
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Introduction
Over the past decade, DNA vaccines have emerged as a promising approach for the 
induction of immune responses. Generally, current DNA vaccination strategies use 
a regimen of multiple intramuscular or intradermal administrations, at intervals of 
2 weeks or more, and require at least 1 month to achieve immunity1, 2, 3, 4, 5, 6. The 
slow development of T-cell responses after DNA vaccination contrasts sharply 
with immune responses induced by a physiological antigen encounter, such as viral 
infection, that build up rapidly and often peak within 10 d7. The reason for this slow 
development of immune responses has remained unclear. It has been postulated 
that DNA vaccination leads to transfection of few cells and to the expression 
of relatively small amounts of antigen8, 9, therefore requiring a time-consuming 
prime-boost strategy. But direct evidence for the proposed low antigen expression 
is scarce and its role in immune induction has not been addressed. To examine 
whether the slow induction of immune responses could be causally related to the 
kinetics of antigen expression induced by DNA vaccines, we analyzed in vivo 
levels of antigen expression after intramuscular and intradermal DNA delivery, 
and correlated these with the induction of T-cell immunity. Based on these data, 
we developed a short-interval DNA vaccination method that generates functional 
T- and B-cell responses within a minimal time frame.
Results
Intradermal DNA vaccination by skin tattooing
To be able to administer DNA to the skin in a controlled manner, over a large surface 
and only in the upper nonvascularized layers, we made use of a simple tattoo 
device10 for intradermal DNA delivery. Histochemical analysis of ‘DNA-tattooed’ 
skin showed that transfected cells were distributed over the upper layers of the 
dermis and the epidermis. (Fig. 1a,b). To test the immunogenicity of this method, 
we vaccinated two groups of mice with a DNA vaccine encoding the influenza A 
nucleoprotein epitope (amino acids 366−374; NP
366
) fused to the carboxy terminus 
of a tetanus toxin fragment (d1TTFC-NP)11, either by intramuscular injection or 
by skin tattoo, following the conventional DNA vaccination regimen of three 
administrations at 2-week intervals. This comparison shows that the intradermal 
delivery of a DNA vaccine using a tattoo device is an efficient strategy for the 
induction of T-cell immunity (Fig. 1c).
Imaging of in vivo antigen expression
To monitor antigen expression upon DNA vaccination, we constructed a plasmid 
encoding the NP
366
 epitope fused to the carboxy terminus of firefly luciferase (Luc-
NP). The Luc-NP vaccine elicits potent NP
366
-specific T-cell responses (Fig. 1d). 
After tattoo or intramuscular administration of the Luc-NP vaccine, we used a light-
sensitive camera to determine longitudinal in vivo antigen expression. Notably, a 
single intramuscular injection of DNA resulted in high levels of luciferase activity, 
peaking after 1 week and remaining detectable up to 1 month after injection. The 
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antigen expression kinetics induced by DNA tattooing were markedly different. 
First, peak values of antigen expression were at least ten times lower. Second, 
luciferase activity in the skin peaked after 6 h (data not shown) and disappeared 
over the next 4 d (Fig. 1e).
We subsequently determined the capacity of both methods to present the vaccine-
encoded NP
366
 epitope to naive, lymph node−resident T cells. For this purpose, 
5 million carboxy-fluorescein diacetate succinimidyl ester (CSFE)-labeled 
splenocytes from F5 TCR transgenic mice12 were injected into mice at different 
time points after a single intramuscular DNA injection or DNA intradermal 
tattoo. Luciferase activity was measured on the day of cell transfer, and 3 d later 
the animals were killed, lymphoid organs excised and the CFSE signal of the 
F5 cells assessed by flow cytometry. These experiments showed that although 
antigen production is markedly greater upon intramuscular delivery, presentation 
of this antigen to naive T cells is markedly more efficient upon intradermal DNA 
delivery. Specifically, in spite of the high antigen expression in the muscle after 
intramuscular injection, the fraction of F5 cells in the draining lymph node that had 
undergone proliferation was marginal in all of the three tested time windows (days 
1−4, days 8−11 and days 22−25; Fig. 2a−c). In marked contrast, the priming of F5 
T cells after tattooing was very efficient (Fig. 2a). Independent of the number of F5 
T cells that were infused (5 million or 1 million; latter not shown), over 80% of the 
draining lymph node−resident F5 cells had lost CFSE signal on day 4, despite the 
low antigen level expressed in skin (Fig. 2d). At later time points, NP
366
-specific 
T-cell activation became substantially less (Fig. 2b,c), consistent with the loss of 
luciferase signal observed by in vivo imaging. Similar results were obtained with 
spleen-resident F5 cells. No F5 T-cell division could be detected in nondraining 
lymph nodes (data not shown).
Induction of T-cell immunity by short-interval DNA tattooing
Based on the transient antigen expression and presentation induced by DNA 
tattooing as compared to intramuscular injection, we speculated that in the case 
of dermal DNA vaccination, shortening of the conventional 2-week interval could 
result in faster T-cell induction. To test this hypothesis, we reduced the interval 
between consecutive vaccinations to 3 d, resulting in a day 0, 3 and 6 regimen. 
Notably, this compact vaccination protocol induced profound T-cell responses of 
4−8% of total CD8+ T cells within 12 d after the start of vaccination (Fig. 3a). This 
regimen of short-interval vaccination does not lead to detectable T-cell responses 
when the vaccine is administered intramuscularly, consistent with the observation 
that the duration of antigen expression is not a limiting factor in intramuscular 
DNA vaccination.
To test the value of this new vaccination regimen for other methods of intradermal 
DNA delivery, we compared T-cell induction by short-interval gene-gun and short-
interval tattoo vaccination, using the previously described Hsp70-HPV-E7 DNA 
vaccine13. Using the short-interval regimen, both methods generated strong T-cell 
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responses within 12 d against the immunodominant human papillomavirus (HPV) 
E7
49−57
 cytotoxic T lymphocyte (CTL) epitope (E7
49
) (Fig. 3b). Comparison of 
T-cell responses induced by short-interval DNA tattooing with other previously 
established vaccination strategies showed that short-interval DNA tattooing yields 
markedly higher T-cell responses (tenfold or more) than peptide−incomplete 
Freund adjuvant−CD40-specific monoclonal antibody14 or peptide-synthetic CpG 
oligodeoxynucleotide15 vaccines (Fig. 3c). Furthermore, T-cell induction is efficient 
for both internal epitopes and those fused at the carboxy terminus (Supplementary 
Fig. 1 online). The resulting T cells are capable of direct effector function, as 
indicated by antigen-induced interferon (IFN)-γ production (Supplementary Fig. 
2 online).
Repetitive application of DNA may conceivably boost T-cell responses by enhancing 
the absolute amount of antigen expression, or by prolonging the duration of antigen 
expression. To address this issue, we compared antigen expression levels and T-cell 
responses induced by three consecutive 4 s tattoos with those induced by one single 
16 s tattoo. The cumulative antigen produced by one 16 s application exceeds that 
of three 4 s applications (Fig. 3d). Whereas three consecutive 4 s applications 
induce a T-cell response that is readily detectable, a single 16 s application 
is essentially without effect (Fig. 3e). To further assess whether the observed 
requirement for repetition reflects a need for continued antigen presence, or is relat 
ed to the prolongation of nonspecific inflammatory signals, groups of mice were 
vaccinated at day 0, 3 and 6 with different combinations of a mock vaccine and the 
Luc-NP vaccine. Replacing either the first or the last Luc-NP vaccine with a mock 
vaccine lead to a significant drop in the size of the ensuing T-cell response (Student 
t-test, P = 0.002 and P = 0.003, respectively; Fig. 3f). Together these results show 
that for the induction of primary T-cell responses by intradermal DNA vaccination, 
prolonged antigen expression is crucial
Functional immunity induced by short-interval DNA tattooing
To assess the ability of short-interval tattoo DNA vaccination to induce therapeutic 
amounts of tumor-specific T cells, we used the transplantable HPV E6/E7-
transformed TC-1 tumor cell model16. Three days after subcutaneous injection of 
105 TC-1 cells, we vaccinated B6 mice using the short-interval tattoo method with 
a plasmid encoding E7
49
 attached to the carboxy terminus of green fluorescent 
protein (GFP-E7; Fig. 4a). Control mice were either given an intramuscular 
injection in the same regimen with the same plasmid (Fig. 4b), or were tattooed 
with a control plasmid encoding green fluorescent protein (GFP) only (Fig. 4c). 
In both control groups, no T-cell responses could be detected after vaccination. 
In contrast, mice that had been tattooed with GFP-E7 mounted a sizeable T-cell 
response, up to 15% of the circulating CD8+ T-cell pool. Notably, the onset of 
E7
49
-specific T-cell responses coincided with rejection of established subcutaneous 
tumors, whereas in both control groups tumors grew out rapidly (Fig. 4d). 
Furthermore, median survival of GFP-E7−tattooed animals was 50 d compared to 
17 d in control animals (Fig. 4e).
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To assess the value of short-interval DNA vaccination in providing antibody-
mediated protection against acute infections, we evaluated its ability to confer 
protection against influenza A virus infection. Given that protection against 
reinfection with homotypic influenza A strains is primarily mediated by antibodies17, 
18, 19, 20, we generated a plasmid that encodes the gene for hemagglutinin of influenza 
A/HK/2/68, a protein that forms a major target for neutralizing antibodies. Using 
this DNA vaccine, mice were vaccinated by short-interval DNA tattooing, whereas 
control groups were either tattooed with a GFP-encoding plasmid, or given 
intramuscular injection with the hemagglutinin-encoding DNA vaccine. Two weeks 
after vaccination, we intranasally infected mice with a sublethal dose of influenza 
A, and determined virus-induced morbidity by measuring body weight loss1. In the 
week after infection, mice that had previously been exposed to influenza A virus 
showed a minimal weight loss (1% at day 4 after infection). In contrast, mice given 
tattoo vaccination with the control plasmid or given an intramuscular injection of 
the hemagglutinin construct showed a sizable (10% and 14%, respectively) drop in 
body weight. Notably, mice that had received a short-interval hemagglutinin tattoo 
were largely protecte d from influenza A−induced morbidity (maximal weight loss 
of 4%; Student t-test, P = 0.039 versus control vaccine; Fig. 5a). The protection 
correlated with the induction of neutralizing antibodies (Fig. 5b). Furthermore, 
intradermal DNA tattooing also conferred long-term (4 months) protection 
(Supplementary Fig. 3 online). Collectively, these experiments indicate that short-
interval intradermal DNA vaccination leads to the rapid and sustained development 
of both T- and B-cell responses and that such responses can mediate the regression 
of established tumors and can prevent virus-induced morbidity.
Discussion
In this study we established a short-interval regimen that induces T- and B-cell 
immunity within 12 d. Analysis of antigen expression levels showed that after 
intradermal tattoo, 1/10 to 1/100 of the amount of antigen is produced than after 
intramuscular injection, and that compared to intramuscular administration, tattoo-
induced antigen production occurs over a limited timespan. In spite of this, the 
presentation of the vaccine-encoded epitope is markedly better upon intradermal 
tattoo vaccination. The efficiency with which dermally expressed antigens are 
presented to T cells probably results from the high numbers of antigen-presenting 
cells (APCs) present in this tissue. Also, the infliction of thousands of perforations 
could conceivably serve as a potent adjuvant.
Contrary to murine skin dendritic cells (DCs), human skin DCs do not express 
Toll-like receptor 9 (TLR9), and this may partly explain why DNA vaccines 
have performed poorly in human trials as compared to mouse model systems21, 22. 
Encouragingly, a comparison of the immunogenicity of tattoo DNA vaccination in 
wild-type and Tlr9-/- mice showed that the absence of TLR9 does not measurably 
affect the immunogenicity of this method (Supplementary Fig. 4 online).
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The short-interval repetitive schedule developed here leads to rapid induction of 
T-cell responses upon either intradermal tattoo or gene-gun vaccination, and may 
well work for all intradermal vaccination techniques. Because of its simplicity 
and because the required equipment is orders of magnitude less expensive, DNA 
tattooing may become the preferred method, in particular in countries with a less 
developed healthcare system.
In the past years, outbreaks of Ebola virus, severe acute respiratory syndrome and 
influenza A have been causes for concern. To contain such outbreaks conventional 
DNA vaccination strategies appear too slow at inducing immunity23, 24. The 
vaccination regimen described here retains the rapid production and the safety of 
DNA vaccines, but gains the speed of immune induction that is the characteristic 
of physiological antigen encounters.
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Methods
Animals.
We obtained C57BL/6 mice and Balb/c mice from the experimental animal 
department of The Netherlands Cancer Institute. The Tlr9-/- mice were a gift of H. 
Wagner ((with permission of S. Akira) Institute for Microbiology, Immunology 
and Hygiene, University of Munich, Germany). We purchased from the US 
National Cancer Institute the C57BL/6 mice used for the experiments involving 
a gene gun and kept them in the oncology animal facility of the Johns Hopkins 
Hospital. We performed all animal procedures according to approved protocols 
and in accordance with recommendations for the proper use and care of laboratory 
animals. All animal experiments were approved by the Dutch Animal Research 
Committee. 
DNA vaccines.
We generated DNA vaccines by the introduction of fusion genes in pcDNA3.1. 
The GFP-E7 fusion gene has been described previously25, all other constructs were 
generated following a similar design. We included the four naturally flanking amino 
acid residues of NP
366−374
 (amino acids GVQI) as a linker at the amino terminus of 
each epitope in all constructs. We constructed the d1TTFC-NP DNA vaccine with 
optimized codon usage, in a template-free PCR using overlapping oligonucleotides 
of 100 bp, spanning the entire first domain of the TTFC gene and the preceding p2 
epitope (amino acids 831−1,315 26). We generated the Luc-NP vaccine, encoding 
influenza A NP
366−374
 epitope fused to the carboxy terminus of firefly luciferase, 
by genetic linkage of the NP
366−374
 fragment to the carboxy terminus of the gene 
encoding full-length firefly luciferase. The gene encoding influenza A/HK/2/68 
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hemagglutinin was obtained by RT-PCR of RNA isolated from virus particles, and 
inserted in pcDNA3.1. to generate the hemagglutinin DNA vaccine. We purchased 
the construct used for histochemical detection of transfected cells (pVAX:LacZ) 
from Invitrogen. Replacement of the lacZ gene with chicken ovalbumin generated 
the construct encoding whole ovalbumin. The generation of the sigE7hsp DNA 
vaccine was described previously13. Sequences were confirmed by sequence 
analysis. All DNA batches were purified using EndoFree Plasmid kit (Qiagen).
DNA vaccination.
For intramuscular DNA vaccination, we shaved the hind leg of the mouse and 
injected it with 100 μg of DNA in 50 μl HBSS (Life Technologies). For intradermal 
DNA vaccination, we shaved the left hind leg of the mouse, applied a droplet of 
20 μg DNA in 10 μl HBSS to the skin and used a sterile disposable 11-needle bar 
(Radical Clean Magnum11, Eurl Toupera) mounted on a rotary tattoo device (Cold 
skin, B&A Trading) to apply the vaccine. Needle depth was adjusted to 0.5 mm, 
and the needle bar oscillated at 100 Hz. DNA vaccines were applied to the skin by 
a 16 s tattoo. Gene-gun particle-mediated DNA vaccination was performed using 
a helium-driven gene gun (Bio-Rad) according to the manufacturer’s protocol. At 
various time points after immunization, we drew approximately 20 μl of peripheral 
blood for analysis of T-cell responses.
Detection of NP- and HPV-specific T cells in peripheral blood.
Peripheral blood lymphocytes were stained with phycoerythrin-conjugated 
antibody to CD8β (BD Pharmingen) plus allophycocyanin-conjugated H-2Db/
NP
366−374
-tetramers or allophycocyanin-conjugated H-2Db/E7
49−47
 tetramers, at 20° 
C. for 15 min in FACS buffer (PBS, 0.5% BSA and 0.02% sodium azide). We 
washed cells three times in PBA and analyzed them using flow cytometry. Live 
cells were selected based on 7-AAD exclusion. We performed IFN-γ assays using 
the BD Cytofix/Cytoperm kit (BD Biosciences) according to the manufacturer’s 
protocol. Peripheral blood lymphocytes were stimulated for 4 h at a 100 nM 
peptide concentration.
Intravital imaging.
We anesthetized mice with isofluorane (Abbott Laboratories). We intraperitoneally 
injected an aqueous solution of the substrate luciferin (150 mg/kg, Xenogen) and 
18 min later the luminescence produced by active luciferase was acquired during 
30 s in an IVIS system100 CCD camera (Xenogen). Signal intensity was quantified 
as the sum of all detected light within the region of interest, after subtraction of 
background luminescence.
Influenza A infection and detection of influenza A−specific antibodies.
Purified influenza A/HK/2/68 virus was provided by G. Rimmelzwaan (Department 
of Virology, Erasmus University). We infected mice intranasally with 20 
hemagglutinating units (HAU) of virus in PBS, under general anesthesia. Influenza 
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A/HK/2/68-specific antibodies were detected in a hemagglutination inhibition (HAI) 
assay. Serum samples (50 μl) were serially 1:2 diluted with PBS (1% BSA) in round-
bottomed polystyrene microtiter plates, in duplicate, and 50 μl of A/HK/2/68 influenza 
virus corresponding to 4 HAU was added to each well. After 45 min incubation at room 
temperature, we added 50 μl of 0.5% chicken red blood cells to each well. After 1 h, we 
determined the maximal serum dilution that fully inhibited the hemagglutination caused 
by the virus in the duplicate wells. The HAI titer was expressed as the reciprocal of this 
serum dilution.
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Figure 1. DNA tattooing results in transfection of epidermal and dermal cells and leads 
to efficient T-cell induction.
(a) The abdominal skin of a mouse was tattooed with a β-galactosidase (lacZ)-encoding 
construct. Six hours after treatment, transfected cells were shown in a skin biopsy, 
using the X-gal substrate to generate a blue precipitate in cells expressing the transgene 
(arrows). (b) The abdominal skin of a mouse tattooed with empty vector and processed 
as in a. (c) NP
366
-specific CD8+ T-cell responses induced by tattoo (tat., circles, n = 5) or 
intramuscular (i.m., triangles, n = 5) DNA vaccination. The d1TTFC-NP DNA vaccine 
was administered three times at 2-week intervals. T-cell responses were measured 7 d 
after the last DNA administration, by staining peripheral blood lymphocytes with H-2Db/
NP
366−374
 tetramers. Horizontal bars depict averages. (d) NP
366
-specific T-cell responses 
induced by tattoo DNA vaccination (circles, n = 5) and i.m. DNA vaccination (triangles, 
n = 5) with the Luc-NP DNA vaccine. (e) Kinetics of Luc-NP antigen expression after 
a single intradermal DNA tattoo (circle) and after a single intramuscular DNA injection 
(triangle).
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Figure 2. Analysis of antigen production and presentation after intradermal and 
intramuscular DNA vaccination.
(a−c) Cohorts of mice (n = 7) were vaccinated once with the Luc-NP vaccine, 
either by intradermal DNA tattooing (filled circles) or by intramuscular DNA 
injection (filled triangles). Control groups (n = 3) received a plasmid encoding 
luciferase only (intradermal, open circles; intramuscular, open triangles). CFSE-
labeled naive F5 T cells were transferred on day 1 (a), day 8 (b) or day 22 (c) after 
DNA administration, and were recovered from the draining lymph nodes 3 d after 
transfer. Proliferation was assessed by analysis of CFSE loss of H-2Db/NP
366−374 
tetramer−positive CD8+ cells. (d) Representative draining lymph node sample from 
the tattooed cohort on day 4.
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Figure 3. Features of tattoo DNA vaccination.
(a) NP
366
-specific T-cell responses in cohorts of mice (n = 5) upon vaccination 
with d1TTFC-NP on day 0, 3 and 6 either by tattoo (filled circles) or intramuscular 
injection (open triangles). Control mice (open circles) were tattooed with a TTFC 
mock vaccine. NP
366
-specific T-cell responses were determined at indicated time 
points by tetramer staining of peripheral blood lymphocytes (n = 5). (b) The 
E7
49
-specific T-cell response after intradermal application of the sigE7hsp DNA 
vaccine at day 0, 3 and 6 in cohorts of mice (n = 6), either by DNA tattooing on 
the left leg (filled circles) or by gene gun on both flanks of the abdomen (filled 
triangles). Control groups of mice (n = 3) were vaccinated with empty vector 
(open triangles and open circles). (c) NP
366
-specific T-cell responses in cohorts of 
mice (n = 5) upon subcutaneous vaccination with the NP
366
 peptide in incomplete 
Freund adjuvant at day 0 (open triangles), subcutaneous injection of NP
366
 peptide 
with CpG in PBS at day 0 (open circles) or at day 0, 3 and 6 (open squares), NP
366
 
peptide with CpG in PBS tattoo vaccination at day 0, 3 and 6 (open diamonds) 
and DNA tattoo vaccination with d1TTFC-NP on day 0, 3 and 6 (filled circles). 
(d) Antigen expression level after single tattoos of 16, 8, 4 and 1 s, as determined 
by a light-sensitive camera 1 d after tattooing with the Luc-NP vaccine. (e) NP
366
-
specific T-cell responses (n = 5) induced by 16 s (open circles), 8 s (open triangles) 
and 4 s (open diamonds) tattoos on day 0, 3 and 6, or a single 16 s tattoo on day 
0 (open squares). (f) In mice vaccinated with the Luc-NP DNA vaccine at day 0, 
3 and 6, the replacement of Luc-NP with a mock DNA vaccine on day 0 (open 
squares; C-2x) or day 6 (open diamonds; 2x-C) reduces T-cell responses from 
levels induced by three consecutive tattoos (open circles; 3x), to levels induced by 
two consecutive tattoos (open triangles; 2x).
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Figure 4. Tattoo DNA vaccination leads to rapid induction of functional tumor-
specific T cells.
(a−c) Mice were injected subcutaneously with 105 TC-1 cells. Three days later, 
mice were vaccinated three times at 3-d intervals either by GFP-E7 tattooing 
(open circles; a), by intramuscular injection (open triangles; b), or by tattooing 
with a mock vaccine (open diamonds; c). E7
49
-specific CD8+ T-cell responses were 
determined by major histocompatibility complex tetramer staining of peripheral 
blood cells at indicated time points. Horizontal bars depict averages. (d) Tumor 
outgrowth in the cohorts of mice depicted in a−c; symbols are as in a−c. (e) Long-
term survival of the mice depicted in a−c; symbols are as in a−c. Values represent 
mean +/- s.d.
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Figure 5. Tattoo DNA vaccination induces B-cell immunity against influenza A 
within 2 weeks.
(a) Cohorts of Balb/c mice (n = 6) were vaccinated at day 0, 3 and 6 either by 
intramuscular injection (filled triangles) or by tattooing (filled circles) with 
a construct encoding hemagglutinin. A positive control group was infected 
intranasally with influenza (open diamonds) and a negative control group tattooed 
using a mock vaccine (open circles). All mice were challenged with a sublethal dose 
of the influenza A virus at day 14 (indicated by the arrow), and weighed daily. The 
hemagglutinin-tattooed mice showed a significantly smaller drop in weight than 
the mock-tattooed mice (Student t-test, P = 0.039). Both in the mock-vaccinated 
and the intramuscularly vaccinated group, one mouse died from influenza-induced 
pneumonia. These animals were not included in the analysis. Values represent the 
weight relative to the weight at time of challenge. Error bars, s.e.m. (b) Influenza 
A/HK/2/68-specific antibodies in the sera of the mice depicted in a, at various time 
points after the start of vaccination and the influenza A challenge (symbols as in a). 
The presence of antibodies was assessed in an HAI assay. Values represent mean 
+/- s.d.
Supplementary Figure 1. DNA tattoo 
vaccination efficiently induces T cells against 
internal epitopes. Responses specific for the 
Chicken Ovalbumin
257-264 
epitope, in mice (n=5) 
that were short-interval tattoo vaccinated with 
a construct encoding whole chicken ovalbumin. 
Values represent the mean +/- standard 
deviation.0
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Supplementary Figure 2. T cells 
induced by DNA tattoo vaccination 
are capable of direct effector 
function. (a) Tetramer staining of 
PBLs of a representative mouse, 
at day 11 after vaccination with 
the Luc-NP DNA vaccine. (b) 
Intracellular interferon-γ staining 
of the same blood sample as in (a).
Supplementary Figure 3. Tattoo 
DNA vaccination induces long-
term immunity against influenza 
A. Cohorts of Balb/c mice (n=6) 
were vaccinated with a construct 
encoding HA, either at day 0, 14 
and 28 by i.m. injection (▲) or 
at day 0,3 and 6 by tattooing (●). 
A negative control group was 
tattooed using a mock vaccine 
(○). All mice were intranasally 
infected with a sublethal dose of 
the influenza A virus 109 days after 
the last DNA administration and 
weighed daily after the challenge. 
The HA tattooed mice showed a 
significantly smaller drop in weight 
than the mock tattooed mice 
(student t-test: P=0.038). Values 
represent the weight relative to the 
weight at time of challenge. Error 
bars depict the standard error of 
the mean.
Supplementary Figure 4. Absence of TLR9 does 
not measurably affect the immunogenicity of DNA 
tattoo vaccination. Peak NP366-specific T cell 
response induced by Luc-NP short interval tattoo 
DNA vaccination, in wildtype C57BL/6 mice 
(black bar) compared to TLR9 -/- mice (gray bar). 
Values represent the mean +/- standard deviation.0
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Introduction
The development of heterologous prime-boost vaccination regimens has 
accentuated the need for potent priming methods, to increase immune responses 
upon boosting with adeno- or pox-based immunogens. DNA vaccines are an 
attractive component for the priming phase of such regimens, as T cell induction is 
unhindered by vector specific immunity and can occur in a flexible, safe and simple 
manner1. Unfortunately, the high efficacy of DNA vaccines seen in early and more 
recent mouse studies has not been mirrored in humans and in non-human primate 
DNA vaccination trials. The poor track record of DNA vaccines in primates has 
been a major impediment for the development of clinical DNA vaccines.
The low immunogenicity of intradermal DNA vaccines in primates has been 
suggested to be a consequence of the low TLR9 expression on skin-resident APCs2 
of primates. Furthermore, in relation to body mass the typical DNA doses used in 
large animals are generally 5-10 fold lower than those used in rodents. Reflecting 
an incomplete understanding of the factors involved, the issue has been termed ‘the 
simian barrier’3.
Recently, a new intradermal DNA vaccination method was developed and optimized 
by us in mouse models. In this strategy -termed DNA tattooing- vaccination is 
performed by applying a droplet of DNA to the skin followed by exposure of 
the skin to the needle head of a rapidly oscillating tattoo device, resulting in 
the creation of thousands of punctures in the DNA-coated area. In mice, DNA 
tattooing leads to a significantly higher level of antigen presentation in the draining 
lymph node as compared to intramuscular injection and to the induction of strong 
T cell responses within a timespan of weeks4. Furthermore, this novel method of 
immunization makes it possible to scale DNA dose, directly linear to the total body 
surface across different species. Based on the poor track record of DNA vaccination 
approaches in primates it seemed of importance to assess the effectiveness of the 
newly developed approach in a non-human primate model. Here we report on the 
efficacy of intradermal DNA tattoo vaccination in Macaca mulatta.
Experimental setup
We vaccinated 5 outbred macaques with a 1mg/ml DNA vaccine containing the 
plasmids pORT-GPN and pORT-gp120 at equimolar concentration. pORT-GPN 
encodes a biologically inactive gag-pol-nef fusion protein of the clade C HIV-1 
strain 97cn54. pORT-gp120 encodes a secreted version of the Env protein from 
the same HIV strain (for a detailed description of the plasmids see supplementary 
information). The vaccination regimen consisted of 3 tattoo applications at 3 day 
intervals. This short-interval vaccination regimen was identical to that previously 
used in mice, where it induces robust cytotoxic T cell responses within 2 weeks4. 
In addition, to allow a comparison with retrospective data sets (see below), animals 
received an identical set of booster vaccinations after 4 weeks.
During each tattoo an area of approximately 5x6 cm (30 cm2) on each leg was 
treated. On two legs together, each treatment covers a fraction of the body surface 
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that is similar to the fraction treated in previous rodent experiments (5-10% of the 
body surface for each application). The first of the three tattoos was placed on the 
inner thighs, the second on the upper thighs and the third on the outer thighs. With 
each tattoo, 0.65 ml of a 1mg/ml DNA solution was applied on each leg and the 
area was treated using a disposable 27-needle bar (each creating skin perforations 
with a diameter of approximately 0.3 mm) mounted on a rotary tattoo machine 
oscillating at 100 Hz. Using this setup, approximately 300,000 skin perforations 
are inflicted during the 2 minute treatment of each leg. A total of approximately 8 
mg DNA was applied over the course of the whole prime-boost regimen.
Kidney and liver function parameters, white and red blood cell counts and 
inflammatory parameters, were determined once every week and 3 days after 
each tattoo. Blood was drawn for enumeration of IFN-γ and IL-4 producing 
peripheral blood mononuclear cells (PBMC) by enzyme-linked immunospot 
(ELIspot) assays at week 4 and 8 post vaccination, and by intracellular cytokine 
staining (ICS) at week 2 post vaccination. Additionally, at week 4 and 8 blood 
was drawn for measurement of Envelope specific IgG antibody titers by enzyme 
linked immunosorbent assays (ELISA). ELIspot and ELISA data generated in the 
experiment were compared to those of 10 macaques that previously received a 
prime-boost vaccination by bolus intramuscular (im) injection of 2 ml of the same 
DNA vaccine batch at week 0 and week 4 (8 mg of DNA in total). As a second 
comparison, responses were compared to those in 10 macaques vaccinated with a 
NYVAC (New York Vaccinia) modified pox vector expressing the same HIV gene 
sequences (1 ml i.m. injection in each arm, at a dose of 5x107 pfu/ml). The study 
design is schematically represented in Figure 1. Analyses of immune responses in 
both control groups had been performed at the same time points post vaccination 
and using exactly the same methods and reagents as in the 5 animals that were 
vaccinated by DNA tattoo. The study protocol and experimental procedures were 
approved by the institutional ‘animal ethical care and use’ committee. 
Results
None of the tattooed animals developed adverse side-effects upon DNA tattooing 
and all animals gained weight normally during the course of the experiment. To 
a variable extent, in all animals a thin yellowish crust of coagulated transudate 
appeared on the treated sites the day after tattooing (Fig 2). However, these 
crusts disappeared within 2 - 5 days. The animals did not scratch nor otherwise 
manipulate the treated skin areas.
Strikingly, at 2 weeks after the start of vaccination, CD8+ IFN-γ secreting PBMC 
directed against Pol or Nef could be detected in 4 of the 5 tattooed animals by ICS 
(suppl. Fig. 1). In accordance with this finding, the ELIspot analysis at 4 weeks 
after the start of vaccination showed that 5 of the 5 tattooed animals had developed 
a robust response of antigen-specific IFN-γ secreting PBMC. These responses 
were predominantly directed against Pol, and consisted of on average 1678 
SFC (Spot Forming Cells) per million PBMC (ranging from 487 to 5398 SFC). 
The consistency of these vaccine-induced cytotoxic responses in all 5 animals 
contrasted sharply with i.m. or NYVAC vaccination (p=0.001 and p=0.001), both 
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of which induced low-level HIV-specific T cell responses in a fraction of animals 
at this time point (average 39 SFC, range 0-130, fig 3a). Four weeks after the 
second vaccination (8 weeks after the first vaccination), the antigen specific IFN-γ 
responses in the tattooed group were 702 SFC on average, compared to 31 SFC 
after i.m (p=0.001) and 1 SFC after NYVAC (p=0.001, Fig 3a). Notably, only 
for the group treated by DNA tattoo these values are significantly higher than the 
background reactivity against the used HIV antigens that was present before the 
onset of vaccination (Mann-Whitney test: p=0.037 for tattoo, p=0.21 for i.m. and 
p=1 for NYVAC). 
Interestingly, at 8 weeks after vaccination, in addition to IFN-γ producing PBMC, 
a population of IL-4 secreting PBMC was also detected in 3 out of 5 tattooed 
animals (Fig 3b). These cells were mainly directed against epitopes in Pol and 
Nef, and consisted of 727 SFC on average. (see suppl. Fig. 2 for detailed graphs). 
In contrast, no significant increase in IL-4 secreting PBMC populations was 
observed upon i.m. DNA or NYVAC vaccination  (2 SFC for i.m. DNA  and 16 
SFC for NYVAC)  (suppl. Fig 1). In spite of the presence of IL-4 secreting PBMC, 
no significant increase in titers of gp140 specific IgG or IgM antibodies were 
observed upon DNA tattoo (data not shown).
Discussion
In the current study we have analyzed the immunogenicity of DNA tattooing in 
non-human primates. A strong induction of IFN-γ T cell responses was observed 
within weeks after priming and the observed induction of cytotoxic responses by 
DNA vaccination in a primate model only upon priming has to our knowledge 
not been observed previously using other methodologies. Also after booster 
immunization, the frequencies of vaccine-specific IFN-γ-secreting cells remained 
10-100 fold higher than those observed upon i.m. DNA vaccination or vaccination 
with a NYVAC vector expressing the same sequences. Possibly, the fact that the 
tattooed area can be scaled-up linear to an increase in body surface, leading to the 
availability of the encoded antigens to a potentially greater population of dermal 
APC, contributes to the efficacy of DNA tattooing in larger animals. These data 
indicate that further exploration of intradermal DNA vaccination by tattoo device 
or equivalent means in clinical trials is mandated. Such trials should focus on 
the use of this technology either in therapeutic settings, or on the use of DNA 
tattoo to induce high level T cell responses against major pathogens in high risk 
populations.
Materials and Methods
DNA vaccine.
Within the EC Eurovacc vaccine development program (QLK2-CT-1999-01321) 
gene-optimised GagPolNef and Env gene vector inserts were designed by 
GENEART GmbH using the GeneOptimizerTM software package. Clade C/B 
GagPolNef (GPN) and Env (gp120) sequences were designed based on sequence 
information derived from a 97cn54 provirus clone5 (sequence submitted to 
GenBank). The gene-optimized 97cn54 Env construct comprises 1500 nucleotides, 
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encoding an artificial signal peptide followed by gp120 97cn54. The 5’ part of the 
CN54 GPN polygene construct encodes the modified (myristylation deficient) 
group specific antigen. The Gag coding sequence is followed by a 952 bp fragment 
encoding the 5’ part of pol including a mutation leading to inactivation of the viral 
protease. A 618 bp fragment encoding a scrambled Nef variant was fused to the 3’ 
end of pol coding sequence replacing the active site of the reverse transcriptase. 
The 3’ pol reading frame lacking the integrase gene was extended by the 3’ end 
of the scrambled Nef gene. The sequence stretch encoding the active site of the 
reverse transcriptase was translocated to the 3’ end of the polygene construct, 
resulting in an open reading frame encoding the 160kDa non-glycosylated artificial 
GPN polyprotein. The C-clade-synGagPolNef gene was cloned into the pCR-
Script amp(+) cloning vector (Stratagene, La Jolla, USA) resulting in the vector 
pCRScript-C-synGagPolNef. The cladeC-syngp120 gene was cloned into the 
pCR-Script amp(+) cloning vector resulting in the vector pCRScript-C-syngp120. 
The pCRScript based vectors were used to generate the DNA vaccine candidate 
plasmids pORT1aGPN and pORT1agp120. pORT1aGPN and pORT1agp120 were 
selected and produced in accordance to GMP standards using the E. coli strain 
DH1lacdapD (Cobra Therapeutics Inc). Upscaling and production of cGMP grade 
material was performed by Cobra Biomanufacturing Plc, Keele, Staffordshire, UK. 
Therapeutics Inc.
NYVAC vector
The NYVAC vector expressing Gag/Pol/Nef and Env of clade C HIV-1 97cn5 
was provided by Dr. MJ Frachette (Sanofi Pasteur, Lyon, France). Functional 
expression of the donor genes was demonstrated by Western blot analysis of the 
proteins produced by the pre-master seed lot. The clinical batch of the vaccine 
was manufactured by Sanofi Pasteur using a process previously developed for the 
manufacture of other ALVAC- and NYVAC-based vaccines.
IFN-γ and IL-4 ELISPOT assays.
Quantification of antigen specific cytokine secreting cells was performed on 
freshly isolated PBMC by IFN-γ and IL-4 enzyme-linked immunospot (ELIspot) 
assays, according to the manufacturer’s instructions (U-Cytech, Utrecht, The 
Netherlands). Positive control was SEB 1µg/ml, negative control was medium 
alone. Antigen specific responses were measured against 5µg/ml peptide pools: 
15-mers with 11 aa overlap spanning the entire Gag/Pol/Nef polygene, and the Env 
clade C of HIV-1 97cn54 (Synpep Corporation, Dublin, CA, USA). Eight peptide 
pools were made as follows: Gag1, 60 peptides (Cg
1-240
); Gag2, 61 peptides (Cg
244-
486
); Pol1, 60 peptides (Cgp
485-721
); Pol2, 61 peptides (Cp
725-817
, Cp
1017-1161
); Pol3, 61 
peptides (Cp
1165-1403
); Nef 49, peptides (Cn
838-1030
); Env1, 49 peptides (CN
9-249
); Env2, 
63 peptides (CN
253-485
). Results are expressed as the mean number of spot forming 
cells (SFC) per 1000000 PBMC from triplicate samples minus background values 
(mean number of SFC plus 2xSD of triplicate samples with medium alone). Mean 
SFC of each animal (dots) are expressed per antigen (responses to 2 Gag pools, 3 
Pol pools and 2 Env pools were combined).
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Intracellular cytokine analysis.
The phenotype of responding T-cells was analyzed by ICS and flow cytometric 
analysis as described elsewhere6 with minor modifications. PBMC were O/N 
incubated, in the presence of stimulatory antibodies specific for CD28 and CD49d 
(2µg/ml each), with medium alone (negative control), 1µg/ml SEB (positive 
control) or stimulated with 5µg/ml of the same 8 peptide pools as used in the 
ELISPOT assay as described above. Cells were stained with directly conjugated 
antibodies (Becton Dickinson, Pharmingen, CA, USA) to CD3 (peridinin-
chlorophyll-protein complex (PerCP)-labeled), CD4 (phycoerythrin-cyanin 7 
(PE-CY7) labeled), CD8 (allophycocyanin (APC)-CY7 labeled), and to CD14 and 
CD20 (Energy Coupled Dye (ECD) labeled, Beckman Coulter, Marseille, France) 
for exclusion of monocytes and B-cells. The cells were fixed and permeabilised 
with Cytofix/Cytoperm buffer (Becton Dickinson) and stained intracellularly with 
antibodies specific for IFN-γ (APC-labeled), IL-2 (PE-labeled), TNF-α (fluorescein 
isothiocyanate (FITC) labeled) in Perm/wash solution (Becton Dickinson). 100,000 
– 200,000 events were acquired on a FACS Aria (Becton Dickinson, CA, USA). 
FACS Diva (Beckton Dickinson) and Summit (Dako, Colorado, USA) software 
was used for analysis. 
ELISA.
Antibodies to HIV-1 Env (gp140 97cn54) in serum were measured by ELISA. 
Plates were coated overnight with Env in 100mM NaHCO
3
 and were blocked for 1 
hour with 1% non-fat milk before application of serum, serially diluted in 1% BSA 
PBS buffer. After 1 hour 1µg/ml anti-human IgG or IgM-HRP conjugate was added 
for 1 hour before addition of ultra-TMB ELISA development reagent. The reaction 
was stopped by addition of 0.5M H
2
SO
4
. Results were expressed as IgG and IgM 
endpoint dilution titers.
I.m. DNA day 0 Boost, day 28
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Boost, day 28-31-34
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new
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Tattoo DNA day 0-3-6
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Fig. 1
Fig 1. Schematic representation of the experimental setup. Arrows indicate time 
points of vaccination, either by DNA tattooing, i.m. DNA injection or NYVAC 
injection.
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Fig 2. Photographs of the skin areas treated by DNA tattooing of 3 representative 
animals, taken either directly after (upper row) or three days after (lower row) the 
treatment. The lower and upper rows display the same animals.
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Fig 3. Quantification of antigen specific cytokine secreting cells by ELIspot at 
week 4 and week 8 post vaccination in the DNA tattoo vaccinated (n=5) group, 
i.m. DNA vaccinated (n=10) group and NYVAC vaccinated group (n=10). The 
assays were performed on freshly isolated PBMC by A) IFN-γ, and B) IL-4 
ELIspot assays, according to the manufacturer’s instructions (U-Cytech, Utrecht, 
The Netherlands). Cytokine responses of individual animals are plotted as 
diamonds (tattoo group), circles (IM group) and triangles (NYVAC group). The 
group averages are indicated as thick closed lines (tattoo group), dotted lines (IM 
.group) and thin closed lines (NYVAC group). Results are expressed as the mean 
number of spot forming cells (SFC) per 106 PBMC from triplicate samples minus 
background values (mean number of SFC plus 2xSD of triplicate samples with 
medium alone). The represented spot number is calculated by summation of the 
readout in 8 separate assays, each done upon stimulation with a distinct fraction of 
the complete peptide pool. For a representation of spot numbers upon stimulation 
with the separate fractions representing pol, gag, nef and env, see Suppl. Fig. 2.
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Suppl. Fig 1. Flow cytometric analysis of peptide stimulated PBMC for TNF-α and 
IFN-γ secretion. In each animal T cell responses against each of 8 fractions of the 
complete peptide pool were tested, together covering the whole vaccine. For each 
animal, the plot in the right column displays cytokine secretion upon stimulation 
with the most stimulant peptide fraction of the pool. All plots are gated on CD8+ 
T-cells. The name of this fraction is printed inside each plot, indicating the HIV 
antigen that it (partly) represents. The plots in the left column displays cytokine 
secretion without peptide stimulation. See supplementary data for technical details 
of the assay. 
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Suppl. Fig 2. Upper panel: IFN-γ production by peripheral blood mononuclear 
cells (PBMC) to Env, Gag, Pol and Nef peptides as measured by ELIspot assay. 
Background responses (mean number of SFC plus 2xSD of triplicate samples with 
medium alone) were subtracted. The solid line represents the mean response of all 
animals within one group. Lower panel: the same display but for IL-4 production.
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Abstract
The factors that determine efficient presentation of antigens encoded by viral 
vaccines or DNA vaccines to cytotoxic T cells in vivo are largely unknown. Prior 
work has suggested that cross-presentation of cytotoxic T cell antigens would 
either involve transfer of peptide antigens from antigen-producing cells to antigen-
presenting cells, or would involve the transfer of protein antigen between the two 
cell types. While these models make predictions on the requirement for in vivo 
accumulation of vaccine-encoded antigens, the influence of antigen stability on 
CD8+ T cell induction has not been addressed in clinically relevant vaccine models, 
nor has the accumulation of vaccine-encoded antigens been monitored in vivo. Here 
we describe the relationship between in vivo antigen stability and immunogenicity 
of DNA vaccine-encoded antigens. We show that in vivo accumulation of DNA 
vaccine-encoded antigens is required for the efficient induction of CD8+ T cell 
responses. These data suggest that many of the currently used transgene designs 
in DNA vaccination trials may be suboptimal, and that one should either use 
pathogen-derived or tumor-associated antigens that are intrinsically stable, or 
should increase the stability of vaccine-encoded antigens by genetic engineering. 
In vivo antigen stability affects vaccine efficacy
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Introduction 
Vaccines that aim to induce cytotoxic T cell responses should achieve two goals: 
First, vaccination should lead to the presentation of sufficient densities of the 
relevant peptide/MHC (pMHC) complexes and second, such presentation should 
occur by mature professional antigen presenting cells (APC). While the signals 
that lead to maturation of professional antigen-presenting cells (APCs) have 
been studied in considerable detail (1), our understanding of the factors that lead 
to efficient MHC class I-restricted presentation of vaccine-encoded antigens 
to naïve T cells is incomplete. Currently, there is solid evidence that peptides 
can be presented by MHC class I molecules by two distinct pathways (2). The 
classical endogenous antigen presentation pathway that processes antigens that are 
generated within the APC itself  (3-6) and the cross-presentation pathway, in which 
professional APCs present T cell antigens that have been acquired from other cell 
types (3). Importantly, for a number of viral vectors that are employed in vaccination 
strategies such as vaccinia and Adenovirus group A, C, D, E and F, T cell induction 
depends to a large extent on cross-presentation of the vaccine-encoded antigens (7,8). 
Likewise, following intradermal (9) or intramuscular DNA vaccination (10,11), cross-
presentation of the DNA vaccine-encoded antigens is a dominant mechanism for 
T cell induction. 
Several studies have shown that cross-presentation of MHC class I-restricted 
epitopes involves the transfer of intact antigens from the antigen-donating cell 
to the APC (12-15). Conversely, other groups have provided evidence for a role 
of proteasomal products and intermediates, possibly in the form of heat shock 
protein (HSP)-bound peptides, as a main antigen source for cross-presentation 
(16-18). Finally, a recent study has indicated that gap junctions can allow transfer 
of peptide fragments between cells, a pathway that could potentially also be 
employed by pAPCs to acquire antigens (19). While the use of in vitro experiments 
(19) transplantable tumor models (12,15,19), the injection of apoptotic tumor cells (17) 
or tumor cell extracts (14,16) in these studies has provided useful information on the 
possible mechanisms underlying cross-presentation, neither of these experimental 
settings mimics clinically accepted vaccination strategies. Consequently, it 
remains unclear whether vaccine development should focus on designs that result 
in accumulation of full-length antigen, or whether production of peptide epitopes 
would be preferred. This issue is particularly relevant for ongoing DNA vaccination 
trials, as the stability of the vaccine-encoded antigen is generally not taken into 
account in vaccine design, thereby potentially limiting vaccination efficiency.
To unravel the parameters that determine efficient priming of cytotoxic T cell 
responses to vaccine-encoded antigens, we have developed a vaccination model 
that allows us to directly follow vaccine-encoded antigen stability in vivo. We have 
used this model to determine the effect of antigen stability on T cell induction. and 
demonstrate that in vivo antigen accumulation profoundly impacts the efficacy of 
in vivo antigen cross-priming.  These data suggest that antigen stability should 
form an important consideration in vaccine design.
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Results
Epitope location affects DNA vaccine efficacy
We have previously shown that tumor-associated T cell epitopes that are derived 
from signal peptides are cross-presented inefficiently (15). To determine whether for 
vaccine-encoded antigens a similar bias occurs, we made use of a recently developed 
multineedle intradermal DNA vaccination strategy (20), hereafter referred as DNA 
tattoo. As is the case for gene gun DNA vaccination (9) induction of T cell responses 
by DNA tattooing occurs at least partially through cross-presentation (Suppl. Fig. 
1, see below). To assess the effect of epitope location on vaccine immunogenicity, 
we generated a pcDNA3.1-based vector that encodes a secreted GFP-based fusion 
protein, sNP-GFP-E7. This model antigen contains two CD8+ T cell epitopes; the 
influenza A nucleoprotein-derived NP
366
 epitope located within the hydrophilic 
segment of the signal peptide, and the Human Papilloma virus-derived E7
49
 epitope 
located within the COOH-terminal part of the GFP protein (Fig 1A). The rationale 
for this design is that it allows the simultaneous measurement of T cell responses 
against two T cell epitopes, of which one is incorporated in the stable mature GFP 
protein and the other within the signal peptide that is thought to be short lived (21,22). 
To be able to correct for possible intrinsic differences in immunogenicity between 
the two T cell epitopes, a second fusion gene (sE7-GFP-NP) containing the same 
two model antigens but in reverse order was used in parallel. Mice were vaccinated 
with the sNP-GFP-E7 or the sE7-GFP-NP DNA vaccines, and T cell responses were 
monitored directly ex vivo by MHC tetramer staining (Fig.1B). Vaccination with 
these DNA vaccines resulted in considerable frequencies of antigen-specific T cells 
specific for the antigen expressed within the mature protein, be it either the NP
366
 
epitope, or the E7
49
 epitope (Fig. 1C). In striking contrast, when the NP
366
 epitope, 
or the E7
49
 epitope was encoded within the signal peptide, DNA vaccination failed 
to induce antigen-specific T cell responses above background (Fig. 1C). These data 
establish that, analogous to tumor cell-associated antigens (15), the immunogenicity 
of DNA vaccine-encoded antigens is biased towards epitopes in mature proteins, 
and against epitopes in signal peptides.
Antigen stability determines the efficiency of DNA vaccination
Signal peptide-derived epitopes may inefficiently enter the cross-presentation 
pathway as a consequence of their limited life-span (15,21). However, no 
measurements exist of the in vivo half-life of signal peptides and it is clearly 
possible that other characteristics of signal peptides adversely affect T cell priming 
via cross-presentation. Consequently, while the data show that signal peptide-
encoded epitopes are strongly disfavored, the broader implications of this finding 
are unclear. To be able to directly assess whether the half-life of a vaccine-encoded 
antigen would influence its immunogenicity, we generated DNA vaccines encoding 
an antigen that could be destabilized to a variable degree by a minor modification 
in its sequence. This antigen consists of three basic components (Fig. 2A). At the 
COOH-terminus of the fusion protein the NP
366
 T cell epitope is present to be able 
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to monitor immunogenicity of the antigen. This epitope is preceded by the Firefly 
luciferase (luc) that is used to follow in vivo expression of the antigen by intravital 
imaging. In addition, the luciferase gene product carries a variable residue at its 
amino-terminus. Finally, a ubiquitin (Ub) moiety is encoded amino-terminal 
to the luciferase gene product, to control antigen half-life. This NH
2
-terminal 
ubiquitin moiety is cotranslationally removed by ubiquitin-specific proteases 
(USPs), thereby exposing the variable amino-terminal residue of the luciferase 
gene product. As previously established by Varshavsky and colleagues, the nature 
of this amino acid can determine protein half-life in a hierarchical manner known 
as the N-end rule (23). Thus, the Ub-X-lucNP fusion proteins described here are 
designed to display a different half-life, depending on the nature of the X-lucNP 
NH
2
-terminal residue. 
To determine if the intracellular stability of X-Luc-NP fusion proteins is controlled 
by the N-end rule pathway, we transfected COS cells with plasmids encoding Ub-M-
lucNP or Ub-R-lucNP (in which M and R are stabilizing and destabilizing residues 
respectively) and determined lucNP expression level by measuring luciferase 
activity (Fig. 2B). Both X-lucNP variants were enzymatically active, as judged by 
bioluminesence measurements after addition of the substrate luciferin (Fig. 2B). 
To determine whether the half-life of the Luc-NP fusion proteins is dependent on 
the nature of the NH
2
-terminal amino acid, proteasomal activity was inhibited by 
addition of MG132 (z-Leu-Leu-Leu-al.) A 4 h inhibition of proteasomal activity 
did not measurably alter bioluminescence of cells transfected with Ub-M-lucNP 
DNA. In contrast, luciferase activity of cells transfected with Ub-R-lucNP DNA 
was increased approximately 4-fold upon inhibition of proteasomal activity, 
indicating that the resulting R-lucNP protein has a significantly shorter half-life 
than M-LucNP. In line with this, immunoprecipitation of luciferase from pulse-
labeled cells transfected with Ub-R-lucNP or Ub-M-lucNP showed a substantial 
difference in half-life between the two proteins (Fig 2C, D). 
The activity of the E3-ligases that recognize different NH
2
-terminal residues may 
be cell type dependent (24). Therefore, it was essential to determine the in vivo half-
life of vaccine-encoded Ub-M-lucNP and Ub-R-lucNP fusion proteins. To this end, 
mice received a single intradermal DNA vaccination with either Ub-M-lucNP or 
Ub-R-lucNP DNA, and in vivo protein stability was subsequently determined by 
measuring luciferase activity at several time points post DNA application (Fig. 
3A). Within the first 12 h post-immunization, luciferase activity increased rapidly 
and (as expected, see legend to Fig. 3) did not substantially differ between Ub-
M-lucNP and Ub-R-lucNP vaccinated animals. However, at later time points the 
luciferase activity in the Ub-R-lucNP group decreased much more rapidly than in 
the Ub-M-lucNP group. Specifically, at 72 h post-vaccination, luciferase activity 
in Ub-M-lucNP vaccinated animals was approximately 100-fold higher than that in 
Ub-R-lucNP vaccinated animals. Based on the rate of decay of luciferase activity 
from 24 h onwards, the in vivo half-life of R-lucNP and M-lucNP are 5 and 11 h, 
respectively. It is noted that these numbers may underestimate the actual difference 
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in antigen half-life of the two proteins, because it assumes that LucNP synthesis 
has ceased after 24h while low level de novo production may still occur at this 
timepoint. 
To examine whether the in vivo difference in intracellular antigen half-life affects 
the immunogenicity of these DNA vaccines, we measured NP-specific CD8+ T 
cell responses by ex vivo MHC tetramer staining of peripheral blood samples 
upon vaccination with either Ub-M-lucNP or Ub-R-lucNP. Whereas vaccination 
with Ub-M-lucNP DNA yielded NP
366
-specific CD8+ T cell responses with a peak 
average of 10.4%, (Fig. 3B), vaccination with the destabilized variant Ub-R-lucNP 
resulted in a 4.7 fold lower antigen-specific T cell response (2.2% on average at the 
peak; p = 0.008). These data suggest that antigen half-life is a major determinant of 
the efficacy of intradermal DNA vaccines.
Antigen stability influences cross-presentation of MHC class I-restricted epitopes 
in the DLN.
The above data demonstrate the effect of in vivo antigen stability on the 
immunogenicity of intradermal DNA vaccines, but do not reveal whether this 
effect is due to enhanced cross-presentation or due to enhanced endogenous 
presentation by transfected APCs. To address this issue, mice were vaccinated with 
DNA vectors encoding the Ub-M-lucNP and Ub-R-lucNP variants under control 
of the K14 promoter. As opposed to the CMV-IE promoter employed in Fig. 1 
and 3 (and in the majority of human vaccination trials (25)), the K14 promoter is 
solely active in epidermal cells (9), thereby eliminating a contribution of directly 
transfected professional APCs to antigen presentation. Mice that were vaccinated 
with the (K14)-Ub-M-lucNP DNA vaccine mounted peak NP
366
-specific T cell 
responses of on average 1.4% (Fig. 4A). In contrast, after vaccination with the 
(K14)-Ub-R-lucNP DNA vaccine, T cell responses remained close to background 
levels (0.1% on average, p = 0.014). These data indicate that antigen stability 
substantially affects the immunogenicity of DNA vaccines in a setting where T cell 
induction can only occur through epitope presentation by APCs that have obtained 
antigen from other cells. Of note, the magnitude of T cell responses induced by 
K14-driven DNA vaccines is close to 10-fold lower as compared to those induced 
by CMV IE-driven vaccines (Fig. 3C versus 4A). This difference is likely to be a 
consequence of the 10-50 fold lower level of protein production from K14-driven 
vaccines (Suppl. Fig. 1B). In addition, it is possible that endogenous antigen 
presentation by transfected APCs enhances T cell induction (26) in the case of CMV-
IE driven vaccines.
Because CD4+ T cell help is required for efficient DNA vaccination (27), we set 
out to determine whether the higher immunogenicity of stable antigens is due to 
enhanced MHC class I-restricted cross-presentation, or can be explained by more 
effective CD4+ T cell help. To this end, CFSE-labeled NP
366
-specific F5 TCR 
transgenic CD8+ T cells were transferred into TCRβ-deficient mice that lack both 
CD4+ and CD8+ T cells. Subsequently, the mice received DNA vaccines encoding 
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Ub-M-lucNP or Ub-R-lucNP, and at day 7 post vaccination the draining lymph 
nodes were excised and analyzed for division of F5 T cells. In mice that were 
vaccinated with Ub-M-lucNP, on average 7.0% of the F5 T cells had divided (Fig. 
4B), whereas vaccination with Ub-R-lucNP led to considerably less T cell division 
(2.8% on average, p = 0.03). As a second approach, we determined the induction 
of NP
366
 specific T cell responses in MHC class II-deficient mice that lack CD4+ T 
cells. Consistent with prior data on the requirement for CD4+ T cell help in DNA 
vaccination (9,27,28), overall CD8+ T cell responses in MHC class II-deficient mice 
are very low. However, Ub-M-lucNP vaccination still induced significantly higher 
CD8+ T cell responses than vaccination with Ub-R-lucNP (0.7% versus 0.2%, p = 
0.0003, Fig 4C). These results demonstrate that for intradermal DNA vaccines, the 
stability of the antigen directly affects the efficiency of cross-presentation of MHC 
class I-restricted epitopes in the draining lymph node (DLN).
To further dissect the effect of antigen stability on T cell induction, we generated 
3 more variants of lucNP that encoded glycine (G), serine (S) or phenylalanine (F) 
as the NH
2
-terminal amino acid that is created upon Ub removal (Ub-G-lucNP, 
Ub-S-lucNP and Ub-F-lucNP). These residues were chosen because they were 
previously (29) found to yield fusion proteins with a range of half-lifes in mouse 
cells in vitro. Specifically, a serine-based fusion protein displayed an identical or 
marginally higher stability in L cells as compared to the wild type Ub-M-lucNP in 
a one hour chase period, and glycine and phenylanaline-based fusion proteins have 
an intermediate and low half-life relative to M and R based fusion proteins. 
First, we assessed the in vivo stability of these variants by intravital bioluminescence 
imaging. Interestingly, comparison of the in vivo half-life revealed that luciferase 
activity upon Ub-S-lucNP DNA vaccination persisted substantially longer than 
after Ub-M-lucNP vaccination (Fig. 5A, half life of 15 h versus 11 h, based on 
decay in luciferase activity from 24 h onwards), whereas the in vivo half-life of Ub-
G-lucNP and Ub-F-lucNP fell in between that of Ub-M-lucNP and Ub-R-lucNP 
(9 h and 7 h, respectively). We then tested the immunogenicity of DNA vaccines 
encoding these three additional stability variants in parallel with DNA vaccines 
encoding Ub-M-lucNP and Ub-R-lucNP. In accordance with the hypothesis that 
antigen half-life controls vaccine efficacy, T cell responses induced by Ub-S-lucNP 
were highly robust and exceeded that of Ub-M-lucNP. Furthermore, the magnitude 
of the T cell responses induced by Ub-G-lucNP and Ub-F-lucNP ranked in between 
Ub-M-lucNP and Ub-R-lucNP, and correlated with their respective in vivo half-
lifes (Fig. 5B,C). 
Effect of antigen stability on intramuscular DNA vaccination
To investigate the possible role of antigen stability upon administration of DNA 
vaccines via other routes, we tested the Ub-M-lucNP, and Ub-R-lucNP DNA 
vaccines for their efficiency in the induction of T cell responses upon intramuscular 
DNA vaccination. Analogous to the results obtained after intradermal tattoo 
vaccination, the magnitude of the CD8+ T cell responses induced by intramuscular 
88
IN VIVO ANTIGEN STABILITY AFFECTS VACCINE EFFICACY
vaccination with the stable Ub-M-lucNP variant exceeded that induced by the 
unstable Ub-R-lucNP variant (average CD8+ T cell responses of 1.2% and 0.2%, 
respectively, p=0.07), with detectable NP
366
-specific CD8+ T cell responses in 4 
out of 5, and 1 out of 5 mice, respectively (Fig. 5D). This finding suggests that the 
mechanisms that govern the efficiency of presentation of intramuscularly expressed 
antigens are similar to those involved in intradermal antigen presentation. 
The effect of transgene design on vaccine immunogenicity.
Most DNA vaccines that enter clinical trials encode a modified version of the 
antigen of interest. Depending on native biological function, viral antigens have 
been shuffled to prevent cellular transformation (e.g. HPV E6 and E7) (30), or to 
prevent other protein functions such as reverse transcriptase activity or protease 
activity (e.g. HIV) (31). Alternatively, fusion proteins have been generated with the 
aim to incorporate additional immunostimulatory signals (32), or strings of T cell 
epitopes (33). 
These types of manipulations that alter the 3-dimensional structure of the resulting 
proteins are likely to result in aberrant folding and thereby affect protein half-
life. Based on the data presented above, vaccines encoding such rearranged gene 
products may be inferior in T cell induction. To directly test this hypothesis we 
constructed a shuffled version of lucNP (hereafter referred to as ulcNP), in which 
the NH
2
-terminal 50 amino acids (a.a.) have been removed from the amino-
terminus and reincorporated into the protein 114 a.a. downstream within the 
sequence. Based on the luciferase X-ray structure, this change is expected to disrupt 
luciferase domain architecture and thereby affect protein stability. Consistent with 
this, immunoprecipitation of ulcNP and lucNP after pulse-chase labeling indicates 
that the in vitro half-life of the ‘scrambled’ ulcNP antigen is decreased as compared 
to the wild type lucNP (Fig. 6A, B). DNA vaccines encoding lucNP and ulcNP 
were then compared with regard to immunogenicity upon intradermal vaccination. 
Consistent with the notion that manipulations that affect antigen half-life influence 
vaccine immunogenicity, NP
366
-specific CD8+ T cell responses induced by 
vaccination with the scrambled ulcNP variant were inferior to those induced by 
vaccination with the unaltered lucNP vaccine (1.0% versus 4.0%, p=0.016). This 
indicates that modification of vaccine-encoded antigens by gene-scrambling can 
substantially affect the potency of DNA vaccines (Fig. 6C). 
Discussion 
Here, we have generated DNA vaccine variants by three types of design to assess 
whether antigen half-life affects the immunogenicity of DNA vaccines. Using 
these constructs for DNA vaccination we have shown that 1) CD8+ T cell responses 
against two signal peptide-encoded epitopes were highly reduced as compared 
to those against the same epitopes contained within the mature part of the same 
carrier protein, 2) 5 different ubiquitin-luciferase fusion proteins induced CD8+ 
T cell responses that correlated fully with their relative in vivo stability, and this 
correlation was observed for both i.d. and i.m. DNA vaccination, and 3) CD8+ 
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T cell responses against a shuffled and as a result instable variant of luciferase 
were substantially reduced as compared to those against the unmodified luciferase 
gene product. Of these experiments, the first and third line of experiments provide 
indirect evidence for an effect of antigen half-life on immunogenicity, and the 
second line of experiments provides direct proof for this link. In addition, we show 
that antigen stability directly affects cross-presentation of MHC class I-restricted 
epitopes, and that the bias towards stable proteins is observed in settings where an 
effect of antigen stability on the availability of CD4+ T cell help is excluded. 
Elegant work by Trombetta and colleagues has recently demonstrated how the 
induction of helper T cell responses by protein vaccination is correlated with 
resistance of the antigen to degradation within the lysosomal pathway of the 
APC (34). Here we complement this study by demonstrating that the induction of 
cytotoxic T cell responses by live vaccines is correlated with antigen stability 
within the cytosol. Given the fact that efficient T cell priming induced by DNA 
vaccines depends on CD4 T cell help (8,9,15,27), it seems plausible that optimal 
immunogens may in fact require a high stability in both the cytosol and within the 
lysosomal pathway, a notion that may be tested in further studies.
While these experiments were primarily intended to examine how DNA vaccines 
may best be designed for the induction of cytotoxic T cell responses, it is interesting 
to consider how the results from these experiments fit with predictions made on the 
basis of existing models for antigen transfer from the antigen donating cell to APC 
(10-16), and in particular whether the transferred material consists of peptides or full 
length protein. For such an analysis it is more informative to use the data from 
i.m. DNA vaccination than that of i.d. DNA vaccination for the following reason. 
It has previously been shown by Neefjes and coworkers that peptide fragments 
have an extremely short half-life in cells (22). Consequently, in cells where de novo 
production of antigen is transient, as is the case for intradermal DNA vaccination 
(19), a rapid decay in protein synthesis of an instable antigen will be mirrored in an 
equally rapid decay in peptide levels. Inefficient induction of antigen-specific T 
cell responses in this setting could therefore either be explained by a low pool of 
protein or a low pool of peptides in the antigen-donating cell. 
However, upon i.m. DNA vaccination de novo production of proteins is highly 
constant (20). In this setting, a short half-life of the vaccine-encoded protein will 
affect steady state protein levels but is not expected to affect steady state peptide 
levels, as these will correlate with the level of steady state protein synthesis. 
Consequently, a beneficial effect of antigen stability on the immunogenicity of 
i.m. DNA vaccines (Fig. 5D) would not be expected if transfer from the antigen 
donating cell to the APC would involve the transport of peptide antigens. In 
contrast, if cross-presentation involves the transfer of proteasomal substrates 
from the antigen donating cell to the APC, a beneficial effect of antigen stability 
is expected, because an increased protein half-life would lead to a proportional 
increase in the pool of antigen available for transfer. Thus, the current data seem 
most consistent with a model where protein antigens rather than peptides are 
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transferred between antigen donating cell and APC following DNA vaccination. 
However, the evidence for this is clearly very indirect and a final resolution of the 
issue will likely only be provided by the direct in vivo visualization of the process 
of cross-presentation.
The effect of antigen stability on vaccine immunogenicity that is shown here for 
i.d. and i.m. DNA vaccination is likely to also hold true for other vaccination 
strategies. Specifically, clinical strategies for vaccination with Modified Vaccinia 
Ankara (MVA)-based vectors by intramuscular injection or skin scarification 
have been shown to be partially dependent on cross-presentation (7). Likewise, the 
induction of T cell responses upon vaccination with recombinant adenoviral vectors 
is expected to occur through cross-presentation, since the CAR receptor that is 
required for efficient infection of cells by commonly used adenoviral vectors such 
as Ad5 is absent on dendritic cells (8). Thus, T cell induction in both the priming as 
well as the boosting phase in DNA-MVA and DNA-Ad5 prime boost regimens that 
are currently in clinical trials (35,36) are likely to benefit from vaccine designs that 
take antigen stability into account. In this respect it is noteworthy that the type of 
fusion gene vaccines used in current and planned large-scale vaccination trials, are 
expected or have in fact been shown to yield instable protein products (37) and will 
therefore likely form suboptimal immunogens. 
The current data imply that vaccine designs that disrupt protein folding should be 
avoided in future vaccine development, and that the in vivo stability of antigens 
should form a consideration when multiple candidate antigens are available. In 
addition, it seems attractive to develop more generally applicable strategies to 
promote the accumulation of otherwise instable antigens. For instance, judicious 
removal of surface exposed lysine residues may increase protein half-life by 
preventing ubiquitin conjugation and thus proteasomal degradation of the antigen 
(38,39). Secondly, incorporation of specific protein domains has previously been 
shown to lead to high level protein accumulation, either as ER aggregates (40) or as 
cytosolic proteins, both with the possibility of pharmacological control (41). Based 
on the data presented here, evaluation of such strategies appears useful and may 
provide novel formats for vaccine transgene design.
Materials and Methods
Mice
C57BL/6 mice, MHC class II-/- (42), TCRβ-/- mice (43), and B10F5 mice (44) were 
obtained from the experimental animal department of The Netherlands Cancer 
Institute (Amsterdam, The Netherlands). All animal procedures were performed 
after approval of the Experimental Animal Committee and in accordance with 
institutional and national guidelines.
DNA vaccines
DNA vaccines were generated by the introduction of fusion genes into pVAX, or 
pcDNA3.1 (Invitrogen, San Diego, CA). The fusion genes sNP-GFP-E7 and sE7-
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GFP-NP have been described elsewhere (15) and were cloned into the BamH I and 
Not I sites of pcDNA3.1. The fusion gene Ub-M-lucNP was generated by addition 
of the ubiquitin gene to the 5’ end of a lucNP-encoding vaccine (20). Briefly, two 
intermediate products were generated with the primers Ub-top: 5’GGGGGATCC
TAAGCCACCATGCAGATC3’, and Ub-M-bottom: 5’CTTTATGTTTTTGGCGT
CTTCCATACCCCCCCTCAAGCGC3’, and luc-M-top: 5’GCGCTTGAGGGGG
GGTATGGAAGACGCCAAAAACATAAAG3’ with luc-NP-bottom: 5’CCCTT
TGCGGCCGCTTACATGGCGTCCATGTTCTCGTTGCTGGCGATCTGCACG
CCCACGGCGATCTTTCCGCCCTTC3’. A second round of amplification was 
performed with Ub-top and Luc-NP bottom primer. To generate Ub-R-lucNP, Ub-top 
was used together with Ub-R-bottom: 5’CTTTATGTTTTTGGCGTCTTCGCGAC
CCCCCCTCAAGCGC3’, and luc-R-top: 5’GCGCTTGAGGGGGGGTCGCGA
AGACGCCAAAAACATAAAG3’ with lucNP-bottom. The variants, Ub-F-lucNP, 
Ub-G-lucNP and Ub-S-lucNP were obtained by changing the first amino acid of 
the luciferase moiety by exchanging the Ub-X part with Ub-top and Ub-F-bottom: 
5’AAACCCCCCCTCAAGCG3’, Ub-S-bottom 5’CTACCCCCCCTCAAGCG3’, 
and Ub-G bottom: 5’CCACCCCCCCTCAAGCG3’. The PCR products Ub-F, Ub-
G and Ub-S were digested with BamH I, and ligated into pVAX-Ub-R-lucNP that 
had been digested with BamH I and Nru I. 
K14 driven Ub-M-lucNP and Ub-R-lucNP plasmids were constructed by replacing 
the CMV-IE promoter of the pVAX backbone with the K14 promoter (generously 
provided by J.H. Cho, Pohang University of Science and Technology, Korea). 
UlcNP was generated by relocating the first 150 nucleotides of the lucNP open 
reading frame into the SSpB1 restriction site at position 492. The fragment was 
generated with ulcNP
1-50
 top: 5’ATATTGTACAAAGACGCCAAAAACATAAAG
AAAGG3’ and ulcNP
1-50
 bottom: 5’ATATATGTACACGTCCACCTCGATATGTG
CATC3’. A Kozak sequence and start codon were inserted at the 5’ end of UlcNP 
by PCR reaction with ulcNP top: 5’ATATATGTACACGTCCACCTCGATATGT
GCATC3’ and ulcNP bottom: 5’ATATTGTACAAAGACGCCAAAAACATAAA
GAAAGG3’. 
All sequences were confirmed by sequence analysis. DNA was grown in DH5α 
and isolated with endotoxin-free DNA purification kit (Qiagen, Hilden, Germany). 
DNA vaccines for intradermal application were dissolved in water, DNA vaccines 
for intramuscular administration were dissolved in PBS (Gibco).
DNA vaccination and intravital imaging 
Intradermal vaccination by DNA tattoo and intravital analysis of protein expression 
was performed as described previously (20). Briefly, mice were anaesthetized and 
a volume of 10 µl of a 2 µg/µl DNA solution in water was applied to the shaved 
skin of the hind leg. The DNA vaccine was applied to the skin by a 20 s tattoo 
with a sterile disposable 11-needle bar oscillating at a frequency of 100Hz. For 
intravital imaging, mice were anaesthetized with isofluorane (Abbott Laboratories, 
Queensborough, UK). An aqueous solution of the substrate luciferin (150 mg/kg, 
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Xenogen, Alameda, CA) was injected intraperitoneally and 18 min. later the 
luminescence produced by active luciferase was acquired during 30s  in an IVIS 
system200 CCD camera (Xenogen). Signal intensity was quantified as the sum of 
all detected light within the region of interest.
Detection of NP
366
 and E7
49
-specific T cells in peripheral blood
Peripheral blood lymphocytes (PBL) were stained with phycoerythrin-conjugated 
anti-CD8β (BD Pharmingen, San Diego, CA) plus allophycocyanin-conjugated H-
2Db/NP
366
-tetramers or allophycocyanin-conjugated H-2Db/E7
49
-tetramers, at room 
temperature for 15 min in PBA (PBS, 0.5% BSA and 0.02% sodium azide). Cells 
were washed three times in PBA and analyzed by flow cytometry. Live cells were 
selected based on 7-AAD exclusion.
Analysis of in vitro protein stability by proteasome inhibition.
COS cells seeded in 10mm dishes with a confluency of 80% were transfected with 
15 µg pVAX encoding Ub-M-lucNP, Ub-R-lucNP, together with DEAE dextran, 
for 30 min. at 37°C, and 80µM chloroquine was added for 2.5 h. DNA-chloroquine 
containing medium was aspirated and cells were treated for 2.5 min with 10% 
DMSO in DMEM culture medium (GIBCO) containing 10% FBS. The DMSO/ 
medium mixture was aspirated and cells were cultured for 24 h at 37°C. To ensure 
equal transfection efficiencies for samples, cells were harvested and seeded into 
6 well plates in triplicates. 48 h post transfection, culture medium was aspirated 
and fresh medium with or without 10 µM MG132 (z-Leu-Leu-Leu-al, Sigma) was 
added. After 4 h at 37°C, cells were trypsinized, harvested, washed twice with PBS 
and resuspended in 20 µl lysis buffer (Promega). Following a 20 min incubation at 
RT, 5 µl of cell lysate was harvested, 20 μl substrate buffer (Promega) was added, 
and luciferase activity was measured. 
Analysis of in vitro protein stability by pulse-chase analysis
COS cells at 80% confluency were transfected with 10µg DNA encoding 
Ub-M-lucNP, Ub-R-lucNP, lucNP or ulcNP using FuGene6, according to the 
manufacturer’s protocol. The cells were starved in Met/Cys-free DMEM medium 
(Gibco) for 60 minutes prior to a 1h pulse labeling with 35S-labeled Met/Cys 
in DMEM. Labeled cells were washed and subsequently cultured in Met/Cys-
containing DMEM for the indicated time points. After cell lysis, luciferase variants 
were immunoprecipitated, and analyzed by SDS-PAGE. Protein quantification was 
performed by phospho-imager analysis (FLA3000, Fujifilm). The images were 
quantitated using TINA 2.09 analysis software.
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Figure 1. Antigen location affects the immunogenicity of DNA vaccines. 
C57BL/6 mice were immunized at day 0, 3, and 6 by means of i.d. DNA tattoo 
with 20 µg pcDNA3.1-sNP-GFP-E7 or pcDNA3.1-sE7-GFP-NP.  (A) At day 12 
post-vaccination, peripheral blood was drawn and antigen-specific CD8+ T cell 
responses were measured ex vivo by combined anti-CD8 and Db-NP
366
 tetramer 
(top), or Db-E7
49
 tetramer (bottom) staining. Schematic representation of sNP-
GFP-E7 and sE7-GFP-NP vaccine insert designs (B) Flow cytometric analysis 
of peripheral blood cells of representative mice for the two groups. (C) Symbols 
represent antigen-specific CD8+ T cell responses of individual mice, bars indicate 
averages of 5 mice. Result is representative of two independent experiments.
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Figure 2. Structure and in vitro stability of Ub-M-lucNP and Ub-R-lucNP fusion 
proteins. (A) Schematic representation of the design of the Ub-M-lucNP and Ub-R-
lucNP fusion gene constructs. The arrowhead indicates the cotranslational cleavage 
site of ubiquitin by Ub-specific proteases (USPs). M and R indicate the methionine 
and arginine starting amino acids. (B) COS cells were transiently transfected with 
Ub-M-lucNP (left) or Ub-R-lucNP (right), and incubated with the proteasomal 
inhibitor MG132 (z-Leu-Leu-Leu-al.) for 4 h (+), or left untreated (-). After cell 
lysis, luciferase activity of the lysate was determined. Results are representative of 
three independent experiments. (C) COS cells that were transiently transfected with 
Ub-M-lucNP or Ub-R-lucNP were starved in Met/Cys-free DMEM medium for 60 
min prior to a 1h pulse labeling with 35S-labeled Met/Cys in DMEM. Labeled cells 
were washed and subsequently cultured in Met/Cys-containing DMEM for the 
indicated time points. After cell lysis, luciferase variants were immunoprecipitated, 
and samples were analyzed by SDS-PAGE. Based on the molecular weight of the 
observed proteins (62 kD), removal of the Ub moiety is complete at all time 
points examined (data not shown).  (D) Graphical representation of an automated 
quantification of C.
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Figure 3. Antigen stability promotes vaccine immunogenicity (A) In vivo kinetics 
of luciferase activity upon intradermal DNA vaccination with Ub-M-lucNP or 
Ub-R-lucNP. Mice were injected once by DNA tattoo with 20 µg Ub-M-lucNP 
(♦), or Ub-R-lucNP (▲). At the indicated time points post vaccination, luciferase 
expression was determined by intravital imaging. It is noted that the difference in 
Iuciferase activity resulting from a differential half life is expected to be maximal at 
late timepoints at which de novo antigen production is low or has ceased, and will 
be suppressed at early timepoints during which antigen production is still rising 
(B) Immunogenicity of Ub-M-lucNP and Ub-R-lucNP DNA vaccines. Mice were 
vaccinated with 20 µg Ub-M-lucNP (♦) or Ub-R-lucNP (▲) at day 0, 3, and 6. At 
the indicated time points, peripheral blood was drawn and antigen-specific CD8+ 
T cell responses were determined ex vivo by Db-NP
366
 tetramer staining. Symbols 
represent CD8+ T cell responses of individual mice, bars indicate group averages. 
Result is representative of 3 independent experiments.
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Figure 4. Antigen stability promotes vaccine immunogenicity through enhanced 
cross-presentation. (A) Mice were vaccinated at day 0, 3, and 6 by with 20 µg 
pVAX(K14)-Ub-M-lucNP, or pVAX(K14)-Ub-R-lucNP, and induction of NP
366
-
specific CD8+ T cell responses was measured by Db-NP
366
 tetramer staining. The 
percentage NP
366
-specific CD8+ T cells at various time points post vaccination is 
plotted. (B) Antigen stability affects MHC class I-restricted antigen presentation in 
the draining lymph node. Mice were vaccinated with 20 µg Ub-M-lucNP, Ub-R-
lucNP or a control plasmid. At day 7 post vaccination, 2x106 NP
366
-specific CFSE 
labeled F5 T cells that were depleted for CD4+ cells by magnetic bead separation 
with a CD4-specific antibody were injected into TCRβ-/- mice. Four days later, 
draining lymph nodes (♦/ ▲ / ✴) and non-draining lymph nodes (◊ / ∆ / x) were 
excised and analyzed for dividing F5 T cells as determined by the percentage of 
CFSE-dull Db-NP
366
 tetramer positive cells. (C) MHC-II -/- mice were vaccinated at 
day 0, 3, and 6 by DNA tattooing with 20 µg of Ub-M-lucNP (♦) or Ub-R-lucNP 
(▲). At day 8, 10 and 11 peripheral blood was drawn and antigen-specific CD8+ T 
cell responses were determined ex vivo by Db-NP
366
 tetramer staining. 
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Figure 5. Antigen immunogenicity correlates with protein half-life. (A) In vivo 
kinetics of luciferase activity upon vaccination with Ub-X-lucNP variants. Mice 
were tattooed once with 20 µg DNA vaccine, encoding Ub-S-lucNP (●),Ub-M-
lucNP (♦), Ub-G-lucNP (-), Ub-F-lucNP (■) or Ub-R-lucNP (▲). At indicated 
time points post vaccination, luciferase expression was determined by intravital 
imaging. (B) CD8+ T cell responses upon vaccination with Ub-X-lucNP variants. 
Mice were vaccinated at day 0, 3, and 6 by DNA tattoo with 20 µg of the Ub-
S-lucNP (●),Ub-M-lucNP (♦), Ub-G-lucNP (x), Ub-F-lucNP (■) or Ub-R-lucNP 
(▲) DNA vaccines. Peripheral blood was drawn and antigen-specific CD8+ T 
cell responses at the peak of the response were determined ex vivo by Db-NP
366
 
tetramer staining. The percentage of NP
366
 specific CD8+ T cells in each mouse 
at the peak of the response is plotted, bars depict group averages. (C) The in vivo 
half-life calculated from the data presented in (A) and the average peak Db-NP
366
 
CD8+ T cell response for each stability variant plotted against each other. Error 
bars represent the standard deviation of antigen-specific CD8+ T cell responses. 
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(D) Mice were vaccinated at day 0, 14, and 28 by i.m. injection of 50 µl (100 µg) 
DNA, encoding Ub-M-lucNP (◊) or Ub-R-lucNP (∆). Because antigen expression 
upon i.m. vaccination is highly variable, presumably due to variability in delivery 
of the DNA vaccine to the target site, luciferase expression was determined by 
intravital imaging at day 7 post vaccination, and three mice within each group 
with the lowest luciferase expression were excluded from the experiment. At day 
7 post second vaccination one additional mouse was excluded from each group in 
a similar fashion. Of the 5 remaining mice in each group NP
366
-specific CD8+ T 
cell responses were determined at day 5, 6, 7, and 8 after the third vaccination by 
Db-NP
366
 tetramer staining. 
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Figure 6. Adverse effect of gene shuffling on vaccine immunogenicity. (A) SDS-
PAGE analysis of a anti-luciferase immunoprecipitates of COS cells that were 
transiently transfected with pVAX encoding either lucNP or ulcNP. (B) Graphical 
representation of an automated quantification of lucNP (♦) and ulcNP (▲) from 
A. 
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(C) Immunogenicity of lucNP and ulcNP DNA vaccines. Mice were vaccinated 
with 20 µg lucNP (●) or ulcNP (♦) at day 0, 3, and 6. At the indicated time points, 
peripheral blood was drawn and antigen-specific CD8+ T cell responses were 
determined ex vivo by Db-NP
366
 tetramer staining. Symbols represent CD8+ T cell 
responses of individual mice, bars indicate group averages.
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Supplementary Figure 1. A K14 driven 
lucNP DNA vaccine induces NP
366
-
specific CD8+ T cell responses. (A) NP
366
 
specific CD8+ T cell responses induced by 
vaccination with a CMV-IE driven lucNP 
DNA vaccine (right panel) and K14 driven 
lucNP DNA vaccine (left panel). Mice 
received 1-minute DNA tattoos at day 0, 3 
and 6 and NP
366
-specific CD8+ T cells were 
enumerated directly ex vivo at the indicated 
time points. Symbols represent CD8+ T cell 
responses of individual mice, bars indicate 
group averages. (B) Luciferase expression 
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induced by K14 driven DNA vaccines is 10 to 50 fold lower than that induced by 
CMV-IE driven DNA vaccines. One day after DNA tattooing with either CMV-
IE or K14 driven lucNP vaccines, luciferase activity was measured by intravital 
imaging. Error bars indicate standard deviation (n=5).
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Abstract 
Advances in fluorescence microscopy and mouse transgenesis have made it 
possible to image molecular events in living animals. However, the generation of 
transgenic mice is a lengthy process and intravital imaging requires specialized 
knowledge and equipment. Here, we report a rapid and undemanding intravital 
imaging method using generally available equipment. By DNA tattooing we 
transfect keratinocytes of living mice with DNA encoding fluorescent biosensors. 
Subsequently, the behavior of individual cells expressing these biosensors can be 
visualized within hours and using conventional microscopy equipment. Using this 
“instant transgenic” model in combination with a corrected coordinate system, 
we followed the in vivo behavior of individual cells expressing either FRET- 
or location-based biosensors for several days. The utility of this approach was 
demonstrated by assessment of in vivo caspase-3 activation upon induction of 
apoptosis. This “instant skin transgenic” model can be used to follow the in vivo 
behavior of individual cells expressing either FRET- or location-based probes 
for several days after tattooing and provides a rapid and inexpensive method for 
intravital imaging in murine skin.
Intravital imaging of fluorescent markers and 
FRET probes by DNA tattooing.
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Background 
The introduction of fluorescent proteins (FP) and the ability to visualize molecular 
events using fluorescence microscopy have been of substantial value for 
understanding intracellular signaling events. FP-based biosensors, and especially 
those based on Fluorescent Resonance Energy Transfer (FRET), can report on 
cellular processes such as apoptosis or cell division, the levels of second messengers 
such as Ca2+, PtdIns(4,5)P2 and cAMP, or the activation status of proteins such as 
RhoA [1]. To date, the vast majority of analyses utilizing FP-based biosensors have 
been carried out on cells in tissue culture. However, for cellular processes that are 
controlled by cellular interactions or by the microenvironment, it would clearly be 
preferable to perform such analyses in vivo. Indeed, the small number of studies 
that have analyzed the behavior of single cells in vivo, have been informative with 
regard to the intracellular interactions of immune cells and early events in tumors 
formation [2-5]. Intravital images of whole mice or tumors can readily be acquired 
with macroscopical resolution using simple instrumentations (e.g. LED flashlight, 
filters and a digital camera [6]). However, for imaging with subcellular resolution, 
sophisticated equipment and expertise (e.g. two-photon microscopes [7] or whole-
mouse imaging systems [8]) are required, which are only available in few specialized 
laboratories. Furthermore, the generation of biosensor-transgenic mice is a lengthy 
process and thereby hampers the use of this technique in settings where a number 
of different biosensors are tested or combinations of biosensors are required. A few 
studies have previously described fast and simple techniques to target selective 
genes to specific sites. For example, Li and Hoffman have targeted reporter genes 
to hair follicles in mice using liposomes [9]. However, it will be important to extend 
such approaches to other cell types. Here we present a rapid and inexpensive DNA 
tattoo method to target FP-genes to keratinocytes in the skin of mice. The behavior 
of these keratinocytes expressing fluorescent or FRET markers were followed for 
multiple days with subcellular resolution using a standard confocal microscope. 
The utility of this tattoo-approach was demonstrated by in vivo imaging of caspase-
3 activation upon apoptosis induction.
Results and Discussion
Prior experiments have demonstrated the feasibility of introducing transgenes in 
murine skin cells by use of a rapidly oscillating tattoo machine [10]. In an effort 
to determine the number of cells that express the introduced transgene upon this 
type of skin application (see Methods), we tattooed a small area (10x15 mm) of 
the abdominal skin of mice with DNA encoding a GFP reporter protein driven 
by the CMV immediate early (CMV-IE) promoter. 3 hours thereafter, mice were 
anesthetized and analyzed for DNA tattoo-induced GFP expression by intravital 
imaging using a conventional confocal microscope. Expression of the GFP reporter 
gene was observed in approximately 160 cells per 10 mm2 tattooed skin, showing 
that the transfection efficiency of DNA tattooing was sufficient for imaging 
purposes. The majority of fluorescent cells obtained after a GFP-encoding DNA 
tattoo were keratinocytes (see Additional file 1).
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The uncorrected GFP images showed considerable autofluorescence of skin 
structures, in particular hair follicles, which was characterized by a substantially 
wider excitation and emission bandwidth. To discriminate the cells expressing GFP 
from these autofluorescent structures, autofluorescence was detected by imaging at 
405nm excitation and 410-440 nm emission. The resulting autofluorescence image 
was then subtracted from the GFP image, resulting in an autofluorescence-free 
GFP image (Figure 1A). Recent studies showed that in addition to GFP, multiple 
FPs can be simultaneously imaged in vivo [11-14]. In line with this, the DNA tattoo 
strategy also allowed (the simultaneous) detection of cells expressing a broad range 
of fluorescent reporters (FP), including cyan fluorescent protein (CFP), yellow 
fluorescent protein (YFP) and DsRed. As expected, the in vivo emission spectra of 
the tested FPs were similar to those reported in vitro (Figure 1B). When performing 
intravital imaging at several time points post-tattoo, the first fluorescent cells could 
be detected as early as 2 hours after DNA application. Although the number of 
transfected cells varies per tattoo (ranging from 100 to 300 cells per 10 mm2), 
the kinetics of expression are the same; within 24 hours the number of detectable 
cells increases approximately 2-fold and gradually declines over 4 days, at which 
point all expression has disappeared (this was observed for all tested FPs, and a 
representative GFP example is shown in Figure 1C). Adding to the flexibility of 
the DNA tattoo approach, tattoo application of a mixture of plasmids encoding 
different FPs (i.e. H2B-GFP and DsRed), resulted in detectable expression of both 
reporter genes in approximately a third of the transfected cells (Figure 1D). This 
number may be an underestimate because the wide range of observed intensities 
suggests that in many transfected cells one of the probes may be expressed below 
the level of detection. 
Having established the feasibility of monitoring biosensor expression in DNA 
tattoo-treated skin, we set out to determine the versatility of this approach to 
report on cellular processes and its ability to follow the fate of individual cells 
through time. Using a 63x 1.2NA water objective, captured skin images showed 
subcellular-resolution with details as small as ~300 nm (FWHM). Two GFP 
fusion proteins, GFP-actin and the PtdIns(4,5)P2 reporter GFP-PH, displayed 
their expected subcellular distribution: at the periphery of the cell in the cortical 
cytoskeleton and at the plasma membrane, respectively (Figure 2A). Importantly, 
we could reproduce the previously made in vitro observation that UV exposure of 
cells results in decreased PtdIns(4,5)P2 levels [15], as revealed by translocation of 
GFP-PH to the cytosol in cells irradiated with UV but not in control cells (Figure 
2A, lower panel).
While many intracellular processes can be followed by monitoring the distribution 
of location-based probes, certain processes, such as conformational changes, 
are better revealed by (kinetic changes in) FRET. To assess the feasibility of in 
vivo FRET measurements and of the longitudinal follow-up of individual cells, 
we first applied the FRET-based Ca2+ sensor ‘Yellow chameleon’ (Ycam) and its 
fluorescent constituents, CFP and YFP on separate skin patches of the same animal. 
In Ycam-tattooed skin areas FRET was readily detectable either by sensitized YFP 
INTRAVITAL IMAGING OF FLUORESCENT MARKERS AND FRET PROBES BY DNA TATTOOING.
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emission (as described in [16], Figure 3A, left panel) or by acceptor photobleaching 
(Figure 3B, right panel, for control experiments, see Figure 3B). In order to follow 
individual cells for multiple days, we subsequently set up a coordinate system that 
allows one to relocate the same cell in subsequent imaging sessions. To this purpose, 
ink reference points are applied at the edge of the tattooed area and the position of 
cells of interest relative to these marker points is recorded during the first imaging 
session (Figure 4A). In subsequent imaging sessions, the coordinates of these cells 
combined with overview images at low (5x) magnification (Figure 4B) are then 
used to retrieve the position of defined cells (for details, see methods). 
To determine the potential of such longitudinal analysis, we performed a time-
lapse experiment to study the involvement of caspase-3 in experimentally-induced 
apoptosis. To this purpose, a FRET-based sensor of caspase-3 activity, consisting 
of CFP and YFP moieties separated by a caspase-3 substrate site (modified from 
[17]) was utilized. DNA encoding this ‘apoptosis-sensor’ was mixed with DNA 
encoding an ‘apoptosis-switch’, consisting of a modified FK506- (tacrolimus) 
binding domain fused to caspase-9 [18], in a bicistronic configuration with tdtomato. 
This mixture was then applied to the abdominal skin of a mouse by DNA tattoo. 
In parallel, as a control for background apoptosis, a separate skin patch was 
tattooed with the apoptosis-sensor mixed with a vector encoding tdtomato only 
(pVax-tdtomato). To follow the consequences of apoptosis induction in vivo, 
autofluorescence, CFP and YFP images were recorded in the same set of cells 
expressing the apoptosis sensor, before and 24 hours after intraperitoneal injection 
of the suicide switch activator AP20187 (Figure 5A). Remarkably, after AP20187 
administration the activation of caspase-3 was readily detected by a drop in YFP/
CFP fluorescence ratio, as shown in the higher magnification images in Figure 
5B. In line with this, after AP20187 administration, the clear peak of sensitized 
YFP emission disappeared (Figure 5C). Importantly, cells in skin areas of the same 
animal treated with the apoptosis-sensor plus control DNA did not show a change 
in emission spectrum upon AP20187 administration (Figure 5D). Collectively, the 
data from this experiment demonstrate that this technique allows one to induce a 
defined process in individual cells and to subsequently monitor the effects of this 
process (in this case caspase-3 activation) in vivo by an appropriate fluorescent 
sensor. 
Conclusions 
Mouse transgenesis in combination with intravital imaging is time-consuming 
and can only be performed in specialized laboratories. Here we have presented a 
tattoo-based intravital imaging assay using techniques that are generally available. 
Clearly, this new approach that is based on the intradermal delivery of fluorescent 
reporters by DNA tattoo has its limitations. First, transgene expression obtained 
by the ‘instant-transgenic’ method as used here is confined to the epidermis and 
second, the expression of fluorescent reporters is restricted to a few days. In future 
studies, the duration of expression may be prolonged by enabling integration [19] or 
episomal maintenance of the plasmid used for transfection [20]. Furthermore, in vivo 
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transfection using naked DNA can be achieved by various means in other tissues, 
including hepatocytes [21], myocytes [22] and lymphocytes [23]. More importantly, for 
many applications the abovementioned drawbacks are balanced by the substantial 
advantages provided by intravital DNA tattoo imaging. Firstly, mice expressing 
multiple cellular reporters can be generated in a time span of hours instead of months 
to years. Secondly, because it is possible to restrict expression of transgenes and 
reporters to a subset of cells amidst a population of unmodified cells, it is feasible 
to follow the behavior of gene-modified cells in isolation. In addition, this allows 
the retracing of individual cells in order to study these cells over a period of days. 
Thirdly, several tattoos with different combinations of transgenes and reporters 
can be compared within the same animal, thereby reducing experimental variation. 
Finally, imaging can be performed on widely available confocal or epifluorescent 
microscopes. These features suggest that intravital DNA tattoo imaging can form 
a highly rapid and versatile system to analyze cellular processes such as cell cycle 
progression, cellular differentiation or apoptosis in an in vivo setting. 
Methods
DNA tattoo
The abdomen of the mouse was shaved and subsequently treated with depilation 
cream (Veet, Reckitt&Colmann, France). The nude abdominal surface was 
thoroughly rinsed to remove remaining cream, and a droplet of 20 µg DNA in 10 
µl water was applied to the skin. Using a sterile disposable 11-needle bar (fine 
magnum 15, 'challenge in colors' China) mounted on a rotary tattoo/permanent 
make-up device (Cold skin, B&A trading, Lijnden, the Netherlands) the DNA was 
tattooed in the skin over a surface of approximately 30 mm2 [10]. During the 15 
second tattoo, the needles oscillated at 100 Hz to a depth of 0.5 mm. Following 
application of the DNA, reference points were tattooed with black permanent 
make-up ink using a single point needle cartridge (Nouveau contour BV, Weert, 
Netherlands) mounted on a permanent make-up device (fine magnum 15, Aella, 
Medium-Tech, Berlin, Germany). All animal experiments were approved by the 
relevant institutional ethical committee (DEC) and performed in accordance with 
the local guidelines.
Microscopy
Anesthetized mice (GFP-MHC class II mice [24] were a kind gift of R. Offringa) 
were transferred to a 37˚C heated cage, mounted to an inverted TC-SP-AOBS 
confocal microscope (Leica, Mannheim, Germany). A 5x dry objective (0.15 HC 
PL Fluotar) and a 20x dry objective (0.7 HC) were used to collect overview images, 
and a 63x water objective (1.2 PL APO) to collect high resolution images.
In vivo FRET imaging
In vivo FRET was measured by three independent methods; measurement of 
sensitized YFP emission, measurement of emission spectra, and measurement of 
the gain in CFP fluorescence upon YFP photo bleaching. For sensitized emission 
(YFP fluorescence upon CFP excitation), three images were collected: a CFP 
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image excited at 405 nm and detected between 430 and 480 nm, a sensitized 
emission image excited at 405 nm and detected between 528 nm and 603 nm, 
and a YFP image excited at 514 nm and detected between 528 nm and 603 nm. 
Sensitized emission (FRET) was calculated from these images by correcting the 
sensitized emission image for leak-through of CFP fluorescence and fluorescence 
due to direct YFP excitation as described in [16]. Correction factors for leak-
through of CFP and indirect excitation of YFP were determined on-line from cells 
expressing CFP or YFP only at different locations on the same animal. For every 
collected FRET image, images of cells expressing CFP or YFP only were collected 
subsequently to re-determine correction factors for laser fluctuations. Emission 
spectra were measured by collecting series of xyλ-images at 405 nm excitation 
and at 10 nm bandwidth emission starting at 430 nm and ending at 650 nm. No 
significant YFP emission was observed in emission spectra of cells expressing only 
YFP. Moreover, FRET observed by spectrum imaging was confirmed by the gain 
of CFP fluorescence after photo-destruction of YFP. The CFP gain was not a result 
of photo conversion of YFP during photo bleaching as described in [25], because 
YFP bleaching of skin cells expressing YFP only did not result in a significant 
increase in fluorescence at CFP wavelengths.
Coordinate system to image the same cells for several days
Cells of interest were retraced using a coordinate system. The coordinate system is 
based on two black ink reference points, which are tattooed on the mouse abdomen: 
an origin and a reference. The distance L(ref) and the angle a(ref) between the 
origin and the reference are determined by a custom-made Visual Basic (v6.0) 
program by calling commands from the Leica macro tool package. For every cell 
coordinate, the distance L(cell) and the angle a(cell) between the cell and the origin 
are determined and saved. During the next imaging session, the re-anaesthetized 
animal is re-positioned on the confocal microscope. While L(ref) and L(cell) will 
be similar (but not identical, see below) at subsequent time-points, the reference 
a(ref) and all cell angles (a(cell)) will vary because of small rotations in the position 
of the mouse. To correct for this, a(ref) is re-determined, and all cell angles (a(cell)) 
are corrected for changes in a(ref). The positions of the cells are then recalculated 
from the corrected a(cell) values and L(cell). Stretching of the skin does result in 
small deviations in L in subsequent imaging sessions and therefore can result in 
misalignment of the position of cells up to 0.5 mm. To avoid this issue we use an 
overview image at low (5x) magnification to determine the exact coordinate of 
each cell (Figure 4). Once a single misalignment has been resolved, all positions 
(within a radius of 5 mm) are corrected for this misalignment.
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Figure 1 - Fluorescent protein expression in single cells after DNA tattooing on the 
skin of a living mouse 
A) Using a standard tattoo machine, a pVAX vector encoding GFP (upper panel) 
or an empty pVAX vector (lower panel) were tattooed into the skin of mice. 
Confocal GFP and autofluorescence images were collected as described in the 
text and GFP images were corrected for autofluorescence by subtracting 0.95x 
the autofluorescence image. B) The in vivo emission spectra of CFP, GFP, YFP or 
DsRed and autofluorescence, the latter at 405nm excitation. C) The number of GFP 
expressing cells counted within the same 10mm2 skin area at different time points 
post tattoo, as indicated in the graph. D) Merged GFP and DsRed images of skin 
tattooed with a mixture of H2B-GFP- and DsRed-encoding vectors. Inset, a cell 
expressing both H2B-GFP and DsRed.
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Figure 2 - Imaging of location-based biosensors with subcellular resolution
A) Images of GFP-actin (top panel) and GFP-PH (lower panel) were collected 
from the medial section of cells using a confocal microscope. Note that GFP-PH 
translocated from the membrane to the cytosol in cells following UV-A exposure, 
but not in non-exposed (control) cells. The post-irradiation time is indicated in the 
images.
6
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Figure 3 - In vivo FRET
A) CFP, YFP and sensitized emission (FRET) images (Left panel) and emission 
spectra (Right panel) were collected from skin cells expressing Ycam. The red 
and blue spectrum are pre- and post-YFP photo destruction respectively. Note the 
gain in CFP fluorescence after photo destruction of YFP. B) Control experiments 
for intravital FRET imaging. (Left panel) The collected FRET images in A were 
corrected as described in methods. FRET was not observed in cells expressing 
only CFP or YFP, consistent with proper correction. (Right panel) The emission 
spectrum acquired using CFP excitation wavelength (405 nm) of a cell expressing 
only YFP. The expression level of YFP is similar to that of Ycam in A. Note that 
YFP is inefficiently excited at 405 nm, and that photo destruction of YFP does not 
result in an increase of fluorescence at CFP wavelengths.
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Figure 4 - Defined cells can be followed over multiple days
A) In order to set up the coordinate system, two black ink reference points are 
tattooed on the abdomen of mice; origin and reference. At T0, the distance L(ref) 
and the angle a(ref) are measured between the two reference points. For cell 
coordinates, the distance L(cell) and the angle a(cell) are measured between the cell 
and origin. B) At a subsequent timepoint (T1), small rotations in the position of the 
mouse alter a(ref) and a(cell), but not L(ref) and L(cell). a(ref) is measured again, 
and a(cell) is corrected by the difference in a(ref) at T0 and T1. Knowing L(cell) 
and a(cell), the positions of the previously recorded cells can be re-calculated. 
(Right panels) Merge of GFP (green) and background (cyan) overview images 
of the skin of a mouse at T=0 and T=24 hours, imaged with a low-magnification 
objective (5x). The same cells are found back using the coordinate system. Insets 
represent the boxed regions, which have been imaged with a higher magnification 
objective (20x).
6
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Figure 5 - Visualizing apoptosis in the skin of a living mouse by FRET
A) An AP20187 sensitive 'apoptosis-switch' and FRET-based 'apoptosis-sensor' 
were tattooed on the skin of living mouse. Apoptosis was induced by injection 
of the chemical inducer of dimerization AP20187 in the peritoneal cavity of the 
mouse. Images were taken by confocal microscopy before and 24 hours after 
injection. Cells were identified by image registration at multiple time points as 
described in the text and supplementary data. A representative cell is boxed. Shown 
are merged images of the tdtomato, YFP and autofluorescence. B) CFP and YFP 
images of the cell as boxed in A imaged at higher resolution. Note the loss in FRET 
as a consequence of apoptosis induction. C) Emission spectrum of the cell boxed 
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in A before injection of AP20187 (left, blue spectrum) and 24 hours after injection 
(right, red spectrum). D) Spectrum of a cell in the same animal as in C, double 
transfected with a control construct plus the FRET based apoptosis-sensor 24 hours 
after injection of AP20187.
Additional text
The fluorescent cells observed after DNA tattooing are predominately keratinocytes 
The epidermal layer of mouse skin is nearly exclusively composed of keratinocytes 
and antigen presenting cells (Langerhans cells). Judged by morphology, a large 
fraction of the cells expressing FPs after DNA tattooing are keratinocytes. In line 
with this, application of a GFP-encoding plasmid in which transcription is driven 
by the keratinocyte-specific K14 promoter yields detectable expression in a high 
number of cells (approximately 50% as compared to the number of FP-positive cells 
observed upon introduction of a CMV IEdriven transgene) (additional file Figure 
1A). Because the K14 promoter is 10-100 fold weaker than CMV IE-promoter, 
the number of GFP-expressing keratinocytes observed upon application of the 
K14-driven GFP vector is likely to be an underestimate. To determine whether 
transgene-expression can also be observed in skin-resident antigenpresenting 
cells, we tattooed an H2B-mRFP-encoding plasmid to transgenic mice in which 
all Langerhans cells are marked by GFP expression (GFP fusion to MHC class 
II [24]). While both GFP-marked Langerhans and mRFP-expressing cells are 
readily observed, co-expression of the two FPs is rare (additional file Figure 1B), 
indicating that only small numbers of Langerhans cells are transfected after DNA 
tattooing. In conclusion, although both keratinocytes and APCs are present in the 
epidermal layer of the skin, the fluorescent epidermal cells that are observed after 
DNA tattooing are predominately keratinocytes.
Additional Figure 
DNA tattooing results in fluorescent keratinocytes. A) GFP expression observed 
upon application of a keratinocyte-specific K14 promoter-driven GFP transgene. 
Application of DNA encoding K14 or CMV IE-driven GFP transgenes resulted in 
approximately 8 or 16 fluorescent cells/mm9respectively. B) Transgenic mice in 
which all Langerhans cells express GFP were tattooed with a plasmid encoding a 
CMV IE-driven H2B-mRFP transgene. Depicted is a merge of a GFP and mRFP 
image.
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Abstract
Major histocompatibility complex (MHC) class I molecules associate with a large 
variety of peptide ligands during biosynthesis and present these ligands on the 
cell surface for recognition by cytotoxic T cells. We have designed conditional 
MHC ligands that form stable complexes with MHC molecules, but that degrade 
on command, by exposure to a defined photostimulus. “Empty MHC molecules” 
generated in this manner can be loaded with arrays of peptide ligands to determine 
MHC binding properties and to monitor antigen-specific T cell responses in a high-
throughput manner. The value of this approach is documented by the identification 
of cytotoxic T cell epitopes within the H5N1 influenza A/Vietnam/1194/04 
genome.
C H A P T E R  7
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Introduction
MHC class I molecules are heterotrimers that consist of an invariant light chain, 
a polymorphic heavy chain and an eight to ten amino acid peptide ligand. The 
peptide forms an essential subunit of the MHC class I complex, as MHC class 
I molecules that fail to associate with peptide ligand are unstable1,2. Association 
of peptides with MHC class I molecules is in large part based on shape and 
electrostatic complementarity between two amino acid side chains at the anchor 
positions of the peptide and MHC allele-specific pockets3,4. In addition, binding of 
peptide ligands depends on the interaction of the MHC molecule with the terminal 
α-NH
2
 and carboxyl groups of the peptide5,6. Because the sequence requirements 
for binding to MHC are largely restricted to two dominant anchor residues7, the 
average protein contains several dozen potential T cell epitopes and, as an example, 
the approximately 100 open reading frames of a member of the herpesviridae 
family contain an estimated 4,000 potential T cell epitopes. Definition of tumor 
and pathogen-encoded MHC ligands and detection of T cell responses specific for 
such ligands remains a major challenge. The visualization of antigen-specific T 
cell responses was first made possible with the development of tetrameric MHC 
reagents by Altman et al.8. In this strategy, soluble MHC monomers complexed 
with a peptide of interest are biotinylated and converted to tetravalent structures 
by binding to fluorochrome-conjugated streptavidin or avidin. The resulting MHC 
tetramers have become essential reagents for the detection of antigen-specific CD4+ 
and CD8+ T cells by flow cytometry. More recent work indicates that definition 
of antigen-specific T cell responses by MHC microarray-based strategies is also 
feasible9,10. Furthermore, MHC-based selection of antigen-specific T cells has been 
proposed as a strategy to boost melanoma-specific T cell responses in melanoma 
patients11 and to provide defined minor histocompatibility antigen-specific and 
virus-specific T cells in recipients of allogeneic stem cell transplants and other 
immunocompromised individuals12-17. At present, the major limitation of MHC 
tetramer-based technologies is formed by the involved nature of the refolding and 
purification steps that are required for every individual peptide/MHC complex. 
Consequently, it has not been feasible to apply MHC tetramer technology for high-
throughput applications. To address this issue, we have explored the possibility of 
identifying conditional MHC ligands that can be used to generate peptide-receptive 
MHC class I molecules at will. 
Results
Design of conditional MHC class I ligands
We set out to create MHC class I ligands that would disintegrate on command, 
while bound to the MHC complex. As a building block for such conditional 
ligands, we synthesized a 9-fluorenylmethyloxycarbonyl (Fmoc)-derivative of 3-
amino-3-(2-nitro)phenyl-propionic acid (J). Subsequently, we used this building 
block to generate variants of the human leukocyte antigen (HLA)-A2.1-restricted 
influenza A matrix (M1)
58-66
 epitope (sequence GILGFVFTL). An example of such 
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a variant, in which the Thr8 is replaced by 3-amino-3-(2-nitro)phenyl-propionic 
acid (resulting in compound I; GILGFVFJL), is given in Fig. 1a. Consistent 
with prior literature18,19, this compound disintegrates upon exposure to UV light 
(Fig. 1a), and following UV exposure, a molecule with a mass of 751.4 becomes 
apparent, corresponding to the mass of the heptameric peptide acetamide fragment 
(Fig. 1a, compound II, Fig. 1b). The small, carboxy-terminal peptide fragment that 
is also generated during this cleavage reaction was not further studied. 
To establish whether UV-sensitive ligands can be used to generate peptide/MHC 
complexes, we used two M1
58-66
 variants with 3-amino-3-(2-nitro)phenyl-propionic 
acid incorporated at position four (compound III; GILJFVFTL, Suppl. Fig. 1) or 
position eight (compound I, Fig. 1a) in MHC class I refolding reactions20. MHC 
refolding reactions with either GILJFVFTL or GILGFVFJL produced high yields 
of HLA-A2.1 complexes. As a first crude test of the sensitivity of the non-natural 
MHC-bound ligands towards UV-mediated cleavage, we exposed HLA-A2.1 
complexes containing either the unmodified influenza A M1
58-66
 epitope, or the 
GILJFVFTL or GILGFVFJL variant to UV and analyzed these reactions by gel-
filtration chromatography. Whereas the conventional HLA-A2.1/peptide complex 
is not affected by exposure to 366 nm light, exposure of either HLA-A2.1-
GILJFVFTL (not shown) or HLA-A2.1-GILGFVFJL (Suppl. Fig. 2a) leads to a 
substantial reduction in MHC recovery. Furthermore, when HLA-A2.1 complexes 
are prepared with an influenza A M1
58-66
 derivative in which the UV-resistant 
building block 3-amino-3-phenyl-propionic acid21 is incorporated, the resulting 
MHC complexes are insensitive to UV exposure, demonstrating that the UV-
induced decay of HLA-A2.1-GILJFVFTL and HLA-A2.1-GILGFVFJL requires 
the presence of the nitrophenyl moiety. Notably, the observed loss of folded MHC 
upon UV exposure of the HLA-A2.1-(GILGFVFJL) complex can be prevented 
by inclusion of HLA-A2.1 binding peptides during the cleavage reaction, but not 
by inclusion of a control HLA-A3 binding peptide (Suppl. Fig. 2b), suggesting 
efficient peptide exchange. 
While these data demonstrate the UV-sensitivity of HLA complexes containing 
3-amino-3-(2-nitro)phenyl-propionic acid-based peptide ligands, it is difficult to 
establish the efficiency of this cleavage reaction by gel-filtration chromatography 
(see Legend to Suppl. Fig. 2a). As a more stringent test for replacement of the 
conditional ligand by the newly added peptide, we exposed HLA-A2.1-GILGFVFJL 
complexes to UV light in the presence of the cytomegalovirus (CMV) pp65
495-503
 
epitope, and following this reaction, purified the peptide/MHC complexes and 
analyzed these complexes by mass spectrometry. The major peptide mass that is 
visible prior to UV exposure corresponds to the Na+ ion of GILGFVFJL, providing 
formal proof that this ligand forms a stable complex with HLA-A2.1 (Fig. 2). 
Following UV-mediated cleavage, no detectable amount of GILGFVFJL remains 
associated with HLA-A2.1. Furthermore, also the levels of cleavage product II 
complexed with HLA-A2.1 are below background, suggesting that dissociation 
of this heptameric peptide fragment is essentially complete. Instead, upon UV-
DESIGN AND USE OF CONDITIONAL MHC CLASS I LIGANDS
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mediated cleavage the sole peptide mass visibly associated with HLA-A2.1 
corresponds to the mass of the CMV pp65
495-503
 epitope (Fig. 2). Collectively, these 
experiments indicate that conditional MHC ligands can be defined that are released 
from MHC molecules at will and that MHC molecules generated in this process 
can be loaded with epitopes of choice. To extend these data to other conditional 
HLA A2.1 ligands, we synthesized a peptide that is predicted to bind avidly to 
HLA-A2.122, with the UV-sensitive building block J incorporated at position 
eight (ILAETVAJV). Refolding reactions with this conditional ligand gave high 
yields of folded HLA-A2.1 complexes and, analogous to the data obtained with 
HLA-A2.1-GILGFVFJL complexes, these complexes disintegrate following UV 
exposure (data not shown).
MHC exchange tetramers
To test the potential value of this MHC exchange technique for the visualization of 
antigen-specific T cells we performed MHC exchange reactions with biotinylated 
HLA-A.2.1- GILGFVFJL or HLA-A.2.1-ILAETVAJV complexes. Subsequently, 
phycoerythrin (PE)-streptavidin was added, and the resulting MHC tetramers 
(hereafter referred to as MHC exchange tetramers) were used to detect antigen-
specific T cells by flow cytometry. MHC exchange tetramers containing the high 
affinity (A2L) variant of the Melan-A/MART-1
26-35
 epitope23 stain a MART-1-
specific CTL clone as efficiently as conventional MHC class I tetramers (Fig. 
3a). Likewise, MHC exchange tetramers can be used to detect low magnitude T 
cell responses in peripheral blood samples (Fig. 3b, Suppl. Fig. 3a). UV-induced 
cleavage of MHC-bound ligands also allows the synthesis and use of MHC 
tetramers that contain the naturally occurring MART-1
26-35
 peptide that binds to 
MHC class I with low affinity, due to the absence of a leucine/ methionine residue at 
the P2 anchor position (Fig. 3a). This indicates that UV-induced peptide exchange 
is sufficiently robust to screen collections of putative T cell epitopes without a 
priori knowledge of MHC binding affinities. Importantly, MHC tetramers prepared 
from HLA-A2.1-GILGFVFJL complexes or A2Kb-GILGFVFJL complexes (see 
further) that have not been exposed to UV light, and that are therefore uniformly 
occupied by the UV-sensitive M1
58-66
 variant, do not stain polyclonal influenza 
A M1
58-66
-specific T cells (Suppl. Fig. 3b and 3c). This indicates that either the 
alteration in the peptide backbone due to the introduction of an unnatural β-amino 
acid, or the replacement of the threonine side chain is incompatible with T cell 
recognition by M1
58-66
–specific T cells. Consequently, even in settings where 
release of conditional ligand would not be optimal, MHC exchange reagents 
are not expected to display background reactivity due to the presence of residual 
conditional ligand. It is noted that if conditional ligand-MHC complexes for other 
alleles would display background reactivity, it should be straightforward to prevent 
such reactivity by modification of T cell receptor-exposed sidechains. Notably, 
MHC tetramers generated by UV exchange compare favorably to MHC-Ig dimers 
generated by passive peptide exchange24,25, both with respect to signal intensity and 
signal-to-noise ratios (Suppl. Fig. 4a, 4b).
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To test whether conditional ligands may readily be identified for other MHC class 
I alleles we synthesized four variants of the H2-Db-restricted ASNENMETM 
influenza A NP
366-374 
epitope. Two of those variants, IV and V (Suppl. Fig. 1), 
fulfilled both criteria in that H2-Db complexes could be generated with these 
conditional ligands and that these ligands could be cleaved in the MHC-bound 
state. Consistent with the data obtained for HLA-A2.1, H-2Db exchange tetramers 
prepared from UV-sensitive H-2Db-ASNENJETM complexes stain antigen-
specific T cells with high specificity (Fig. 3c). Furthermore, as is the case for HLA-
A2.1-GILGFVFJL tetramers, H-2Db-ASNENJETM tetramers that are uniformly 
occupied by the UV-sensitive variant of NP
366-374
, do not stain influenza A NP
366-374
-
specific T cells (Fig. 3c). 
High-throughput screening with MHC exchange reagents
As a first test of the potential of MHC exchange for high-throughput epitope 
mapping, we cloned and sequenced the four genes encoding the immunodominant 
proteins of A/Vietnam/1194/04, an influenza A H5N1 strain isolated from a fatal 
human case in Vietnam, and scanned the encoded proteins for potential HLA-A2.1 
binding peptides. Within the hemagglutinin (HA), neuraminidase (NA), matrix-1 
(M1) and nucleoprotein (NP) gene products, we identified 132 potential epitopes 
with a score for predicted MHC binding of ≥2022, and these peptides were produced 
by micro-scale synthesis. In parallel, we used the same set of genes to prepare 
vectors for DNA vaccination and groups of HLA-A2.1 transgenic mice26 were 
vaccinated by DNA tattoo27. At the peak of the vaccination-induced T cell response, 
we generated a collection of MHC exchange tetramers by performing 132 parallel 
UV-mediated exchange reactions on A2Kb-GILGFVFJL complexes28 in microtiter 
format, and the resulting MHC tetramer collection was used to screen peripheral 
blood samples of vaccinated mice. This analysis demonstrated the presence of two 
T cell epitopes within these four gene products of A/Vietnam/1194/04. Specifically, 
this screen confirmed the immunogenicity of the known influenza A M1
58-66
 epitope 
that is conserved between the majority of influenza A strains. In addition, this scan 
revealed the presence of a previously unknown HLA-A2.1-restricted T cell epitope 
located in the A/Vietnam/1194/04 nucleoprotein (Fig. 4). Interestingly, in this 
HLA-A2.1 transgenic mouse model, the immunogenicity of this epitope (NP
373-381
) 
is substantially higher than that of the classical M1
58-66
 epitope (M1
58-66
: one out 
of five responding mice after primary vaccination, three out of five responding 
mice after secondary vaccination; NP
373-381
: five out of five responding mice after 
primary vaccination). This novel T cell epitope is shared between H5N1 strains of 
the past years but is distinct in older influenza A strains. 
Discussion
Here we have described conditional MHC ligands that can disintegrate in the 
MHC bound state under conditions that do not affect the integrity of the MHC 
molecule, thereby permitting the reloading of assembled MHC molecules with 
epitopes of choice. Importantly, the peptide ligands that are bound to the MHC 
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in these reactions are unmodified, nor is the MHC backbone altered. In line with 
this, MHC complexes generated by this exchange technology display the predicted 
binding specificity in all cases tested. This strategy and related chemical cleavage 
strategies should be of substantial use in the high-throughput identification of 
both MHC ligands and cytotoxic T cell responses. In this strategy, a single batch 
of UV-sensitive MHC complex is prepared by the classical in vitro MHC class 
I refolding and purification protocols, and this UV-sensitive MHC complex is 
subsequently used to generate large arrays of desired pMHC complexes in 1 h 
exchange reactions. 
MHC-Ig dimers purified from eukaryotic cells have previously been used 
to generate peptide/MHC reagents, by performing exchange reactions with 
exogenously added peptide24,25. While the overall goal of this technology is similar 
to that of UV-induced peptide exchange, the technologies differ at essential points. 
Specifically, while the MHC-Ig dimer technology depends on the slow release of a 
pool of unknown endogenous peptides, and is facilitated by conditions (e.g. low or 
high pH) that also destabilize the MHC molecule, UV-induced peptide exchange is 
based on the release of a single ligand, by exposure to a defined trigger that does 
not affect the integrity of the MHC molecule. Furthermore, the capacity of MHC-Ig 
based reagents to reveal antigen-specific T cell responses is limited as compared to 
MHC exchange tetramers (Suppl. Fig. 4). 
The observation that ligands that disintegrate on command could readily be 
identified for both tested MHC alleles suggests that it will be straightforward to 
identify 2-nitrophenyl-based conditional ligands for other MHC class I alleles. 
Conditional ligands can be designed by replacement of amino acids in either a 
known peptide ligand, or in a predicted high affinity ligand based on the peptide 
binding motif for this allele, and for HLA A2.1 both approaches proved successful. 
For MHC alleles for which structural information is available, the water-
accessibility of sidechains may also be used as a criterion to select positions at 
which the UV-sensitive building block can be incorporated. 
Various types of functional assays for antigen-specific T cell detection such as 
intracellular cytokine staining and cytokine capture have been developed in the 
past few years and these assays may be utilized for high-throughput analysis of T 
cells that display a given effector function. MHC exchange multimer technology 
should complement these technologies by allowing high-throughput analysis 
of T cell responses, irrespective of the capacity of T cells to produce a given 
cytokine. Also the combination of the two technologies, in which high complexity 
MHC multimer arrays are used to probe T cell reactivity by monitoring cytokine 
production may be particularly useful. On-command cleavage of MHC ligands 
also seems attractive for the production of sets of clinical grade MHC reagents 
for adoptive T cell therapy13. Specifically, the generation of a single large batch of 
clinical grade MHC molecules complexed with conditional ligand should allow the 
straightforward assembly of an MHC reagent desired for clinical use, by performing 
MHC exchange reactions with the relevant peptide ligands. Such high-grade MHC 
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reagents should be particularly attractive for the isolation of melanoma-specific T 
cells29, and for the isolation of defined minor histocompatibility antigen-specific T 
cells12. Finally, in addition to the use of conditional MHC class I ligands for high-
throughput diagnostic screening and for adoptive T cell therapy, we speculate that 
cleavage of ligands bound to MHC molecules in the crystalline state30 might be 
used to obtain the elusive structure of empty MHC class I.
Methods
Peptide synthesis and preparation of recombinant MHC. We obtained the 
UV-sensitive building block for peptide synthesis (N-fluorenylmethyloxycar
bonyl 3-amino-3-(2-nitro)phenyl-propionic acid) by protection of 3-amino-3-
(2-nitro)phenyl-propionic acid (Lancaster) with fluorenylmethyl chloroformate 
(Sigma-Aldrich) in dioxane/ 10% aqueous Na
2
CO
3
 3/2 v/v according to a 
published procedure21. We synthesized naturally occurring peptides and UV-
sensitive peptide variants by standard Fmoc synthesis. We performed MHC class I 
refolding reactions as described20 and we purified refolded MHC class I molecules 
by gel-filtration chromatography on a Phenomenex Biosep SEC S3000 column 
(Phenomenex) in 20 mM Tris-HCl pH 7.0/ 150 mM NaCl. Purified MHC class I 
complexes are stored at -20 °C in 20 mM Tris-HCl pH 7.0/ 150 mM NaCl and 16% 
glycerol. 
MHC exchange reactions. To produce single or small sets of MHC reagents by 
MHC exchange, we exposed biotinylated HLA-A2.1- GILGFVFJL, HLA-A2.1-
ILAETVAJV or H-2Db-ASNENJETM complexes (0.5 µM in 20 mM Tris-HCl 
pH 7.0/ 150 mM NaCl/ 0.5 mM dithiothreitol (DTT)) to UV (366 nm UV lamp, 
CAMAG) in the presence of 50 µM of the indicated peptides for 1-2 h on ice. 
Following exchange, samples were spun at 16,000g for 5 min, (PE)-streptavidin 
was added and we used the resulting MHC exchange tetramers for T cell staining 
without further purification.
To generate the collection of H5N1 A2Kb tetramers, we predicted potential peptide 
epitopes within four gene segments of influenza A/Vietnam/1194/04 using the 
SYFPEITHI prediction program22 and all peptides with a SYFPEITHI score ≥20 
were produced by micro-scale (60 nmole) synthesis (JPT Peptide Technologies 
GmbH). Of the 132 potential epitopes, 116 terminated in either a valine, leucine or 
isoleucine residue and these were synthesized with the naturally occurring carboxy-
terminal amino acid. The remaining 16 peptides, terminating in various non-
aliphatic amino acids, were all synthesized with a carboxy-terminal isoleucine to 
facilitate peptide production. We prepared MHC exchange tetramers by performing 
parallel small scale exchange reactions on biotinylated A2Kb-GILGFVFJL class 
I complexes (0.5 µM)28 with the 132 candidate influenza A/Vietnam/1194/04 
epitopes and a set of control peptides (all peptides at 50 µM), by exposure to UV 
(366 nm UV lamp, CAMAG) for 1 h on ice in 20 mM Tris-HCl pH 7.0/ 150 mM 
NaCl/ 0.5 mM DTT in 96 well tissue culture V-bottom polystyrene plates (NUNC). 
Subsequently, samples were spun at 3,300g for 5 min, (PE)-streptavidin (10 µg/ml 
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final concentration) was added, and we used the resulting MHC exchange tetramers 
for T cell staining without further purification. 
Mice and vaccinations. 
We obtained C57BL/6 mice and mice transgenic for the HLA-A2Kb fusion 
gene26 from the animal department of the Netherlands Cancer Institute. All 
animal experiments were carried out in accordance with institutional and national 
guidelines and were approved by the Experimental Animal Committee of the 
Netherlands Cancer Institute (DEC). 
For live influenza A infections, we intranasally administered 50 µl of HEPES-
buffered saline solution (Life Technologies) containing 200 hemagglutinating 
units influenza A/HKx31 virus to anesthetized mice. For vaccination of HLA-
A2 transgenic mice with H5N1 gene segments, we obtained the indicated gene 
segments from influenza A/Vietnam/1194/04, isolated from a human case in 
Vietnam and cloned these into pVAX. Groups of four to six mice were vaccinated 
by DNA tattoo27 on day 0, 3 and 6 with 20 µg of pVAX expressing either the 
influenza A/Vietnam/1194/04 M1, HA, NA or NP gene under control of the CMV 
promoter. 
Cells and Flow cytometry. For analysis of MHC multimer binding and T cell 
responses in mouse samples, we obtained peripheral blood and erythrocytes 
were removed by incubation in erythrocyte lysis buffer (155 mM NH
4
Cl, 10 
mM KHCO
3
, 0.1 mM EDTA, pH 7.4) on ice. Cells were stained with antibody to 
CD8α (BD Biosciences) and the indicated MHC tetramers for 10–15 min at room 
temperature. 
For analysis of MHC multimer binding and T cell responses in human samples, 
we obtained peripheral blood mononuclear cells of healthy volunteers by Ficoll 
gradient separation. The MART-1
26-35
 specific CTL clone was obtained by 
repetitive stimulation and cloning of tumor-infiltrating lymphocytes of a melanoma 
patient. Cells were stained with the indicated MHC tetramers for 5 min at 37 °C. 
Subsequently, CD8-specific antibody (BD Biosciences) was added and cells were 
incubated for 10–15 min at room temperature. Data acquisition and analysis was 
carried out on a FacsCalibur (Becton Dickinson) using CellQuest software.
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Figure 1: Photocleavage strategy. (a). Top: Structure of I, the photocleavable 
analog of the influenza A M1
58-66
 epitope obtained as an approximate one to one 
mixture of diastereoisomers. Single amino acid sequence: GILGFVFJL. Bottom: 
Structure of II, the heptameric peptide fragment generated upon UV-induced 
degradation of I. Asterisks in I and II indicate the preferred cleavage site. (b). 
Liquid chromatography-mass spectrometry (LC-MS) of I prior to and following 
exposure to 366 nm light (CAMAG) for 60 min, in the presence of 0.5 mM DTT. 
Expected masses: single-protonated I: 1,057.6; single-protonated II: 751.4. 
TOF MS ES+
           73.3
TOF MS ES+
           89.8
m/z
m/z
1,079.6  [I-Na+]
1,080.6     
1,057.6
966.6     
943.6
965.6  [CMV pp65495-503-Na+]     
750 800 850 900 950 1,000 1,050 1,100 1,150700
Percent
Percent
0
0
100
100
Figure 2: UV-mediated peptide exchange. Mass spectrometry of HLA-A2.1-
associated peptide of HLA-A2.1-GILGFVFJL complexes prior to (left panel) and 
following (right panel) UV exposure in the presence of CMV pp65
495-503
 peptide. 
Observed masses and assignments are indicated. Expected masses: Na+ ion of I: 
1,079.6; Na+ ion of CMV pp65
495-503
: 965.5. Note the absence of detectable I-Na+ 
following UV-induce peptide exchange (arrow). 25 µM HLA-A2.1-GILGFVFJL 
in 20 mM Tris-HCl pH 7.0/ 150 mM NaCl and 0.5 mM DTT was exposed to 366 
nm light for 60 min on ice in the presence of 500 µM CMV pp65
495-503
 peptide. 
Subsequently, HLA-A2.1-peptide complexes were purified by gel-filtration 
chromatography on a Biosep SEC S-3000 column in 25 mM NH
4
OAc pH 7.0 
and directly used for analysis on a Waters LCT ESI mass spectrometer by direct 
infusion under optimized conditions (160 V cone voltage, 160 °C desolvation 
temperature). Note that the use of high cone voltage/ high temperature results in 
the detection of predominantly sodiated species.
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Figure 3: T cell staining with MHC exchange tetramers. (a). Flow cytometric 
analysis of MHC tetramer staining of a MART-1
26-35
-specific CTL clone with 
classical MHC tetramers containing the MART-1
26-35(A2L)
 epitope (top left panel), or 
MHC exchange tetramers containing the MART-1
26-35(A2L)
 epitope (top right panel), 
a control peptide (HY
311-319
, bottom left panel), or the naturally occurring low 
affinity MART-1
26-35
 epitope (bottom right panel). (b). Flow cytometric analysis 
of peripheral blood mononuclear cells from an HLA-A2.1 positive individual 
stained with classical MHC tetramers containing the CMV pp65
495-503
 epitope (top 
left panel) or influenza A M1
58-66
 epitope (top right panel), or with MHC exchange 
tetramers containing a control peptide (HY
311-319
, bottom left panel), the CMV 
pp65
495-503
 epitope (bottom middle panel) or the influenza A M1
58-66
 epitope (bottom 
right panel). 
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(c). Flow cytometric analysis of MHC tetramer staining of peripheral blood cells 
of a C57BL/6 mouse (top panel) or a C57BL/6 mouse eight days post intranasal 
infection with influenza A/HKx31, encoding the A/PR8/34 NP
366-374 
ASNENMETM 
epitope (bottom panels). Analysis was performed with H-2Db exchange tetramers 
containing the A/PR8/34 NP
366-374
 epitope (left panels), a control peptide (SMCY
738-
746
 bottom middle panel), or H-2Db tetramers prepared from biotinylated H-2Db-
ASNENJETM monomers that had not undergone exchange reactions (bottom right 
panel). 
Figure 4: High-throughput screen of H5N1 T cell epitopes. (a). Flow cytometric 
analysis of mouse peripheral blood mononuclear cells stained with A2Kb-NP
373-381
 
exchange tetramers of either a non-vaccinated HLA-A2.1 transgenic mouse (left) 
or of an HLA-A2.1 transgenic mouse vaccinated at days 0, 3, 6 with 20 µg of A/
Vietnam/1194/04 NP-encoding DNA.
A2Kb-(I) UV NP373-381-PE A2Kb-(I) UV NP373-381-PE
0.03% 9.9%
anti-CD8-APC
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(b). Top: T cell responses of individual mice (closed squares) and average T cell 
responses (stripes) of non-vaccinated mice (–) and mice vaccinated with the 
influenza A/Vietnam/1194/04 M1 (left, +) and NP (right, +) genes, analyzed with 
the indicated A2Kb exchange tetramers at day 13 post primary vaccination. At the 
peak of the vaccination-induced T cell response, peripheral blood was drawn. 
Blood of mice in each of the four groups was pooled and analyzed by MHC 
tetramer staining. MHC tetramers that scored positive were used for re-analysis of 
individual mice. Bottom: T cell responses of individual mice (closed squares) and 
average T cell responses (stripes) of non-vaccinated mice (–) and mice vaccinated 
with the influenza A/Vietnam/1194/04 M1 (left, +) and NP (right, +) genes, 
analyzed with the indicated A2Kb exchange tetramers at day 11 post secondary 
vaccination. The identity of the NP
373-381
 epitope was confirmed by synthesis of this 
sequence on a preparative scale followed by HPLC purification and screening of 
vaccinated mice by MHC exchange tetramer staining and intracellular interferon-γ 
staining (data not shown).
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Supplementary Figure 1: Conditional ligands for HLA-A2.1 and H-2Db. Top: 
Structure of III, the photocleavable analog of the influenza A M1
58-66
 epitope 
in which Gly4 has been replaced by photolabile 3-amino-3-(2-nitro)phenyl-
propionic acid (single letter sequence: GILJFVFTL). Middle: Structure of IV, 
the photocleavable analog of the influenza A/PR8/34 NP
366-374 
epitope in which 
Met6 has been replaced by 3-amino-3-(2-nitro)phenyl-propionic acid (single letter 
sequence: ASNENJETM). Bottom: Structure of V, the photocleavable analog of 
the influenza A/PR8/34 NP
366-374 
in which Glu7 has been replaced by 3-amino-3-(2-
nitro)phenyl-propionic acid (single letter sequence: ASNENMJTM).
Supplementary Figure 2: Conditional peptide/MHC complexes are sensitive to 
UV. (a). Gel-filtration chromatography of HLA-A2.1 complexes occupied with 
the parental M1
58-66
 epitope (top) or HLA-A2.1 complexes occupied with the UV-
sensitive compound GILGFVFJL (bottom), with (green) or without (red) prior 
exposure to UV for 1 h on ice in 20 mM Tris-HCl pH 7.0/ 150 mM NaCl and 0.5 
mM DTT.
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(b). Gel-filtration chromatography of HLA-A2.1 complexes occupied with the UV-
sensitive peptide GILGFVFJL exposed to UV for 1 h on ice in 20 mM Tris-HCl 
pH 7.0/ 150 mM NaCl and 0.5 mM DTT without peptide (red), or in the presence 
of 100 µM of the HLA-A2.1-binding peptides MART-1
26-35(A2L)
 (green) or HY
311-
319
 (blue), or the HLA-A3-binding peptide gp100
614-62
 (black). Note: Free MHC 
class I heavy chains have a propensity to aggregate and this aggregation of free 
MHC class I heavy chains results in a loss of material eluting with a retention 
time of 11.8-12 min. This analysis underestimates the extent of UV-induced 
MHC destruction, as aggregation of MHC class I heavy chains is incomplete and 
separation of MHC class I complexes and free MHC class I heavy chains by gel-
filtration chromatography is inefficient.
Supplementary Figure 3: Sensitivity and specificity of MHC exchange tetramers. 
(a). Peripheral blood mononuclear cells of an HLA-A2.1 positive individual were 
stained with the indicated concentrations of conventional HLA-A2.1 tetramers 
or with HLA-A2.1 exchange tetramers containing either the influenza A M1
58-66
 
epitope or the CMV pp65
495-503
 epitope. Mean fluorescence intensity of the MHC 
tetramer+ cells was determined and is plotted as a function of MHC tetramer 
concentration. 
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(b). Flow cytometric analysis of peripheral blood mononuclear cells of an HLA-
A2.1 positive individual with HLA-A2.1 tetramers containing the UV-sensitive 
peptide GILGFVFJL (left panel), or the parental M1
58-66
 epitope (right panel). (c). 
Flow cytometric analysis of peripheral blood mononuclear cells of an HLA-A2.1 
transgenic mouse vaccinated with the influenza A/Vietnam/1194/04 M1-encoding 
expression plasmid with HLA-A2Kb tetramers containing the UV-sensitive peptide 
GILGFVFJL (left panel), or the parental M1
58-66
 epitope (right panel).
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Supplementary Figure 4: Detection of antigen specific T cells with MHC-Ig 
dimers and MHC exchange tetramers. (a). Flow cytometric analysis of peripheral 
blood mononuclear cells of four CMV-positive HLA-A2.1 positive individuals 
with MHC-Ig (DimerX) reagents (left) prepared with a control peptide (HY
311-
319
) or the CMV pp65
495-503
 peptide, or with HLA-A2.1 exchange tetramers (right) 
prepared with a control peptide (HY
311-319
) or the CMV pp65
495-503
 peptide. 
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(b). Plots of the background and specific 
staining obtained with MHC-Ig reagents 
and MHC exchange tetramers in four 
donors. Note that the intensity of 
staining of CMV pp65
495-503
 specific T 
cells is higher with HLA-A2.1 exchange 
tetramers than with MHC-Ig dimers 
and that the background observed with 
control MHC multimers is substantially 
lower than the background observed 
with MHC-Ig dimers. MHC-Ig dimers 
for HLA-A2.1 (BD Biosciences) were 
loaded with the HY
311-319 
or CMV 
pp65
495-503
 peptide per manufacturer’s 
protocol. In brief, DimerX reagents 
were prepared overnight at 37 °C, using 
a 640-fold molar excess of peptide 
over MHC-Ig (protocol 1, peptide 
concentration of 750 µM). Cells were 
stained with 1.5 µg of DimerX reagent 
for 1 h at 4 °C, followed by staining with 
PE-labeled anti-mouse IgG
1
 (clone A85-
1, BD Biosciences) plus FITC-labeled 
CD8-specific antibody (clone G42-8 
BD Biosciences) for 30 min at room 
temperature (protocol 2). 
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MHC exchange tetramers with the HY
311-319 
or CMV pp65
495-503
 peptide were 
prepared by performing 1 h UV-exchange reactions on HLA-A2.1-GILGFVFJL 
monomers in the presence of 50 µM of the indicated peptide on ice. Subsequently, 
samples were spun at 3,300g for 5 min, (PE)-streptavidin (10 µg/ml final 
concentration) was added, and the resulting MHC exchange tetramers were used 
for T cell staining without further purification. 
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Discussion
A short summary of the data described in this thesis
This thesis deals with the problems posed by active tumor immunization 
in cancer patients. It describes the failure of spontaneous T cell responses 
to sort a clinical effect in end-stage melanoma patients and studies the 
effect of a peptide-based vaccine in such patients, detecting no impact 
on clinical status nor on T cell function. In search for means to improve 
current active immunization strategies, the intradermal administration of 
DNA with a tattoo device is explored in mice and macaques, and found to 
be highly immunogenic in both species.
With regard to “DNA tattooing” it is not realistic to expect this novel 
immunization method to have a clinical effect in end-stage melanoma 
patients. In these patients the high tumor load and the tolerized 
state of the tumor specific T cell repertoire decimate the chances on 
successful immune mediated tumor eradication. Nevertheless, it may 
prove beneficial in earlier stages of this disease and in the treatment 
of virally induced tumors. Additionally, the method may be suitable for 
immunization against infectious diseases in remote, underdeveloped 
areas, due to the excellent keeping qualities of DNA and the low-tech 
application method.
Subsequently, this thesis presents evidence that antigens encoded by 
DNA vaccines should be stable in order to maximize the efficacy of the 
vaccine, both upon intradermal and intramuscular injection. Besides this 
clear message, the finding that antigen stability affects the efficacy of 
cross presentation contributes to the evolving insight in the mechanisms 
that govern cross-presentation: it suggests that upon DNA vaccination 
intact proteins are transferred form the antigen donor cell to the antigen 
presenting cell.
Finally, this thesis reports on two tools, one that facilitates the monitoring 
of vaccine induced T cell responses by peptide-MHC tetramers and 
another to further study the mechanism of dermal DNA vaccines, 
which may be helpful for their improvement. I’ll finalize this thesis by 
discussing the alleged steps of the mechanism of tattoo DNA vaccination. 
Doing so, I will try to point out where the bottlenecks may be and make 
suggestions on how these bottlenecks may be alleviated in order to 
improve the technology.
Suggestions for the improvement of tattoo DNA vaccination
 Transfection efficiency
After DNA tattooing, skin resident cells take up the DNA. In some of 
these cells the plasmid DNA passes through the cytosol and enters the 
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nucleus. Once the nuclei of a sufficient number of cells contain a plasmid, 
the first important bottleneck has been passed; when production starts 
approximately a few hours after the tattoo, a maximal number of antigen 
donor cells will help to generate sufficient antigen to induce a T cell 
response.
To increase the amount of transfected cells after DNA application, the 
DNA vaccine may be formulated in lipoplexes. This is a routine procedure 
for in vitro transfection. Also, some laboratories have shown that the 
transfection efficiency upon intradermal DNA administration increases 
by the addition of certain substances (e.g. aurintricarboxylic acid41, 
ATA) to the DNA. An equally simple method leading to the same result 
is to increase the concentration of the DNA vaccine. However, constraints 
imposed by the DNA production method limit the maximal concentration. 
Alternative and technologically more advanced approaches to optimize 
the transfection efficiency include the addition of a protein group to the 
DNA, that helps to target the plasmid to the nucleus42;43.
 Asynchronicity of antigen and danger signal: early events
During the DNA tattoo many perforations are made in the dermis. These 
microscopic wounds will be infected with the skin-resident bacterial 
flora and injected with the CpG containing DNA vaccine. The danger 
signals generated this way will lead to the rapid maturation of skin 
resident APCs and in a later stage to the recruitment and infiltration of 
immune cells from the circulation. 
Upon strong maturation signals, most skin resident APCs migrate away 
from the skin within a few hours44;45. Hence, a substantial part may 
leave before antigen production starts. Such a ‘timing-mismatch’ may 
compromise the efficacy of the method. The preliminary finding that the 
addition of oligomeric CpG sequences, a very strong adjuvant, to the 
DNA vaccine abolishes T cell priming fits with this idea. 
It should be noted that, before making an effort to compensate this 
timing issue, more experimental data are required; for example an 
analysis of tattoo induced APC influx in the DLN, combined with a 
characterization of the dominant APC type. Furthermore, it goes without 
saying that this issue only affects cross-presentation mediated T cell 
priming. Nonetheless, the presence of danger signals before production 
of the antigen and not during its production, is an unphysiological aspect 
of tattoo DNA vaccination that needs attention.
It may be difficult to tackle this issue by accelerating the onset of 
antigen production. Maybe the addition of mRNA encoding the antigen 
to the DNA vaccine, or the addition of the antigen itself will prove 
to be beneficial. Although RNA vaccines are known to be functional 
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intramuscularly , their half life in the dermis is likely to be very short due 
to the abundant presence of RNAases. Regarding the addition of proteins 
or peptides it should be noted that ‘peptide tattooing’ per se does not 
lead to a T cell response (unpublished data). Nevertheless, mixing RNA 
or protein to DNA tattoo vaccines may have a synergistic effect. Both 
additions compromise the easy production of the vaccine though.
It may be more feasible to delay the APC maturation in order to 
compensate the timing-mismatch. Firstly, simple measures like 
disinfection of the skin before applying the tattoo may have a positive 
effect. Secondly, the effect of the elimination of CpG sequences in the 
DNA vaccine, or of the addition of ‘tolerizing’46 instead of activating CpG 
sequences, is definitively worth testing. 
 Asynchronicity of antigen and danger signal: late events
A similar timing issue may come about when, at a later stage, systemic 
APCs infiltrate the tattooed area. At this time the tattoo induced antigen 
expression may have waned to suboptimal levels. The current regimen 
of 3 sequential tattoos may partly compensate this issue. However, in 
the current regimen each tattoo is placed on a fresh skin patch; hence 
outside the area where the cellular infiltrate of the previous tattoo (with 
the recruitment of APCs) is emerging.
If further experiments confirm that the peak of the APC recruitment 
in the tattooed area occurs after the ‘antigen production stop’, than 
one may either accelerate the first or prolong the latter. With regard 
to prolongation of the antigen expression, exchanging the immediate 
early cytomegalovirus promoter (IE-CMV) for one that is less liable 
to silencing (i.e. the EF1-alpha promoter or the CAGGs expression 
cassette47;48) may further prolong antigen expression. On the other hand, 
the acceleration of APC infiltration may be achieved by the inclusion 
in the DNA vaccine of genes encoding cytokines that accelerate the 
recruitment of APCs. The addition of adjuvants is further discussed 
below. Hopefully, a combination of these measures may eventually lead 
to a single tattoo regimen. 
Partly related to this timing issue, another approach that has been shown 
to augment the vaccine induced responses is the combination of dermal 
and intramuscular administration of the DNA vaccine. Intramuscular 
injection results in expression lasting for months, and preliminary 
results suggest a synergistic effect with intradermal tattoo administration 
(unpublished data). The mechanism behind this effect is yet unclear, 
however.
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 Quantity and quality of APCs: the impact of adjuvants
In light of the alleged late timing issue, the addition of adjuvants that 
accelerate the recruitment of APCs may be beneficial. In the past, the 
addition of adjuvants to protein vaccines49 and intramuscular DNA 
vaccines50 has lead to dramatic improvements in vaccine potency, either 
by augmenting APC recruitment or by accelerating APC maturation. 
However, as illustrated by the negative effect of the addition of CpGs 
to DNA tattoo vaccines, finding the right adjuvant for DNA tattooing is 
not trivial. So far, the addition of DNA encoding GM-CSF, MIP3a, soluble 
CD70 multimers, and IL-23 have been tested without clear success 
(unpublished data). Recently, a strong adjuvant effect of flagellin on 
intradermal DNA vaccination by gene gun was reported51. This adjuvant 
will probably be equally effective in DNA vaccines administered 
by tattooing. Therefore, it should be the first on the list of candidate 
adjuvants scheduled for testing. 
 Other issues
As described in chapter 5, the stability of the encoded antigen has an 
important impact on the efficacy of T cell induction (as described in 
chapter 5). Therefore, future vaccines should encode antigens that are 
inherently stable or antigens that have been modified to increase their 
stability. 
Currently, we do not yet know the intricacies of the cross presentation 
process, and it is likely that besides the stability of an antigen other 
properties of the antigen contribute to the efficiency of the cross 
presentation process as well. As our insight in the presentation of skin-
derived antigens increases, additional modifications to the antigens 
encoded by tattoo DNA vaccines may lead to further improvement.
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Nederlandse samenvatting
In de jaren ’70 van de vorige eeuw werd duidelijk dat in patiënten met 
bepaalde soorten kanker, spontane activatie van het afweersysteem 
soms leidt tot genezing. Het concept van immunotherapie bij 
melanoompatiënten is gebaseerd op dat inzicht: de bedoeling is de T 
cellen van het afweersysteem gericht tegen de kanker te stimuleren, 
zodat deze kunnen bijdragen aan het opruimen van kankercellen. Maar 
de methoden voor het gericht aanwakkeren van T cel immuniteit (T cel 
vaccinatie) staan nog in de kinderschoenen en werken tot nu toe alleen 
in kleine proefdieren (muizen). Bovendien is duidelijk geworden dat 
veel kankers over een trukendoos beschikken om aanvallen van T cellen 
te ontwijken. 
In dit proefschrift worden de resultaten van T cel metingen in melanoom 
patiënten gepresenteerd waaruit blijkt dat in melanoom patiënten met 
een vergevorderde ziekte vaak spontaan een melanoom specifieke T cel 
respons optreedt, maar de aanwezigheid van deze cellen geen gunstig 
effect heeft op het ziektebeloop. Als zulke cellen door vaccinatie beter 
(eerder en sterker) kunnen worden geactiveerd, biedt dat therapeutische 
mogelijkheden. Daarom werd vervolgens de kracht van een op eiwit 
fragmenten (peptides) gebaseerd vaccin getest in melanoom patiënten. 
Helaas wekte dit vaccin nauwelijks melanoom specifieke T cellen op.
Vervolgens introduceert dit proefschrift een nieuwe experimentele 
vaccinatie methode, waarbij een (tumor specifiek) DNA vaccin met een 
tattoo apparaat in de huid wordt geïnjecteerd. In vergelijking met andere 
experimentele vaccinatie methoden, is de T cel inductie na tattoo DNA 
vaccinatie erg sterk. Zo blijkt dat met deze methode niet alleen muizen, 
maar ook grote proefdieren (apen) succesvol gevaccineerd kunnen 
worden. Toekomstige testen in melanoom patiënten moeten uitwijzen 
of ook in mensen T cellen door DNA tattooing aangewakkerd kunnen 
worden, om te helpen bij het opruimen van tumorcellen.
Verder werd met proefdier modellen gebaseerd op deze nieuwe 
vaccinatie methode het inzicht vergroot in de manier waarop afweer 
cellen de huid controleren. Hieruit kwam een nieuw praktisch inzicht 
voort: om T cellen optimaal te stimuleren, moet een DNA vaccin coderen 
voor een stabiel eiwit . 
Tot slot worden in dit proefschrift nog twee technieken beschreven; een 
voor de bereiding van reagentia waarmee T cel immuniteit in patiënten 
sneller en beter gemeten kan worden (zogenaamde tetrameren) en een 
voor microscopisch onderzoek naar de immunologische processen in 
de huid, volgend op een infectie. Hopelijk zullen deze technieken verder 
bijdragen aan de ontwikkeling van een veilig en sterk tumor vaccin.
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